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ABSTRACT
Molecular and cell biological characterisation of neuronal nicotinic acetylcholine 
receptors (nAChRs) provides an insight into their functional roles and potential as 
therapeutic targets for neurological disorders. Nicotinic receptors are oligomeric ligand- 
gated ion channels, comprising five subunits. Twelve vertebrate neuronal nAChR 
subunits (a2-al0  and (32-|34) have been cloned to date, with considerable diversity 
observed in nAChR subunit composition. Heterologous expression of cloned subunits is 
a powerful method for investigating ion channel receptor pharmacology and subunit 
composition, but achieving efficient expression of some nAChRs in cultured cell lines 
has proved difficult. In this study, chimeras containing the N-terminal domain of the 
nAChR subunits, fused to the C-terminal region of the 5-hydroxtryptamine type 3 
receptor subunit, 5HT3A, were constructed to overcome some of the challenges of 
recombinant nAChR expression. When combinations of wild-type and chimeric 
subunits were expressed in human embryonic kidney tsA201 cells, inclusion of 
nAChR/5HT3A chimeras enhanced the expression of nAChRs containing each of the a2, 
a3, a4, a6 , a7, a9, alO, p2 or (34 nAChR subunits, determined by detection of 
radioligand binding sites. This was particularly significant for a6- or a9/alO-containing 
nAChRs, as radioligand binding to wild-type nAChRs containing these subunits was not 
detected in tsA201 cells. A detailed pharmacological characterisation of receptors 
containing a9/5HT3A + alO/5HT3A chimeras in tsA201 cells via competition binding 
suggested that the chimeras provide suitable models for characterisation of wild-type 
nAChRs. Radioligand binding to intact cells and enzyme-linked assays to detect 
epitope-tagged subunits expressed in transfected cells, suggested that ot9/5HT3A- 
containing receptors were expressed at the cell surface in high levels. Comparison of 
radioligand binding to nAChR subtypes containing combinations of wild-type and 
chimeric a2-a6 and P2-J34 subunits implicated the N- and C-terminal domains of both 
the a  and p type nAChR subunits in subunit oligomerisation events and provided an 
insight into nAChR assembly.
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CHAPTER 1 
INTRODUCTION
Two types of ACh-sensitive receptor have been classified according to their activation 
by the plant alkaloids, muscarine and nicotine. These receptors are also distinguished by 
their sensitivity to different antagonists, where, for example, muscarinic acetylcholine 
receptors are sensitive to atropine and nicotinic acetylcholine receptors are sensitive to d- 
tubocurarine. In vertebrates, the nicotinic acetylcholine receptors (nAChRs) can be 
further divided into two broad classes defined by their location. “Muscle-type” nAChRs 
are expressed at the neuromuscular junction, while “neuronal” nAChRs are expressed 
widely in the central and peripheral nervous systems (Lukas et al., 1999). These two 
subclasses of nicotinic receptor also differ with respect to their subunit composition and 
pharmacological profiles.
The nAChRs belong to a superfamily of neurotransmitter-gated ion channels that also 
includes the y-aminobutyric acid type A (GABAa) receptor, the glycine receptor and the 
5-hydroxytryptamine type 3 (5HT3) receptor (Stroud et al., 1990). These oligomeric 
proteins, comprising five membrane-spanning subunits, are involved in fast 
communication events between nerve cells and sensory or effector cells. A chemical 
signal released by the nerve cell and detected by the ion channel receptor is converted 
into an electrical signal via the opening of the ion channel to allow a brief influx of ions 
into the cell (see also Section 1.6). The members of the superfamily can be classified 
according to the nature of the ions that pass through the channel, where nAChRs and 
5HT3 receptors conduct cations and elicit an excitatory response, while glycine and 
GABAa receptors conduct anions and are, therefore, classified as inhibitory, as receptor 
activation leads to membrane hyperpolarisation.
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1.1 The nicotinic acetylcholine receptor (nAChR)
1.1.1 The nAChR from the Torpedo electric organ
The electric organs of the marine rays, Torpedo califomica and Torpedo marmorata and 
the electric eel, Electrophorus electricus, are comprised of stacks of electrocytes; cells 
that differentiate from embryonic tissue common to that of skeletal muscle. The nAChR 
isolated from these modified muscle cells resembles the nAChR isolated from the 
vertebrate neuromuscular junction (Section 1.1.2). The entire ventral surface of the 
electrocyte forms an excitable membrane, providing an extremely high density of 
nAChRs (100 pmol/mg protein) at levels approximately 1000-fold higher than those of 
skeletal muscle. The snake a-toxin, a-bungarotoxin (a-BTX), isolated from the venom 
of the Malayan banded krait, Bungarus multicinctus (Lee and Chang, 1966) binds almost 
irreversibly to Torpedo electric organ nAChRs to inactivate receptor function and 
allowed the purification of the nAChR from this rich source of receptors (Changeux et 
a l , 1970; Miledi etal., 1971).
The Torpedo electric organ nAChR is composed of four different subunits designated a, 
P, y and 5, arranged as a pentamer in the stoichiometry a 2Py6 (Hucho et al., 1976; 
Reynolds and Karlin, 1978; Brisson and Unwin, 1985; Unwin, 1993). This pentameric 
glycoprotein has a molecular mass of approximately 290 kilodaltons (kDa), with each 
subunit contributing 40 - 64 kDa. The native Torpedo electric organ nAChR exists as a 
single pentamer and in a “dimeric” form, where two nAChR pentamers are cross-linked 
by a disulphide bond, determined by sucrose gradient centrifugation with sediment 
coefficients of 9S and 13S, respectively (Hamilton et al., 1979; DiPaola et al., 1989). 
The five membrane spanning subunits of each pentamer are arranged to form a ring 
around a narrow central pore, which comprises the ion channel and is impermeable to 
ions when the nAChR is in the resting state (Cooper et al., 1991; Unwin, 1993). Upon 
ligand binding and nAChR activation, a conformational change occurs to open the
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channel pore, allowing the selective passage of ions through the plasma membrane (e.g. 
Miyazawa et al., 1999; Miyazawa et al., 2003).
Cloning of the genes encoding the Torpedo electric organ a, p, 8 and y subunits (Noda et 
al., 1982; Claudio et a l, 1983; Noda et al., 1983c) allowed reconstitution of functional 
recombinant nAChRs in the oocytes of the South African clawed frog, Xenopus laevis 
(Sumikawa et al., 1981; Barnard et al, 1982) in an approach that has been widely used 
in the characterisation of nicotinic receptors.
1.1.2 The nAChR of the vertebrate neuromuscular junction
The nucleotide sequences of the Torpedo electric organ subunits were used to construct 
cDNA probes, then used to screen mammalian libraries and identify genes encoding 
nAChR subunits expressed at the vertebrate neuromuscular junction (Noda et al., 1983b; 
LaPolla et al., 1984; Nef et al., 1984; Tanabe et a l, 1984). This approach identified 
mammalian a l ,  p i, y and 8 subunits and a novel subunit, designated e, resembling the y 
subunit (Takai et a l, 1985). The muscle nAChR can exist in two forms, where the 
a l 2PlyS form occurs in foetal muscle and a switch during postnatal development 
produces the a l 2ple8 form in adult muscle (Mishina et al., 1986). Small changes in the 
biophysical properties of the two nAChR subtypes are observed, where channel 
conductance is low in foetal muscle ( a l2piyS) and high in adult muscle ( a l2plsS) 
(Mishina et a l, 1986).
The nAChRs at the vertebrate neuromuscular junction are situated postsynaptically 
within the membrane of the muscle endplate. In this location, nAChRs are involved in 
chemical signalling between motor neurones and the muscle effector cells.
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1.1.3 Neuronal nAChRs
In addition to nAChRs of the neuromuscular junction, cholinergic innervation is 
observed in the brain and the peripheral ganglia (Green et al., 1973; Hunt and Schmidt, 
1978). High affinity a-BTX binding sites were identified in the brain and ganglia, but 
ganglia containing [125I]-a-BTX binding sites also elicit nicotine-induced responses that 
are not inhibited by the application of a-BTX, suggesting the presence of two different 
receptors, one that binds a-BTX and one stimulated by nicotine (Patrick and Stallcup, 
1977; Carbonetto et al., 1978).
Since the cloning of the first neuronal nAChR subunit from a rat adrenal medulla 
phaeochromocytoma (PC 12) cDNA library (Boulter et al., 1986), twelve vertebrate 
neuronal-type subunits, designated a2 - alO and (32 - (34 have been identified and cloned 
(Sargent, 1993; McGehee and Role, 1995; Elgoyhen et al., 2001) (Table 1.1). The a8 
subunit has only been identified in chick (Schoepfer et al., 1990; Sargent, 1993). The a- 
subunits are classified by the presence of a pair of adjacent cysteine residues that are 
present in the muscle and Torpedo electric organ a  subunits (a-Cysl92 and a-Cysl93 of 
the electric organ nAChR) and are thought to comprise at least part of the ligand binding 
site (Kao et al., 1984; Kao and Karlin, 1986; Galzi et al., 1991b) (Section 1.2.3). The 
non-a subunits (|32, (33 and (34) do not contain this cysteine pair (Lukas et al., 1999).
Neuronal nAChRs show considerable diversity in subunit composition, with evidence for 
nAChRs containing one, two, or more different subunit subtypes in the pentameric 
structure (Millar, 2003). Expression of combinations of the different neuronal subunits 
in heterologous expression systems is one approach used to ascertain the possible subunit 
composition of native nAChRs.
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Rat Subunit Probe Number of amino acids Mr Reference
a l chicken a2 484 55.5 Wada et al., 1988
a3 mouse a l 474 54.8 Boulter et al., 1986
a4 rata3 
mouse a l
600 67.1 Boulter et al., 1987 
Goldman et al., 1987
a5 rat (33 424 48.8 Boulter et al., 1990
a6 PCR 463 53.3 Lamar et al., 1990
a l PCR (based on chicken a l  
and a8 primers)
480 54.2 Seguela et al., 1993
a9 rat a l 457 52.0 Elgoyhen et al., 1994
alO rat a9 423 47.1 Elgoyhen et al., 2001
P2 rat a3 475 54.3 Deneris et al., 1988
P3 rat a3 434 50.2 Deneris et al., 1989
P4 rat P2 475 53.3 Duvoisin et al., 1989; Boulter et a/., 1990
TABLE 1.1. Summary of the cloned rat nAChR subunits. Adapted from Sargent, 1993. The a8 subunit has only been identified in chicken 
(Schoepfer etal., 1990).
In the majority of cases, a combination of both a  and P subunits appears necessary for 
assembly of functional nAChRs. When expressed in Xenopus oocytes, the a2, a3 and 
a4 subunits each assemble into functional ion channels upon co-expression with P2 or 
P4 subunits (Boulter et al., 1987; Ballivet et al., 1988; Deneris et al., 1988; Wada et al., 
1988; Sargent, 1993). The a5 subunit does not form functional nAChRs when expressed 
in pairwise combination with any P subunit (Boulter et al., 1990; Couturier et al., 
1990b), but may participate in the formation of nAChRs containing more than two 
different types of subunit, such as a3p4a5 and a4P2a5 (Millar, 2003). Similarly, while 
the P3 subunit does not participate in the formation of functional channels when 
expressed in pairwise combinations of subunits, p3 may participate in nAChR complexes 
containing more than one type of P subunit, such as a4P2p3P4 nAChRs (Forsayeth and 
Kobrin, 1997; Boorman et al., 2000; Kuryatov et al., 2000). Heterologous expression of 
the chick a6 subunit in mammalian cells suggests the formation of functional a6P2 and 
a6P4 nAChRs (Fucile et al., 1998), while expression of human subunits in Xenopus 
oocytes suggests a6 assembles more efficiently into complexes that contain more than 
one type of a  or P subunit, such as a3p4a6 and a6P2a5 nAChRs (Fucile et al., 1998; 
Kuryatov et al., 2000). Each heteromeric nAChR subtype appears to be stimulated by 
the application of nicotine, though none of the aforementioned combinations shows 
sensitivity to a-BTX (McGehee and Role, 1995; Itier and Bertrand, 2001).
The a7, a  8 and a9  subunits are capable of forming homomeric complexes that are 
sensitive to a-BTX when expressed alone in Xenopus oocytes (Couturier et al., 1990a; 
Seguela et al., 1993; Elgoyhen et al., 1994; Gerzanich et al., 1994; Gotti et al., 1994). 
Early studies suggested that the pharmacological properties of the a l  homomer were not 
affected by the co-injection of any of the a3, a5, P2, P3 or P4 subunits (Couturier et al., 
1990b; Seguela et al., 1993), but more recent data has suggested that in vivo, a l  may co- 
assemble with subunits such as P2, P3 or a5 (Yu and Role, 1998a; Yu and Role, 1998b; 
Palma et al., 1999b; Khiroug et al., 2002). In the chick nervous system, the a l  and a8 
subunits are able to co-assemble to form heteromeric nAChRs in addition to homomeric
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nAChRs (Keyser et a l, 1993; Gotti et a l , 1994; Gotti et a l , 1997). The alO subunit 
does not form functional ion channels when expressed alone or in combination with any 
neuronal P subunit in Xenopus oocytes, but does appear to co-assemble with the a9 
subunit (Elgoyhen et a l , 2001; Sgard et al., 2002).
1.2 Structure of nAChRs
1.2.1 Primary structure of subunits
All nAChR subunit sequences contain a signal peptide at the extreme amino-terminal (N- 
terminal) that is cleaved during translocation to form the mature protein. The large 
hydrophilic extracellular N-terminal domain of each subunit contains potential sites for 
asparagine (N)-linked glycosylation (Nomoto et al., 1986). Four hydrophobic stretches 
of amino acids comprise the putative transmembrane domains and are termed Ml - M4 
(Noda et al., 1983b; Sargent, 1993). Each subunit also contains a highly variable 
hydrophilic domain between M3 and M4 that is exposed to the cytoplasm and contains 
sites for phosphorylation (Huganir and Greengard, 1990). A short hydrophobic 
extracellular carboxy terminal region completes each subunit (Figure 1.1).
1.2.2 Subunit stoichiometry and arrangement
The native nAChR of the Torpedo electric organ exists predominantly in a “dimeric” 
form, in which two oc2PyS nAChRs are cross-linked between 5 subunits of adjacent 
nAChRs by a disulphide bond (Hamilton et al., 1979; DiPaola et al., 1989). The 
suggested arrangement of subunits in a pentameric ring around the ion pore of the 
monomer is shown in Figure 1.2 and places the y subunit in a position between the two a  
subunits (Karlin et a l, 1983; Brejc et a l, 2001; Unwin et a l, 2002).
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FIGURE 1.1. The predicted topology of the nAChR subunit family. The large 
hydrophilic extracellular N-terminal domain of each subunit contains potential sites for 
N-linked glycosylation and, in the case of the a-subunits, is thought to contain the ligand 
binding site. Four hydrophobic stretches of amino acids com prise the putative 
transmembrane domains and are termed M l - M4. Each subunit possesses a highly 
variable hydrophilic domain exposed to the cytoplasm  that contains sites for 
phosphorylation and a short hydrophobic extracellular carboxy terminal region.
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FIGURE 1.2. The structure and predicted stoichiometry of the nAChR of Torpedo 
electric organ and foetal muscle. The four a ,  p, y and 8 subunits oligomerise to form a 
pentameric transmembrane glycoprotein with stoichiometry c^PyS. In adult muscle, the 
y subunit is replaced by an 8 subunit. The five subunits form a ring around a narrow 
central pore. The nAChR complex possess two agonist binding sites, represented by 
black circles, at the a-y  and oc-5 subunit interfaces. The predicted order of the subunits 
around the ion channel pore positions the y subunit between the two a  subunits.
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The sediment coefficients and molecular weights of neuronal nAChRs are comparable to 
those of the muscle-type nAChR, suggesting that neuronal nAChRs also exist as 
pentamers (Anand et al., 1993b; Sargent, 1993). Immunoprecipitation of [35S]- 
methionine labelled a4p2  nAChRs expressed in Xenopus oocytes, revealed an 
approximate a4:P2 subunit ratio of 1:1.5, suggesting the stoichiometry of neuronal 
nAChRs to be a 2P3 (Anand et a l, 1991). The putative arrangement of the subunits 
around the ion channel is a(3aPP, consistent with the separation of the a  subunits by a 
non-a subunit observed in the muscle-type nAChR, but is complicated by the existence 
of nAChRs containing more than one type of a  or P subunit (e.g. Wang et al., 1996; 
Gerzanich et a l, 1998; Kuryatov et a l, 2000). The existence of nAChRs with 
alternative stoichiometries has also been demonstrated, following expression of varying 
ratios of a4 and p2 subunits in Xenopus oocytes (Zwart and Vijverberg, 1998; Nelson et 
al, 2003).
1.2.3 The ligand binding site
Affinity labelling of the Torpedo electric organ and muscle nAChR complexes localised 
the ACh-binding sites at the interface between the a  subunit and the adjacent non-a 
subunit (Galzi et a l, 1991b; Changeux et a l, 1998; Taylor et a l, 2000). The muscle- 
type nAChR, with composition a 2PyS, contains two non-identical ligand binding sites at 
the interfaces between the a  subunit and either the y or 5 subunit (Pederson and Cohen, 
1990). Expression of pairwise combinations of muscle subunits in fibroblast cells 
revealed the assembly of ay and aS complexes able to bind the nicotinic antagonist, d- 
tubocurarine with differing affinities (Blount and Merlie, 1989). Residues from both the 
a  and non-a subunit thus appear to contribute to the formation of the ligand binding site 
(Reynolds and Karlin, 1978; Neubig and Cohen, 1979; Pederson and Cohen, 1990). 
Expression of the a  subunit alone or in combination with the P subunit does not produce 
high affinity binding sites for either ACh or d-tubocurarine (Kurosaki et a l, 1987; 
Blount and Merlie, 1988; Pederson and Cohen, 1990).
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With a stoichiometry of a 2(33, heteromeric neuronal nAChRs would also contain two 
ligand binding sites at the interfaces between the a  and non-a subunits. In the 
homomeric a7, a8 and a9 nAChR complexes, assembly of five a  subunits provides five 
a-a  subunit interfaces and five putative ligand binding sites (Wang et al., 1996). 
Assembly of five ligand binding sites in the formation of homomeric a l  nAChRs was 
suggested by kinetic studies using the potent a l  nAChR antagonist, methyllycaconitine 
(MLA), an insecticide from the seeds of Delphinium brownii (Palma et al., 1996). 
Inhibition of the a l  nAChR by MLA and the recovery from this block are best described 
by a five-site model, while the block of a4|32 nAChRs is best suited to a two-site model 
(Palma etal., 1996).
Six loops, designated A - F, have been identified within the nAChR complex that are 
important for the formation of the ACh-binding site (Kao and Karlin, 1986; Galzi et al., 
1990; Czajkowski et al., 1993; Fu and Sine, 1994; Corringer et al., 1995; Martin et al., 
1996; Prince and Sine, 1996). The a  subunit possesses the primary components of the 
ligand binding site and contains loops A, B and C, while the D, E and F loops are present 
at the subunit adjacent to the a  subunit forming the ligand binding interface (Figure 1.3). 
Tyrosine residues and two cysteine residues are thought to be important in ligand 
binding. The electron-rich side chains of the tyrosine residues may interact with the 
diffuse positive charge of the quartemary ammonium group found in ACh (Dougherty 
and Stauffer, 1990; Galzi et al., 1990).
Affinity labelling experiments have identified several residues within the A - F loops. 
For example, 4-(A-maleimido)benzyltri[3H]-methylammonium iodide ([3H]-MBTA), 
which competes with ligand for the binding site, was used to label Cysl92 and Cysl93 
of the Torpedo electric organ nAChR a  subunit (Kao et al., 1984). Labelling with p- 
(jV,A-dimethyl)aminobenzenediazonium fluoroborate (DDF) identified a-Trp86 and a- 
Tyr93 (in the A loop), a-Trpl49 (in the B loop) and a-Tyrl90 and a-Tyrl98 (in the C 
loop) (Galzi et a l, 1991b; Galzi and Changeux, 1995). In the D loop, y-Trp55 and 8-
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Trp57 were labelled with nicotine and d-tubocurarine (Chiara et al., 1998), while 8- 
Aspl80 (in the F loop) was implicated in radioligand binding through mutation of this 
residue to asparagine, which caused a reduced affinity for ACh (Martin et al., 1996).
The residues identified in loops A - C are conserved in all of the identified a  subunits 
except a5, which does not contain tyrosine residues at positions analogous to a-Tyr93 or 
a-Tyrl90 of Torpedo electric organ nAChR subunits (Boulter et al., 1990; Couturier et 
al., 1990b). The atypical a5 subunit may serve a more structural role associated with 
non-a subunits, assuming the position of the muscle-type p i subunit in nAChR 
complexes that contain more than one a  subunit (Ramirez-Latorre et al., 1996; Wang et 
al., 1996; Kuryatov et al., 2000). The residues labelled in the D loop are conserved in 
the neuronal P2, P4, a7 and a 8 subunits, such that the a l  subunit carries both the 
principal and complementary components of the ligand binding site (Corringer et al., 
2000). Mutation of the conserved Trp54, Tyr92, Trpl49 and Tyrl88 residues in the a l  
subunit results in a reduction of the apparent affinity of the nAChR for agonists and 
competitive antagonists, demonstrating the involvement of these residues in ligand 
binding (Galzi et al., 1991a; Corringer et al., 2000).
Agonist affinities of nAChRs are dependent upon the subunit composition of the 
receptor, consistent with the involvement of residues from both the a  subunit and its 
adjacent subunit in the formation of the ligand binding site (Parker et al., 1998). 
Identification of conserved residues suggests amino acids essential in the formation of a 
ligand binding site, while the residues that differ between subunits must be responsible 
for the differences in pharmacology of each nAChR subtype. For example, mutation of 
residues within the D loop of the P2 subunit to the corresponding residues of the P4 
subunit sequence, resulted in lower affinities for ACh and nicotine when the mutated P2 
subunit was co-expressed with a2 in Xenopus oocytes (Parker et al., 2001), compared to 
wild-type a4P2 nAChRs.
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FIGURE 1.3. Model of the nAChR ligand binding domain. (A) Heteropentameric 
complex of neuronal nAChR a  and p subunits. The ACh-binding site is located at the 
interface between the a  subunit and the adjacent (3 subunit. (.B) Representation of the 
principal component ( a  subunit), with its three loops, A, B and C and two of the loops 
(D and E) from the complementary component (P subunit) of the ligand binding site. 
Each loop is modelled with the principal amino acids identified within the chick a l  
subunit. Adapted from Itier and Bertrand, 2001.
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Whilst competitive nicotinic antagonists, such as a-BTX and MLA, probably interact at 
the agonist binding site, they are also thought to interact with additional residues outside 
of the A - F loops (Galzi et a l , 1991b; Sine, 1993). Neurotoxins, such as a-BTX, are 
highly flexible molecules with little secondary structure, so a large proportion of the 
toxin may be involved in binding to the nAChR, with parts of the toxin reaching down 
from the crest of the nAChR molecule to the agonist binding site (Stroud et al., 1990).
1.2.4 The ion channel
At the neuromuscular junction, nAChRs are permeable to monovalent cations, but 
relatively impermeable to divalent cations (see Itier and Bertrand, 2001). Neuronal 
nAChRs are permeable to both monovalent and divalent cations, showing a significant 
permeability to calcium (Sargent, 1993; Seguela et al., 1993; McGehee and Role, 1995). 
Homomeric a7 nAChRs expressed in Xenopus oocytes demonstrate a ratio of calcium 
permeability: sodium permeability (Po/P^) °f approximately 20, while a3p4 nAChRs 
demonstrate PCa/PNa = 1-1 (McGehee and Role, 1995).
The structure of the ion channel was initially investigated by photo-labelling of the 
muscle-type nAChR using non-competitive, open channel blockers, such as 
chlorpromazine, and suggested that the second putative transmembrane domain (M2) 
formed the lining of the ion channel (Giraudat et al., 1986; Hucho et al., 1986; Revah et 
a l, 1990; Stroud et a l, 1990). Evidence that M2 exists as an a-helix has been provided 
by electron microscopy of crystalline postsynaptic membranes of electric organ (Unwin, 
1993; Miyazawa et a l, 2003) (Section 1.2.5). In an a-helical conformation, M2 is 
amphipathic, with an abundance of serine and threonine residues pointing towards the 
ion channel lumen. Chlorpromazine labels residues corresponding to a-Thr244, a- 
Ser248, a-Leu251, a-Val255 and a-Glu262 of M2 (Giraudat et a l, 1986; Hucho et a l, 
1986; Revah et a l, 1990). Conservation of these residues across the different subunits 
within the pentameric nAChR, produces rings of residues with similar charge, side chain 
size or hydrophobicity within the lumen of the ion channel (Figure 1.4).
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FIGURE 1.4. A model of the high affinity binding site of the open channel blocker, 
chlorpromazine. The sphere represents the space occupied by chlorpromazine. The M2 
domains of the P and y subunits are arranged as transmembrane a-helices, depicting the 
a-carbons of the indicated amino acids. The filled circles represent three rings of amino 
acids w ithin the M2 domain of each nA ChR subunit photolabelled  by [3H]- 
chlorpromazine Rings of negatively charged subunits are located at either end of the 
putative channel pore and have been implicated in ion transport following mutagenesis 
experiments. Taken from Revah et a l, 1990.
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A ring of conserved leucine residues located near the centre of the lipid bilayer may be 
involved in the formation of the channel gate (Miyazawa et al., 1999; Miyazawa et al., 
2003). Leu247 of the neuronal a l  subunit, is thought to be located close to the channel 
selectivity filter in a section of the ion channel that should demonstrate high 
conformational flexibility (Miyazawa et al., 1999). Mutation of a7-Leu247 to polar 
serine or threonine residues dramatically alters the ion channel properties, creating a 
200-fold increase in the sensitivity of the nAChR to ACh, a loss in desensitisation and 
changes in nAChR pharmacology, where competitive antagonists behave as agonists 
(Revah et al., 1991; Bertrand et al., 1992; Palma et al., 1999a). The mutation converts 
the high affinity closed desensitised state into a state that conducts ions, implicating the 
leucine ring in the permeability of the ion channel when the nAChR is in a desensitised 
state (Revah et al., 1991; Bertrand et al, 1992).
Rings of negative charge at either side of M2 (at a-Glu259 and a-Glu280) may attract 
cations to the entrance of the channel, as mutation of the residues at the inner or outer 
mouth of M2 affects the ion selectivity of the channel pore (Imoto et al., 1988; Galzi et 
al., 1992). Mutation of the well conserved glutamate residue at the cytoplasmic end of 
M2 of the neuronal a l  subunit (E237A) reduces Ca2+ permeability by 1000-fold, but 
does not alter permeability to monovalent cations (Galzi et al., 1992; Bertrand et al.,
1993). This suggests that the presence of a residue with negatively charged side chains 
is essential for the high calcium permeability of neuronal nAChRs and is critical for 
cation selectivity (Imoto et a l, 1988; Galzi et al., 1992). Substitution of amino acids of 
the chick a l  subunit with corresponding residues from GABAa or glycine receptor 
subunits produced a conversion of ion selectivity from cationic to anionic (Galzi et a l, 
1992; Corringer et al., 1999). The (X7-E237A mutation is necessary but not sufficient for 
the conversion of anion selectivity (requiring introduction of alanine or proline residues 
to the putative selectivity filter region), suggesting that the ring of negative charge at the 
cytoplasmic end of M2 may also provide a barrier to chloride ions (Corringer et a l, 
2000).
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1.2.5 The 3-Dimensional structure of the nAChR
The extremely high density and regular arrangement of nAChRs in the Torpedo electric 
organ allowed the structure of the electric organ nAChR to be analysed by electron 
microscopy following preservation of the structure by rapid freezing (see Toyoshima and 
Unwin, 1990; Unwin, 1993; Miyazawa et al., 1999). The structure of the nAChR shown 
at a resolution of 17 A (Toyoshima and Unwin, 1990; Unwin et al., 2002) revealed a 
pseudo-5-fold symmetry of subunits seen as rods ~ 120 A long and 20 A wide, arranged 
around a narrow central pore that spans the membrane. The nAChR extends ~ 65 A 
above the extracellular surface of the membrane, while the extension below the 
membrane into the interior of the cell is shorter (15 A) and associated with an underlying 
density, attributed in part to interaction of the intracellular loop region of the nAChR 
with rapsyn, a 43 kDa protein involved in muscle-type nAChR clustering (Sealock, 
1982; Moransard et al., 2003) (see Section 1.5.4). The ACh-binding sites are located at 
~ 30 A above the surface of the cell membrane and the channel gate is thought to lie 
deep within the ion channel, 15 A from the surface of the cytoplasmic membrane 
(Unwin, 1993; Miyazawa et al., 1999; Tierney and Unwin, 2000). The predicted 
topology of the channel includes a wide opening (25 A) in the extracellular domain, with 
the channel becoming gradually narrower to a point of constriction, becoming wider 
again at the intracellular domain (see Itier and Bertrand, 2001).
Recently, an ACh-binding protein (ACh-BP), released from glial cells of the snail 
Lymnaea stagnalis and involved in modulation of synaptic transmission through ACh 
binding, has been identified and its crystal structure resolved at 2.7 A (Brejc et al., 2001; 
Smit et al., 2001). The ACh-BP forms homopentameric structures that closely resemble 
the N-terminal domain of nAChRs, containing many of the conserved residues involved 
in ligand binding (such as the vicinal cysteine residues) and able to bind nicotinic ligands 
including ACh, a-BTX, nicotine and epibatidine. The ACh-BP does not possess the 
transmembrane or intracellular domains observed in nAChRs, but has been used to gain
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insights into the nAChR ligand binding domain (Brejc et al., 2001). The ACh-BP crystal 
structure supports the biochemical analysis of the nAChR ligand binding site, revealing 
the sites within a cleft formed by a series of A - C loops from the face of one subunit and 
a series of p-strands contributing to loops E - F from the face of the adjacent subunit 
(Brejc et al., 2001).
The most recent structural analysis of the Torpedo electric organ nAChR reveals the 
receptor structure at 4 A (Miyazawa et al., 2003) and suggests that the four 
transmembrane domains exist in the form of a-helices. The M2 helices of each of the 
five subunits form the lining of the pore, while the Ml, M3 and M4 helices form an outer 
lipid-facing scaffold (Miyazawa et al., 2003). The M2 a-helix contains a kink near the 
centre of the membrane at a-Pro265 that tilts the helix outwards, away from the pore, on 
either side. A kink in the vicinity of the conserved leucine residue (a-Leu251; Section 
1.2.4), observed as a narrow strip of density in the structure of the closed-channel form 
of the nAChR, probably represents the channel gate (Unwin, 1993; Miyazawa et al.,
1999). At its narrowest point, at a-Leu251 and a-Val255 and over an 8 A long 
hydrophobic stretch extending to a-Val259, the 6 - 7 A diameter of the pore provides an 
energetic barrier to restrict the passage of monovalent ions (with an effective diameter of 
8 A) that cannot lose their first hydration shell without the presence of a polar surface 
(Miyazawa et al., 2003).
The structure of each of the a  subunits appears to be modified by its interaction with the 
neighbouring subunits and upon binding of ACh (Unwin et al., 2002). Before ligand 
binding, the a  subunits exist in a conformation that differs from the non-a subunits and 
this distorted configuration may result from subunit-subunit interactions. Upon ACh 
binding, the a  subunits overcome the distortion and relax to switch configuration to that 
of the non-a subunits, so that the activated nAChR complex demonstrates a more 
symmetrical form (Unwin et al., 2002). The conformational change involves a 15 - 16° 
clockwise rotation of the a  subunit polypeptide chains on the inner surface of the
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vestibule next to the central pore. The M2 pore-lining region and the M2 - M3 loop are 
both located close to the rotating polypeptide chains, so the switch in configuration could 
undermine the channel gate, pulling apart the weak interactions between the side chains 
of residues within M2, causing the pore to open (Unwin et al., 2002; Miyazawa et al., 
2003).
1.3 The nAChR as an allosteric protein
There are four putative inter-convertible, functionally distinct conformational states in 
which nAChRs can exist (Lena and Changeux, 1993; Edelstein et al., 1996). In the 
resting state (R), the ion channel is closed. In the activated state (A), the channel opens 
following ligand binding and demonstrates a low affinity for ACh (Kd of the Torpedo 
electric organ nAChR = 60 - 100 jiM). During prolonged periods of agonist exposure, 
the nAChR is converted from the A state to a closed intermediate state of desensitisation 
(I), in which the affinity for ACh is higher than in the A state (Kd = 10 jiM). A closed 
channel desensitised state (D) that exhibits a high affinity for ACh (^ fd = 10  nM) and 
nicotinic ligands, leads to a progressive reduction in the number of nAChRs in the active 
state and a decline of the agonist-evoked current (Galzi and Changeux, 1995).
In an allosteric model of receptor function, the nAChR can change state spontaneously in 
the absence of ligand, though the probability of spontaneous channel activation is very 
low. Ligand binding to the ACh binding site or other allosteric sites modifies the 
equilibrium that exists between the different conformational states, probably by 
stabilising the state to which the ligand preferentially binds (Lena and Changeux, 1993; 
Edelstein et al., 1996). Prolonged exposure to agonist causes nAChR desensitisation, a 
slow and reversible decline in the amplitude of the response that follows channel 
activation. Longer exposure to agonist permits slower rates of desensitisation, achieving 
longer lasting states of desensitisation (Dani, 2001). At the neuromuscular junction, 
ACh is cleared from the synaptic cleft in a few hundred microseconds by AChE or in a
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few milliseconds by diffusion (Jones and Westbrook, 1996). Therefore, under normal 
physiological conditions, desensitisation may have little impact on cholinergic 
transmission. It may, however, become relevant in the brains of smokers, where tobacco 
smoking may cause levels of nicotine to build to a low steady concentration. In the 
brains of smokers, chronic exposure to nicotine creates a deficit in cholinergic receptor 
function following nAChR desensitisation that appears to be countered by an 
upregulation of receptor number (Olale et al.t 1997) (see Section 1.6.3).
1.4 Distribution and subunit composition of native neuronal nAChRs
Neuronal nAChRs are frequently classified into a-BTX-sensitive and a-BTX-insensitive 
sites. The nAChRs insensitive to a-BTX bind the nicotinic ligands, ACh, nicotine and 
cytisine with higher affinity and the majority of these sites appear to contain a4 and p2 
subunits (Whiting et al., 1987a; Zoli et al., 1998). Heteromeric nAChRs containing a3 
and P4 subunits appear to comprise the major a-BTX-insensitive nAChR subtype of the 
ganglia (Flores et a l , 1996). In the mammalian brain, high affinity [125I]-a-BTX binding 
sites correspond to a7-containing nAChRs and transgenic mice with a homozygous null 
mutation for the a l  subunit do not contain [125I]-a-BTX binding sites (Seguela et a l , 
1993; Orr-Urtreger et a l , 1997; Paterson and Nordberg, 2000). Receptors containing the 
a8 subunit are also sensitive to a-BTX, but have only been identified in the chicken 
(Britto et a l , 1992; Keyser et a l , 1993).
1.4.1 a-BTX-insensitive nAChR subtypes of the central nervous system
The major high affinity nAChR subtype in the central nervous system is thought to 
contain a4 and p2 subunits (Whiting et a l , 1987a; Flores et a l , 1992; Zoli et a l , 1998). 
High levels of mRNA corresponding to the a4 gene product are observed in the cortex 
and cerebellum, while P2 expression is fairly homogeneous in human brain (Paterson 
and Nordberg, 2000). A monoclonal antibody raised against the neuronal P2 subunit,
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mAb270 was used to immunoprecipitate more than 90% of the high affinity [3H]- 
nicotine binding sites from solubilised chick brain extracts (Whiting and Lindstrom, 
1986; Nef et al., 1988; Schoepfer et al., 1988). Subunits of 79 kDa from rat brain and 75 
kDa from chick brain, identified as a4, were also precipitated using mAb270 (Whiting et 
al., 1987b; Whiting et al., 1987c; Nef et al., 1988).
The effects of genes corresponding to nAChR subunits have also been investigated using 
transgenic mice. Deletion of the gene encoding the P2 subunit leads to the complete loss 
of high affinity nicotinic-binding sites in the mouse brain (Picciotto et al., 1995). 
Similarly, [3H]-nicotine and [3H]-epibatidine binding sites observed in the cortex or 
hippocampus of wild-type mice, are not detectable in mice lacking the a4 subunit (a4‘/ ) 
(Marubio and Changeux, 2000), providing further evidence for the role of a4 and p2 
subunits in the major brain nAChR subtype. Minor populations of non-a4-containing 
nicotinic binding sites remain in brain regions such as the substantia nigra of a4'/' mice 
and may correspond to a3- or a6-containing nAChRs (Marubio and Changeux, 2000).
In human thalamus, a3-containing nAChRs may correspond to the [3H]-nicotine and 
[3H]-cytisine binding observed (Paterson and Nordberg, 2000). Lower levels of a3 
expression are observed in most cortical regions and the hippocampus (Paterson and 
Nordberg, 2000). Neuronal bungarotoxin (n-BTX) binds with high affinity to a3|32-type 
nAChRs (Luetje et al., 1990; Cartier et al., 1996) and [125I]-n-BTX binding sites are 
observed in rat brain regions including the hypothalamus, ventral tegmental area (VTA) 
and substantia nigra. Distribution of the a2 subunit is fairly restricted in rat brain, with 
expression at high levels seen only in the interpenduncular nucleus of the brainstem 
(Wada et al, 1989). The a5 subunit is most abundant in the human cortex, but has also 
been observed in post-mortem brain tissue of the medulla oblongata, pons, cerebellum 
and spinal cord (Paterson and Nordberg, 2000). Expression of a6 is observed in limited 
brain areas, such as the substantia nigra and VTA, frequently observed with p3 subunits 
(Goldner et al., 1997; Le Novere et al., 1999). The P3 subunit is also expressed in areas
39
of rat brain such as the reticular nucleus of thalamus (Deneris et al., 1989), while (34 is 
expressed in most areas of rat cerebellum and striatum (Forsayeth and Kobrin, 1997). 
Overlapping expression patterns of a3 and p4 further suggests the co-assembly of these 
subunits (Flores et al.y 1996).
Immunoprecipitation with subunit-specific antibodies has been used to investigate the 
receptor subtypes present in the central nervous system. Such studies have, for example, 
suggested the presence of a2|32a5 nAChR complexes in chick optic lobe (Balestra et al.,
2000). Immunodepletion studies with extracts of chick brain indicate a major population 
of a4|32 nAChRs, with a smaller fraction of complexes also containing the a5 subunit 
(Conroy and Berg, 1998). Immunoprecipitation of brain extracts using antibodies 
generated against the cytoplasmic domains of the [33 and P4 subunits, demonstrate the 
co-assembly of both subunits with a4P2 in the cerebellum (Forsayeth and Kobrin, 1997). 
Therefore, a small proportion of a4p2P3p4 nAChRs appear to exist in vivo and this form 
of receptor complex is reminiscent of the muscle-type nAChR, in which the two a  
subunits interact with three different non-a subunits. In the central nervous system of 
the chick, P3 is expressed at the highest levels in the retina. Immunoprecipitation data 
suggest that P3 participates in two main populations of nAChR in this area, the first 
containing a6 and P4 subunits and the second, containing a2, a3 , a4, P2 and P4 
subunits (Vailati et al., 2000). Loss of epibatidine binding from the striatum of P3'A mice 
implicates the P3 subunit in striatal nAChRs, where it has been suggested to co-assemble 
into complexes also containing a6 and P2 subunits (Cordero-Erausquin et al., 2000).
1.4.2 a-BTX-insensitive nAChR subtypes of the ganglia
Chick ciliary ganglia have been studied widely and RNase protection assays have shown 
that a3, a5, P2 and P4 (as well as a7, which forms a-BTX sensitive nAChRs) are 
expressed in these cholinergic neurones (Corriveau and Berg, 1993; Mandelzys et al.,
1994). Embryonic chick ciliary neurones show expression of at least four different
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nAChR subtypes, containing: (i) a3, a5 and (34, (ii) a3, a5, (32 and (34, (iii) a7, (iv) a 
nAChR of unknown composition (Conroy et al., 1992; Vemallis et a l, 1993; Conroy 
and Berg, 1995; Pugh et al., 1995). Little, if any a4 is present, so the 02 in ciliary 
ganglia appears to co-assemble with a3, P4 and a5 subunits (Conroy and Berg, 1995). 
Neonatal rat sympathetic ganglia express a3, a5, (a7), P2 and p4, but not a2 or P3 
(Corriveau and Berg, 1993; Zoli et a l, 1995), while a4 mRNA is seen in adult rats (Rust 
etal., 1994).
1.4.3 a-BTX sensitive nAChRs in the brain and ganglia
Sites identified by [125I]-a-BTX binding appear to closely parallel the expression of al 
mRNA in the rat brain (Clarke et al., 1985; Seguela et al., 1993). Transgenic a7'/'mice 
do not contain high affinity [125I]-a-BTX binding sites, while the levels of [3H]-nicotine 
binding sites remain unchanged in comparison to wild-type animals (Orr-Urtreger et al.,
1997). The levels of [125I]-a-BTX binding sites are unaltered in the brains of a4'A or p2'A 
mice in comparison to binding sites observed with wild-type animals (Zoli et al., 1998; 
Marubio et al., 1999).
In the human brain, al mRNA is detected at high levels in the hippocampus, brainstem, 
olfactory regions, amygdala and hypothalamus, with lower density in the cortex and 
cerebellum and only very low levels in the thalamus (Paterson and Nordberg, 2000). 
Expression of al mRNA is also observed widely within the peripheral ganglia (Rust et 
al., 1994). In chick brain, three classes of a-BTX sensitive nAChRs are suggested, with 
the majority (approximately 70%) comprising al homomers and 20% composed of 
a7a8 heteromers (Gotti et al., 1994). These proportions differ in chick retina, where the 
major nAChR subtype (50 - 70%) comprises a8 homomers, with 10 - 17% a7a8 
heteromers and 14-27% al homomers (Keyser et al., 1993; Gotti et al., 1997).
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1.4.4 The nAChR of the inner ear
Expression of the a9 and alO subunits is largely restricted to the hair cells of the inner 
ear and neither subunit is observed in the central nervous system (Elgoyhen et al., 1994; 
Hiel et al., 1996; Elgoyhen et al., 2001; Lustig et al., 2001). Homomeric a9 and 
heteromeric a 9 a l0  nAChRs, characterised upon expression in Xenopus oocytes, 
demonstrate a pharmacological profile unique among nAChRs that, consistent with their 
distinct localisation in cochlea hair cells, means that nAChRs containing a9 and alO do 
not fall conveniently into the conventional classification of either muscle-type or 
neuronal nAChRs (Elgoyhen et a l, 1994; Rothlin et al., 1999; Verbitsky et al., 2000; 
Elgoyhen et al., 2001). This unique profile (Sections 1.5.1 and 4.5) includes antagonism 
by a-BTX, strychnine and atropine and resembles that of the native cholinergic receptor 
of cochlea hair cells (Elgoyhen etal., 1994; Guth and Norris, 1996; Rothlin et al., 1999; 
Jagger et al., 2000; Verbitsky et al., 2000; Elgoyhen et al., 2001).
1.5 Heterologous expression of nAChRs
In 1981, a decisive experiment demonstrated the expression and assembly of 
recombinant nAChRs of the Torpedo electric organ in Xenopus oocytes (Sumikawa et 
al., 1981). When mRNA isolated from the Torpedo electric organ was injected into 
oocytes, the a , P , y and 8 subunits underwent correct post-translational modification 
events including glycosylation and removal of signal peptides from each subunit 
(Sumikawa et a l, 1981). Subsequent experiments revealed cell surface receptors that 
formed functional ion channels with properties resembling those of the native Torpedo 
electric organ nAChRs (Barnard et a l, 1982).
The Xenopus oocyte has been used widely as a heterologous expression system for the 
characterisation of both muscle-type and neuronal-type nAChRs. Injecting oocytes with 
known combinations of neuronal subunit cDNA or mRNA permits comparison with
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native nAChRs, aiding the elucidation of nAChR composition. However, the usefulness 
of the oocyte as an expression system is limited for investigation of nAChRs by 
techniques such as radioligand binding, where heterologous expression in cultured 
mammalian cell lines may be more appropriate. In these cell lines, much larger 
quantities of protein can be generated and both transient and stable expression of nAChR 
protein can be accomplished. Mammalian cell lines may also provide an environment 
for nAChR expression that more closely resembles the native environment, compared to 
that provided by the Xenopus oocyte.
1.5.1 Characteristics of recombinant neuronal nAChRs
Analysis of pairwise combinations of neuronal subunits in heterologous expression 
systems has demonstrated differences in the pharmacological profiles of certain nAChR 
subtypes. A comprehensive study comparing the properties of recombinant a2f2, a2(34, 
a3P2, a3p4, a4P2 and a4P4 nAChR subtypes in Xenopus oocytes, suggested that the 
agonist profiles are affected by the nature of both the a  and the P subunit, with the p 
subunit exerting the greatest influence (Parker et al., 1998). For example, the affinity of 
each subtype for [3H]-epibatidine differs, where the Kd values for a2P2, a2P4 and a4P2 
nAChRs are 10.3±1.1 pM, 86.8±9.4 pM and 30.0±3.9 pM, respectively (Parker et a l ,
1998).
Nicotine is a partial agonist of human a3P2 nAChRs and a full agonist of a3P4 nAChRs 
(Wang et a l , 1996; Wang et a l , 1998), while conotoxin Mil specifically antagonises 
a3P2, but not a3p4 nAChRs (Cartier et a l , 1996; Wang et a l , 1996; Wang et a l , 1998). 
The a3P2 nAChRs also desensitise more rapidly than the a3P4 subtype and exposure to 
chronic nicotine induces efficient upregulation of oc3P2, but not a3p4 nAChRs (Wang et 
al., 1998). In Xenopus oocytes, the a5 subunit co-assembles efficiently with a3P2 and 
a3P4 nAChRs (Wang et a l , 1998), causing increases in the rates of desensitisation and 
the permeability to Ca2+ ions (Gerzanich et a l , 1998).
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The a5 nAChR subunit also efficiently co-assembles with <*402 in Xenopus oocytes 
causing an increase in the rate of desensitisation, a decreased sensitivity to ACh and a 
higher single channel conductance (Ramirez-Latorre et al., 1996). Nicotinic receptors 
that contain a4  are distinguished by their high affinity for nicotine and their 
susceptibility to nicotine-induced upregulation and functional inactivation (Flores et al., 
1992; Peng et al., 1994; Hsu et al, 1996; Olale et al., 1997).
Following pairwise expression of the a 6 subunit with (3 subunits in Xenopus oocytes or 
mammalian cells, a6 assembles relatively inefficiently with |32 or p4 and not at all with 
p3 (Gerzanich et al., 1997; Fucile et al., 1998). However, a6-containing nAChRs 
appear to assemble much more efficiently with P2 or P4 when a3, a4 or a5 are also 
included (Fucile et al., 1998; Kuryatov et al., 2000).
Homomeric a l  and a8 ion channels expressed in Xenopus oocytes are highly permeable 
to calcium and undergo rapid desensitisation in the presence of agonist (Seguela et al., 
1993; Gerzanich et al., 1994). The M2 region of these two subunits show 100% 
sequence homology and agreeably, the ion permeabilities of the homomers are similar. 
However, pharmacological differences are observed, with a8 homomers generally 
appearing more sensitive to agonists and less sensitive to antagonists than the a l  
nAChRs (Gerzanich e ta l, 1994).
The ion channel properties of the a9 homomer are unaffected by the co-injection of any 
neuronal P subunit, but a9 appears to co-assemble with the a  10 subunit (Elgoyhen et al., 
2001; Sgard et al., 2002). Homomeric a9 and heteromeric a9 a l0  nAChRs expressed in 
Xenopus oocytes are activated by ACh and blocked reversibly by a-BTX, but also 
demonstrate a unique pharmacological profile that is neither classically nicotinic nor 
muscarinic (Elgoyhen et al., 1994; Rothlin et al., 1999; Verbitsky et al., 2000; Elgoyhen 
et al., 2001; Sgard et al., 2002). l,l-Dimethyl-4-phenlypiperazinium (DMPP) and the 
muscarinic agonist oxotremorine M, act as partial agonists, while nicotine inhibits ACh-
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induced currents in Xenopus oocytes injected with a9 (Elgoyhen et al., 1994; Elgoyhen 
et al., 2001). The a9-containing nAChRs are also sensitive to the nicotinic antagonist, 
d-tubocurarine, the glycine receptor antagonist, strychnine, the GABAa receptor 
antagonist, bicuculline and the muscarinic receptor antagonist, atropine (Elgoyhen et al., 
1994; Rothlin et al., 1999; Verbitsky et al, 2000; Elgoyhen et a l, 2001). The nAChRs 
containing a9 desensitise rapidly and exhibit a very high permeability to calcium ions 
(Katz et al., 2000; Elgoyhen et al., 2001; Weisstaub et al., 2002).
1.5.2 Comparison of native and recombinant nAChRs
Heterologous expression is a useful tool for the characterisation of nAChRs, but while 
the profiles of many recombinant nAChRs resemble those of native nAChRs, the profiles 
are not identical (Sivilotti et al., 2000). Where variations in experimental technique do 
not account for the alternative profiles, these differences may reflect the influence of the 
cellular environment or heterogeneity of either the recombinant or native nAChRs. For 
example, when expressed in Xenopus oocytes, the Torpedo electric organ nAChR occurs 
only as pentameric nAChR units and not in the “dimeric” form cross-linked by a 
disulphide bond between the 5 subunits observed with the native nAChR (Sumikawa et 
al., 1981; DiPaola et al., 1989).
The pharmacological profiles of the chick a l  and a8 homomeric ion channels expressed 
in Xenopus oocytes correlate well with the a-BTX sensitive nAChRs identified in chick 
optic lobe (Anand et a l, 1993a; Anand et al., 1993b; Gotti et a l, 1994; Gotti et al.,
1997), but there are several differences observed in the ligand profile (Anand et al., 
1993b). For example, the recombinant a l  homomers demonstrate a 50-fold higher 
affinity for cytisine than the a7-containing nAChRs of embryonic chick brain (Anand et 
a l, 1993b). In addition, differences exist between the single channel conductance of a l  
nAChRs in different expression systems, where two conductance states are observed in a 
mammalian cell line expressing a l  (19-23 pS and 32-45 pS) (Ragozzino et al., 1997),
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while only one conductance state is observed in Xenopus oocytes injected with a7 (45 
pS) (Revah et al., 1991; Bertrand et al., 1992a). The rat adrenal medulla 
phaeochromocytoma PC12 cell line endogenously expresses a3, a4, a5, a l  and (34 
subunits (Blumenthal et al., 1997; Virginio et al., 2002). The pharmacology of the a l-  
containing nAChR expressed in PC 12 cells resembles that of recombinant a l  nAChRs 
expressed in the rat pituitary tumour-derived cell line, GH4Cj (which expresses only (34), 
with the same sensitivity for choline, MLA and dihydro-P-erythroidine (DHPE). 
However, using the open channel blocker, mecamylamine, a heterogeneous population 
of nAChRs was demonstrated in the PC 12 cell line, while G H ^  cells appeared to 
express only a single nAChR population (Virginio et al., 2002).
Differences between native and recombinant nAChRs suggest that the a l  subunit may 
co-assemble with other nicotinic subunits in vivo (Anand et al., 1993b; Yu and Role, 
1998b; Yu and Role, 1998a; Palma et al., 1999b; Crabtree et al., 2000; Khiroug et al., 
2002; Virginio et al., 2002). For example, a l  and p2 subunits were co-precipitated from 
transiently transfected kidney cells and functional a7P2 heteromers have been observed 
in Xenopus oocytes that demonstrate slower rates of desensitisation and differences in 
agonist sensitivity in comparison to a l  homomers (Khiroug et a/., 2002).
1.5.3 Influence of the host cell environment
The nature of the host cell environment is able to significantly affect the appropriate 
folding, assembly and cell surface expression of nAChRs and has been clearly 
demonstrated by observing expression of homomeric a l  and a8 nAChRs in mammalian 
cell lines (Blumenthal et al., 1997; Cooper and Millar, 1997; Cooper and Millar, 1998; 
Sweileh et al., 2000). While subunit protein can be detected in a variety of mammalian 
cell lines following transfection with a l  or a8 cDNA, correctly folded cell surface 
nAChRs are only detected in certain cell lines, such as human neuroblastoma SH-SY5Y 
cells. In contrast, misfolding in human embryonic kidney HEK293 cells, results in
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subunit aggregation and retention in the endoplasmic reticulum (Cooper and Millar, 
1997; Cooper and Millar, 1998). The effect of the host cell is also apparent between 
separate isolates of the same cell line (Blumenthal et al., 1997). For example, three 
isolates of rat PC 12 cells revealed differences in the ability to express functional al 
homomers, but were each able to express heteromeric ion channels (Blumenthal et al.,
1997). In addition, cells within the same cell line isolate can demonstrate differences in 
their ability to express cell surface nAChRs (Cooper and Millar, 1998).
Nicotinic receptors are synthesised in the endoplasmic reticulum, where a variety of 
post-translational processing events can occur, including glycosylation, formation of 
disulphide bonds, proteolytic cleavage and phosphorylation (Green and Millar, 1995). 
Post-translational modification can affect subunit folding and assembly. For example, 
disruption of cysteine residues involved in the formation of disulphide bonds reduces the 
efficiency of subunit folding (Green and Wanamaker, 1997).
Cell-specific folding is not a characteristic of the 5HT3A receptor and the relatively 
inefficient folding and cell-surface expression of several nicotinic subunits can be 
enhanced through construction of subunit chimeras in which the C-terminal region of the 
nicotinic subunit is replaced with the corresponding region of the 5HT3A subunit (Cooper 
and Millar, 1997; Cooper and Millar, 1998; Cooper et al., 1999; Rakhilin et a l , 1999; 
Harkness and Millar, 2002). Chimeric subunits containing the N-terminal region of the 
al and a8 subunits, fused to the C-terminal domain of the 5HT3A receptor subunit 
(Eisele et al., 1993; Cooper and Millar, 1998) readily form high levels of cell surface a- 
BTX binding sites in cell types which inefficiently fold wild-type subunits (Cooper and 
Millar, 1997; Cooper and Millar, 1998).
An enhancement of nAChR cell surface expression can also be achieved by incubation 
of transfected cells at lower temperature. Transfected HEK293 cells are generally 
cultured at 37°C, but incubation at 30°C has revealed a 5-fold upregulation of cell 
surface cc4|32 nAChRs, while the total cellular protein levels remain unchanged (Cooper
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et al., 1999). At lower temperatures, the rate of subunit turnover may be slowed, with a 
reduction in the rate of protein degradation. Such observations may also help to explain 
why heterologous expression of nAChRs has been most successful in Xenopus oocytes, 
in which proteins are expressed at 18°C, in comparison to mammalian cell lines 
incubated at 37°C.
1.5.4 Interaction of nAChRs with intracellular proteins
Identification of proteins that interact with nAChR subunits may provide a valuable 
insight into proteins or mechanisms involved in aspects of nAChR folding, assembly and 
cell surface expression as well as revealing aspects of signal transduction. For example, 
a 43-kDa protein, rapsyn, co-localises with muscle-type nAChRs and is involved in 
nAChR clustering at the postsynaptic membrane of the neuromuscular junction (Sealock, 
1982; Froehner, 1991; Sanes and Lichtman, 2001; Moransard et al., 2003). In muscle, it 
is suggested that pre-assembled rapsyn-nAChR complexes appear at the cell surface and 
are driven to clustering via a tyrosine kinase-dependent pathway, induced by agrin 
released from the motor nerve terminal (Sanes and Lichtman, 2001; Moransard et a l , 
2003).
The intracellular loop region of the nAChR subunits, positioned between M3 and M4, 
contains potential sites for protein phosphorylation. Tyrosine kinase can phosphorylate 
the p, y and 8 subunits of the Torpedo electric organ nAChR (Huganir et al., 1984) and 
cAMP-dependent kinase (PKA) phosphorylates the y and 8 subunits (Huganir and 
Greengard, 1983). Phosphorylation may influence nAChR desensitisation. For example, 
stimulation of protein kinase C (PKC), through addition of a phorbol ester to mouse or 
chick embryonic muscle cells, increases the rate of nAChR desensitisation and affects 
channel conductance upon application of agonist (Eusebi et a l , 1987). Application of 
forskolin, which activates adenylate cyclase and subsequently PKA, causes 
desensitisation of muscle nAChRs without affecting channel conductance and causes 
nAChR upregulation (Seamon et al., 1981; Albuquerque et al., 1986; Gopalakrishnan et
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al., 1997). Therefore, receptor phosphorylation at separate sites with PKC and PKA has 
different effects on nAChR function.
Recently, the activity of recombinant a l  nAChRs has been enhanced through co­
expression with the product of the RIC-3 gene (Halevi et al., 2002; Halevi et al., 2003). 
RIC-3 (resistant to inhibitors of cholinesterase) was identified during screening of genes 
required for nAChR activity in Caenorhabditis elegans and both C. elegans and human 
Ric-3 homologues have been cloned (Halevi et al., 2002; Halevi et al., 2003). The Ric-3 
protein contains two putative transmembrane domains, with the N- and C-termini 
predicted to be intracellular, suggesting that Ric-3 is located on membranes. Ric-3 
enhances the ACh-evoked whole cell currents in Xenopus oocytes expressing certain C. 
elegans nAChRs or expressing mammalian a l  nAChRs (Halevi et al., 2002; Halevi et 
al., 2003), though whether the effect of Ric-3 on nAChR activity is the result of a direct 
interaction between the proteins has not been demonstrated.
1.6 nAChR function in the central nervous system
Nicotine exerts a number of effects in the central nervous system, with administration of 
acute or chronic levels of nicotine in humans observed to enhance visual attention, 
perception and arousal (Jones et al., 1999). Post-synaptic nAChRs involved in control of 
fast ACh-gated synaptic transmission (Section 1.6.1) are observed in the hippocampus 
and sensory cortex and are likely to be important in aspects of cognitive function (Levin 
and Simon, 1998; Jones et al., 1999). Both the a l  and a4|32 nAChR subtypes have been 
implicated in memory and learning (Levin and Simon, 1998). The high Ca2+ permeability 
of nAChRs supports a role in regulation of early gene expression, providing a route for 
the entry of calcium at negative potentials at which NMDA receptors and voltage-gated 
calcium channels would be closed. The nAChR-mediated influx of Ca2+can cause 
activation of second messenger cascades, which could play a role in a number of diverse 
functions including neuronal survival (Section 1.6.4) and neurotransmitter release 
(Section 1.6.3).
49
1.6.1 The role of postsynaptic nAChRs
The mediation of cholinergic transmission by postsynaptic nAChRs is well documented 
in autonomic ganglia and at the efferent synapse of the cochlea hair cells (Role and Berg,
1996). Nicotinic receptors expressed in outer hair cells of the cochlea are involved in 
modulating auditory nerve responses to acoustic stimulation and in protection from 
acoustic overstimulation (Sridhar et al., 1997; Luebke and Foster, 2002; Maison et al., 
2002). In hair cells, a9-containing nAChRs function in association with calcium- 
activated potassium (K^) channels, coupling entry of Ca2+ to the efflux of K+. The 
resulting hyperpolarisation of outer hair cells causes a decrease in the amplification of 
basilar membrane motion, decreasing stimulation of the inner hair cells and resulting in 
suppression of the sound-evoked afferent discharge (Housley and Ashmore, 1991; Fuchs 
and Murrow, 1992; Maison et al., 2002).
Identification of postsynaptic sites involved in cholinergic transmission in the brain has 
proved much more elusive than in the peripheral nervous system. Nicotinic receptors 
have been identified at postsynaptic sites on hippocampal intemeurones and may include 
a7-containing nAChRs, as nicotine induced currents can be blocked by a-BTX and 
MLA (Hunt and Schmidt, 1978; Jones et al., 1999). The minimal evidence for 
postsynaptic receptors suggests a role for nAChRs in aspects of brain function other than 
direct synaptic transmission (Role and Berg, 1996).
1.6.2 The role of presynaptic nAChRs
The primary roles for nAChRs in the central nervous system have been suggested to 
involve presynaptic functions, such as indirect mediation of synaptic transmission 
through subtle modulation of neurotransmitter release (Role and Berg, 1996; Wonnacott, 
1997; Levin and Simon, 1998). For example, high affinity nicotine binding sites are 
observed on the terminals of dopamine neurones in the striatum (Wonnacott, 1997;
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Wonnacott et al., 2000). Cytisine is a partial agonist of these nAChRs in rat brain, 
suggesting the presence of an a4p2-containing nAChR subtype. However, antagonism 
of receptors with n-BTX in striatal preparations suggests a role for a3-containing 
nAChRs in presynaptic modulation of dopamine release (Wonnacott, 1997), so it is 
possible that a heterogeneous population of presynaptic nAChRs exists.
In addition to the heteroreceptors observed on nerve terminals involved in release of 
neurotransmitters such as dopamine, presynaptic receptors on cholinergic nerve 
terminals may serve as autoreceptors to modulate ACh-release via a feedback 
mechanism. Stimulation of autoreceptors following release of ACh from the nerve 
terminal could lead to the mobilisation of ACh from a reserve store to a readily 
releasable store, so the availability of neurotransmitter corresponds to the demand for its 
release (Wonnacott, 1997).
An alternative role for presynaptic nAChRs is in the modulation of other functional 
aspects at the nerve terminal. Nicotinic receptors are observed on growth cones, where 
they respond to ACh released by the growth cone and may participate in the regulation 
of neurite outgrowth (see Role and Berg, 1996; Wonnacott, 1997). When the extending 
neurite reaches a postsynaptic target, the subsequent increase in ACh release may signal 
an end to growth and the ensuing stabilisation and maturation of the synapse. Receptors 
containing a l  appear to be involved in this function, with their high Ca2+-permeability 
playing a role via activation of Ca2+-dependent signalling cascades (Lev et al., 1995).
Tetrodotoxin (TTX) blocks voltage-gated sodium channels and, therefore, blocks the 
propagation of an action potential along the axon of a neurone. TTX can be used to 
distinguish between the modulation of neurotransmitter release by presynaptic nAChRs, 
which are insensitive to TTX treatment and transmitter release modulated by TTX- 
sensitive preterminal nAChRs. Facilitation of GAB A release from CA1 intemeurones of 
the hippocampus by ACh and choline is sensitive to TTX treatment and attributed to
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nAChRs in preterminal locations (Alkondon et al., 2000). The choline-induced increase 
in GABA-mediated postsynaptic current is blocked by MLA so may correspond to a7- 
containing nAChRs, while the block of the ACh-induced current by dihydro-|3- 
erythroidine (DHpE), but not by MLA, is more suggestive of an a4p2 nAChR subtype.
1.6.3 Tobacco dependence
Tobacco smoking in humans and nicotine self-administration in animals appears to be 
associated with an increase in dopamine release that follows the action of nicotine upon 
mesencephalic dopaminergic neurones (see Lena and Changeux, 1998). Addictive drugs 
can exploit the intrinsic reward pathways of the nervous system that mediate the 
reinforcing effects of natural rewards such as food, by increasing dopamine-mediated 
activity (Jones et al., 1999).
The mesolimbic dopaminergic system has its origins in the dopaminergic neurones of the 
ventral tegmental area (VTA) of the midbrain. The VTA projects to the nucleus 
accumbens (NAc), amygdala and limbic cortex. The VTA and its target NAc are 
thought to play a major role in reward and nicotine may induce an increase in dopamine 
transmission in the NAc (Raggenbass and Bertrand, 2002). The majority of neurones in 
the VTA possess P2-containing nAChRs and nicotine-induced dopamine release in the 
NAc does not occur in P2 knockout mice. In addition, P2'A mice do not self-administer 
nicotine following priming with cocaine, suggesting that the P2 subunit is involved in 
nicotine addiction (Picciotto et al., 1998).
Glutamatergic transmission from the prefrontal cortex provides excitatory control of 
VTA neurone activity and hence dopamine output in the reward pathway and may be 
under the modulatory influence of nicotine (see Mansvelder and McGehee, 2000). Block 
of a7-containing nAChRs in VTA neurones with MLA prevents nicotine-induced 
increases in dopamine release. Somatic nAChRs can directly excite VTA dopaminergic
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neurones, but nAChR desensitisation means that this excitation is transient. However, 
activation of presynaptic a7-containing nAChRs present on glutamatergic terminals 
appears to promote long term potentiation (LTP) of the excitatory input from prefrontal 
cortex to the VTA, leading to more persistent elevations in dopamine release in the NAc 
that are independent of nAChR desensitisation (Mansvelder and McGehee, 2000). 
Stimulation of presynaptic nAChRs in the VTA promotes Ca2+ influx into the 
glutamatergic terminal, enhancing release of glutamate. The increase in glutamate 
release causes increased Ca2+ entry into postsynaptic dopaminergic neurones and 
subsequent induction of LTP and hence, long term excitation of areas of the brain 
involved in reward (Mansvelder and McGehee, 2000). A relatively short exposure to 
nicotine may cause long-lasting changes in the reward pathway of the brain, correlating 
to an early stage in nicotine addiction.
VTA neurones also receive innervation from GABAergic intemeurones and from 
afferent projections from the NAc (see Mansvelder et al., 2002). The afferent 
projections from the NAc possess nAChRs that demonstrate desensitisation 
characteristics distinct from the a7-containing nAChRs of the glutamatergic nerve 
terminals in the VTA and are thought to comprise a4P2 nAChRs. Therefore, the 
glutamatergic and GABAergic inputs would respond differently to a nicotine stimulus 
that may occur during tobacco smoking (Mansvelder et al., 2002)
During chronic tobacco smoking, low concentrations of nicotine can cause an increase in 
nAChR number, demonstrated by an increase in the density of nicotinic ligand binding 
sites in the postmortem brain tissue of smokers (Benwell et al., 1988) and in the brains of 
animals following chronic exposure to nicotine (Marks et al., 1985; Schwartz and Kellar, 
1985; Flores et al., 1992; Marks et al., 1992). These upregulated nAChRs accumulate in 
a deep state of desensitisation (Peng et al., 1997; Fenster et al., 1999) and the 
inappropriate changes in nAChR number could be important in mechanisms of nicotine 
addiction.
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Not all nAChR subtypes are upregulated to the same extent and chronic nicotine 
exposure affects various nAChR subtypes differently (Olale et al., 1997; Molinari et a l,
1998). The substantial desensitisation of a4|32 and a l  nAChRs contrasts to the effects 
of chronic nicotine on a3-subtypes and may reflect differences in the sensitivities of the 
nAChR subtypes for activation by nicotinic agonists (Hsu et al., 1996; Olale et al.,
1997). In Xenopus oocytes, recombinant a l  nAChRs demonstrate the lowest sensitivity 
for acute activation by nicotine compared to a4(32- and cx3-containing nAChRs, but 
show the highest sensitivity to inactivation by exposure to prolonged low concentrations 
of nicotine, probably reflecting the rapid desensitisation characteristic of a l  nAChRs. In 
a chronic smoker, blood plasma levels of nicotine of 100 - 500 nM (Lena and Changeux,
1998) would be sufficient to inactivate virtually all a4fl2 nAChRs, ~ 90% of a l  nAChRs 
and 20% of a3-containing nAChRs (Olale et a l, 1997). This suggests that the 
behavioural effects, such as withdrawal and tolerance and the reward associated with 
tobacco smoking, depend on a l  and a4P2 nAChRs (Olale et al., 1997).
1.6.4 Pathology
In addition to their involvement in complex brain function, nAChRs are implicated in the 
pathogenesis of several neurological disorders. A decrease in high affinity nicotine 
binding is a characteristic of several forms of neurodegenerative disease, including 
Alzheimer's disease, Parkinson's disease, Lewy-body disease and Downs syndrome 
(Picciotto and Zoli, 2002). While the brain areas showing a reduction in nicotine binding 
sites correlate to areas demonstrating neuronal loss, the disappearance of nAChRs 
appears to be more prominent than the loss of neurones, suggesting that the loss of 
nAChRs precedes neurodegeneration (Perry et a l, 1995).
Aged P2*A mice do not express high affinity [3H]-nicotine binding sites (Picciotto et al.,
1995) and show a loss of neurones in several brain regions in a manner resembling 
neurodegenerative disease (see Clementi et al., 2000), suggesting that nAChRs provide
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protection against neurodegenerative disorders during the ageing process (Picciotto and 
Zoli, 2002). This is consistent with epidemiological data that suggests chronic smoking 
can have neuroprotective effects and reduces the incidence of Parkinson's disease 
(Morens et al., 1995). In addition, drug-induced neurotoxicity in cultured neurones can 
be alleviated through exposure to nicotine (Quik and Jeyarasasingam, 2000; Picciotto 
and Zoli, 2002). However, nicotine can be toxic to cells, particularly developing 
neurones, perhaps due to the inability of immature cells to cope with the increased 
calcium load (Picciotto and Zoli, 2002). The administration of nicotine may also 
influence whether the effect is protective or toxic, where extreme doses or continuous 
infusion of nicotine may prove toxic, while intermittent nicotine exposure, more likely to 
occur in the brains of smokers, may demonstrate a more protective effect (Picciotto and 
Zoli, 2002).
Patients with autosomal dominant frontal lobe epilepsy (ADNFLE) experience brief, 
clustered nocturnal motor seizures and are often misdiagnosed as suffering from sleep 
disorders. The clinical onset is usually in childhood and the disease often persists 
throughout adult life. Mutations have been identified in CHRNA4, the gene encoding the 
a4 nAChR subunit, which is expressed in all layers of the frontal cortex. Two missense 
mutations (S248F and S252L) in the M2 domain (involved in cation selectivity) of the 
a4 subunit were identified in families with ADNFLE. Functional studies have shown 
that the efficacy of the a4-S248F mutant channel is altered with respect to loss of Ca2+ 
permeability, increased desensitisation and reduced channel open-time and conductance 
(Weiland et al., 1996). Two other mutations (V287L and V287M) have been found in 
CHRNB2, which encodes the nAChR 02 subunit. These mutations also affect the pore- 
forming M2 region, but in this case, the mutant nAChRs appear to be more sensitive to 
ACh and give larger responses with less desensitisation (Rodrigues-Pinguet et al., 2003). 
The absence of seizures in a4 '/' and §2'' mice also implicate the cc402 subtype in the 
pathology of epilepsy (Picciotto et al., 1998; Marubio et al., 1999).
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1.7 Aim of this study
This thesis describes experiments aimed at gaining a better understanding of nAChR 
assembly, subunit composition and pharmacology through heterologous expression of 
cloned nAChR subunits in mammalian cell lines. Heterologous expression is a valuable 
method to study neurotransmitter-gated ion channels, but expression of nAChRs in 
cultured cell lines has proved extremely challenging. Difficulties reported in the 
expression of recombinant a7 or a8 nAChRs in cultured cell lines (Puchacz et al., 1994; 
Quik et al., 1996; Cooper and Millar, 1997; Rangwala et al., 1997; Cooper and Millar, 
1998; Sweileh et al., 2000) have led to the conclusion that appropriate subunit folding 
and assembly events are influenced strongly by the nature of the host cell type (Millar, 
1999; Sivilotti et al., 2000).
To overcome some of the challenges of recombinant nAChR expression in mammalian 
cells, the construction of a series of chimeric subunit cDNAs, containing the N-terminal 
domain of each rat nAChR subunit fused to the C-terminal domain of the 5HT3A receptor 
subunit, will be examined. Previously constructed a7/5HT3A or a8/5HT3A chimeric 
receptors assemble efficiently in cells in which wild-type nAChRs misfold (Eisele et al., 
1993; Cooper and Millar, 1998). Receptor assembly and subunit composition is 
investigated via expression of wild-type and chimeric subunits in mammalian cells and 
through detection of radioligand binding sites. The sub-cellular distribution of chimeric 
receptors is analysed through detection of epitope-tagged subunits in mammalian cells 
via enzyme-linked assays and by radioligand binding to intact cells. Pharmacological 
profiles for chimeric receptors are constructed by competition radioligand binding and 
compared to those of wild-type recombinant or native nAChRs to assess the validity of 
chimeras as models for nAChR characterisation.
Understanding the mechanisms that govern nAChR assembly and function should aid the 
elucidation of the mechanisms by which neurones achieve the accurate assembly of 
complex oligomeric nAChRs. Characterisation of nAChRs is pivotal to understanding 
their functional roles in the human brain and their potential as therapeutic targets for 
neurological disorders.
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CHAPTER 2 
MATERIALS AND METHODS
All tissue culture media was obtained from Gibco BRL and all biochemicals were 
obtained from BDH unless otherwise specified.
2.1 PLASMID CONSTRUCTS AND SUBCLONING
2.1.1 Competent Cells
In general, plasmid constructs were transformed into chemocompetent XLI-Blue 
Escherichia coli (E. coli) cells (Stratagene). When subcloning required digestion with 
the dam methylation sensitive restriction enzyme, BelI, the dcm-/dam- E. coli strain, 
GM2163 was used (Dr. Ralf Schoepfer, University College London). When the 
construct being amplified was within the plasmid expression vector, pCDNAlneo, E. 
coli strain MC1061 was used, which contains a P3 episome. The P3 episome encodes 
the wild-type kanamycin resistance gene and amber mutations in the ampicillin and 
tetracycline resistance genes. Plasmid pCDNAlneo encodes the SupF suppressor 
transfer RNA (tRNA), which suppresses the amber mutations so that transformants can 
be selected with ampicillin and tetracycline.
Competent cells were generated according to the supplier's instructions. Cells from an 
agar stab were streaked onto SOB agar plates (20 g/L tryptone, 5 g/L yeast extract, 0.5 
g/L NaCl, 2.5 mM KC1, 10 mM MgCl2, 15 g/L agar) and grown at 37°C for ~ 17 h. A 
scraping of cells from the plate was used to inoculate 500 ml SOB media (20 g/L 
tryptone, 5 g/L yeast extract, 0.5 g/L NaCl, 2.5 mM KC1, 10 mM MgCl2). The 
inoculated culture was grown at 37°C with shaking at 200 rpm until the optical density at 
550 nm (OD550) reached 0.5 - 0.55. Cells were pelleted by centrifugation at 2500 rpm 
(960 x g) for 15 min at 4°C in a Beckman J2-M1 centrifuge using a JA-14 rotor. The
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cell pellet was resuspended in 40 ml ice-cold RF1 solution (100 mM RbCl, 50 mM 
MnCl2.4H20 , 30 mM potassium acetate, 10 mM CaCl2.2H20 , 15% (w/v) glycerol, pH 
adjusted to 5.8 with 1 M acetic acid, filter sterilised (0.22 Jim)) and incubated on ice for 
15 min. Cells were pelleted by centrifugation at 2500 rpm for 9 min and the cell pellet 
resuspended in 7 ml ice-cold RF2 solution (10 mM RbCl, 10 mM 3-N- 
morpholinopropanesulphonic acid (MOPS), 75 mM CaCl2.2H20 , 15% (w/v) glycerol, 
pH adjusted to 6.8 with 1 M NaOH, filter sterilised (0.22 pm)) and incubated on ice for 
15 min. Aliquots of competent cells were snap frozen in a dry ice/ethanol bath and 
stored at -70°C.
2.1.2 Polymerase chain reaction (PCR)
Polymerase chain reaction (PCR) thermocycling was performed in a Peltier Thermal 
Cycler, PTC-225 (MJ Research). Typical reactions were performed in 20 jul volumes 
and contained 10 - 20 ng plasmid DNA, 250 pM dNTPs, 0.25 pM forward and reverse 
primers and 2.5 U Pfu polymerase (Stratagene) in IX Pfu polymerase reaction buffer. 
Pfu polymerase was only used for the generation of PCR fragments for use in subcloning 
reactions. For standard PCR carried out as a diagnostic test, Taq polymerase 
(Stratagene) was used and reactions supplemented with 2.5 mM MgCl2 in IX Taq 
polymerase reaction buffer. Pfu polymerase possesses both 5-3' DNA polymerase and 
3'-5' exonuclease proof-reading activity, resulting in a 12-fold increase in DNA synthesis 
fidelity compared with Taq polymerase, which exhibits 5'-3' exonuclease activity.
Typical reactions for the generation of fragments for use in subcloning involved a 5 min 
denaturation step at 95°C, followed by thermocycling with denaturation at 95°C for 30 
sec, annealing at 55°C for 30 sec and extension at 72°C for 90 sec, repeated for 30 
cycles. A final extension step was carried out at 72°C for 5 min.
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2.1.3 Restriction digestion of DNA
Typically, 2 - 3 pg plasmid DNA was subjected to digestion with 5 - 10 U restriction 
enzyme in a 20 - 30 pi reaction volume containing IX reaction buffer compatible with 
the specific enzyme. Digests were incubated for 1 h at the incubation temperature 
required for optimal enzyme activity (usually 37°C, but some enzymes require 
incubation at 25°C or 55°C). For double digests in which the reaction buffers of the two 
enzymes were incompatible, digestion with the first enzyme was carried out in a 20 pi 
reaction volume for 1 h. The reaction mix was then diluted to 60 pi with milli-Q (MQ) 
water, the second reaction buffer added to a IX final concentration and the digestion 
continued with the second enzyme for 1 h.
2.1.4 Dephosphorylation of DNA
When subcloning strategies involved digestion with a single enzyme, 5'-phosphate 
groups were removed from the digested DNA using calf intestinal alkaline phosphatase 
(CIAP; Promega) to prevent re-ligation of the plasmid vector. Typically, 2 - 3 pg 
digested plasmid DNA was incubated with 0.2 U CIAP for 30 min at 37°C. A further 
0.2 U CIAP was added and the samples incubated again at 37°C for 30 min. For 
dephosphorylation of DNA with 5' recessed or blunt ends, DNA was incubated with 
CIAP at 37°C for 15 min, then at 56°C for 15 min to ensure accessibility of the recessed 
ends. A second aliquot of CIAP was added and the samples incubated at 37°C for a 
further 15 min, then at 56°C for 15 min.
2.1.5 Agarose gel electrophoresis and DNA purification
Agarose gel electrophoresis allows the visualisation and separation of digested plasmid 
DNA or PCR products according to molecular weight. Restriction enzyme digests or 
PCR products were separated by electrophoresis through 1% agarose gels (GibcoBRL)
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and run against 1 pg HindUl digested Lambda (X) DNA standard markers (Invitrogen) in 
order to estimate the relative size of the DNA bands. When the DNA fragments were 
required for further subcloning steps, low melting point agarose gels were used to allow 
subsequent purification. DNA bands were excised from the gel with a scalpel and 
transferred to microfuge tubes. DNA was extracted from the gel slices using the 
Wizard™ DNA clean-up system (Promega) according to the manufacturer's instructions. 
Briefly, the gel slices are dissolved in 1 ml Wizard™ DNA Clean-Up Resin and forced 
through a mini-column using a 2 ml syringe. DNA bound to the column is washed with 
2 ml isopropanol and the excess isopropanol removed by centrifugation at 13000 rpm for 
2 min in a bench-top microfuge. The DNA is eluted in 50 pi pre-warmed (65°C) MQ 
water, by centrifugation for 1 min at 13000 rpm. 5 pi purified DNA was run on a 1% 
agarose gel against HindUl digested X DNA to assess the yield.
2.1.6 DNA Ligations
Ligation reactions typically contained a molar ratio of vector:insert of 1:3 in a reaction 
volume of 10 pi. Background levels of re-ligated vector were assessed through control 
reactions in which insert was substituted with MQ water. Reactions contained 1 mM 
ATP and 0.5 U T4 DNA ligase (Roche) and were incubated at 16°C overnight.
2.1.7 E. coli Transformations
2 pi ligation mixture or 1 - 20 ng plasmid DNA was added to 50 pi chemocompetent 
cells in a 5 ml polypropylene transformation tube (Falcon) pre-chilled on ice. The DNA 
and competent cells were mixed gently by swirling and incubated on ice for 30 min. The 
cells were subjected to heat-shock at 42°C for 90 sec and allowed to recover for 2 min on 
ice. 600 pi SOC medium (20 g/L tryptone, 5 g/L yeast extract, 0.5 g/L NaCl, 2.5 mM 
KC1, 10 mM MgCl2, 20 mM glucose, sterilised by autoclaving at 10 lb./sq. in. for 15 
min) was added to the cells and the tubes incubated at 37°C with shaking at 200 rpm for
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1 h to allow expression of the plasmid's antibiotic resistance gene. 20 - 200 |xl aliquots 
of transformation mixture were plated onto Luria-Bertani (LB)-agar plates (10 g/L 
tryptone, 5 g/L yeast extract, 10 g/L NaCl, pH 7.0 using NaOH, 15 g/L agar) containing 
inhibitory concentrations of an appropriate antibiotic (50 jig/ml ampicillin ±10 |ig/ml 
tetracycline) and grown at 37°C overnight (~ 17 h).
2.1.8 Screening colonies
Individual colonies were picked from the agar plates and screened for the presence of the 
correct DNA construct either by PCR or by extraction of DNA and subsequent 
restriction mapping. In a typical PCR of bacterial colonies, thermocycling steps 
followed a 5 min denaturation step to help lyse the bacterial cells and involved 
denaturation at 95°C for 30sec, annealing at 55°C for 30 sec, extension at 72°C for 60 
sec, repeated for 30 cycles. A final extension step was carried out at 72°C for 5 min.
Where PCR was an inappropriate screening method, small scale, miniature preparations 
(mini-preps) of plasmid DNA were extracted via an alkaline lysis method (Sambrook et 
a l , 1989). 2 ml aliquots of LB medium (10 g/L tryptone, 5 g/L yeast extract, 10 g/L 
NaCl, pH 7.0 using NaOH) were inoculated with individual bacterial colonies and grown 
at 37°C with shaking at 225 rpm overnight. Bacterial cultures were pelleted by 
centrifugation at 13000 rpm for 1 min in a bench-top microfuge. Pellets were 
resuspended in 100 jLtl ice-cold Solution I (50 mM glucose, 25 mM Tris/Cl pH 8.0, 10 
mM EDTA pH 8.0, autoclaved at 10 lb./ sq. in. for 15 min) and lysed with the addition 
of 200 p,l Solution II (0.2 M NaOH, 1% SDS), mixing gently by inversion. 150 jil ice- 
cold Solution m  (per 100 ml: 60 ml 5 M potassium acetate, 11.5 ml glacial acetic acid, 
28.5 ml MQ water) was added and mixed to halt the lysis reaction and induce 
precipitation of chromosomal DNA. Samples were incubated on ice for 5 min and 
centrifuged at 13000 rpm, 5 min. The supernatant was phenol:chloroform (1:1, pH 8.0) 
extracted and ethanol precipitated, incubating in 2X volumes of 99% ethanol for 2 min at
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room temperature. Samples were centrifuged for 5 min at 13000 rpm and the DNA 
pellets washed in 1 ml ice-cold 70% ethanol. Air-dried pellets were resuspended in 50 
til Tris-EDTA (TE) buffer, pH 8.0, containing 10 pg/ml RNase A (DNase-free, Sigma). 
Positive clones were identified by restriction mapping and subsequent agarose gel 
electrophoresis.
2.1.9 Large-scale preparation of plasmid DNA
Single E. coli colonies containing plasmid DNA were used to inoculate 250 ml LB 
medium cultures for large-scale plasmid DNA purification using Qiagen™ Plasmid 
Maxi Kit purification columns. Bacterial cultures were pelleted by centrifugation in a 
Beckman J2-M1 centrifuge for 10 min at 6000 rpm (6000 x g), 4°C using a JA-14 rotor. 
Pellets were resuspended in 10 ml ice-cold Buffer PI (50 mM Tris-Cl pH 8.0, 10 mM 
EDTA, 100 pg/ml RNase A) and lysed with incubation in 10 ml Buffer P2 (200 mM 
NaOH, 1% (w/v) SDS) for 5 min at room temperature. Lysis was terminated and 
precipitation initiated by addition of 10 ml ice-cold Buffer P3 (3 M potassium acetate, 
pH 5.5), incubating on ice for 20 min. Samples were centrifuged at 13000 rpm (> 20000 
x g) for 30 min at 4°C in a JA14 rotor. Sample supernatants were added to the Qiagen™ 
purification columns to extract the plasmid DNA following equilibration of the columns 
through addition of 10 ml Buffer QBT (750 mM NaCl, 50 mM MOPS pH 7.0, 15% (v/v) 
isopropanol). DNA bound to the columns was washed twice in 30 ml Buffer QC (1 M 
NaCl, 50 mM MOPS pH 7.0, 15% (v/v) isopropanol) and eluted in 15 ml Buffer QF 
(1.25 M NaCl, 50 mM Tris-Cl pH 8.5, 15% (v/v) isopropanol). Plasmid DNA was 
precipitated with 0.7 volumes (10.5 ml) isopropanol via centrifugation at 10500 rpm (> 
15000 x g) for 30 min at 4°C in a JA17 rotor. DNA pellets were washed in ice-cold 70% 
ethanol and resuspended in 1 ml sterile MQ water. DNA purity and concentration was 
determined by measurement of absorbance at 260 nm (A260) and 280 nm (A280) in a BIO­
RAD SmartSpec™ 3000 spectrophotometer. A260 = 1 represents approximately 50 pg/ml 
double stranded DNA. An A ^A ^q ratio of 1.6 - 2.0 indicates a pure DNA preparation.
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Ratios significantly less than 1.6 indicate protein contamination and ratios greater than 
2.0 indicate salt impurities. Maxi prep DNA of positive clones was analysed by 
restriction mapping and sequencing (Section 2.4).
2.1.10 Plasmid expression vectors
Expression
Vector
Promoter Inducible/
Constitutive
Poly-A
Signal
Prokaryotic
Selection
Eukaryotic
Selection
pBSSK LacZ Constitutive Ampicillin -
pCDM6xl CMV Constitutive SV40 *SupF
(amp/tet)
pcDNAlneo CMV Constitutive SV40 Kanamycin
*SupF
(amp/tet)
Neomycin
(G418)
pcDNA3neo CMV Constitutive Bgh Kanamycin
Ampicillin
Neomycin
pClneo CMV Constitutive SV40 Ampicillin Neomycin
pRK5 CMV/SP6 Constitutive SV40 Ampicillin -
pZeoSV2(+) SV40 Constitutive SV40 Zeocin Zeocin
Table 2.1. Summary of the plasmid expression vectors used in this study.
Abbreviations: amp, ampicillin; Bgh, bovine growth hormone; CMV, cytomegalovirus; 
poly-A, polyadenylation; SV40, Simian virus; tet, tetracycline
*SupF: Plasmid constructs expressing SupF transfer RNA require growth in a bacterial 
strain such as MC1061 that contains the P3 episome. The P3 episome contains amp and 
tet selectable markers, containing amber mutations and is corrected by the SupF transfer 
RNA.
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2.1.11 Plasmid constructs
The rat a2, a3, a4, a5, a6, a7, p2, P3 and p4 subunit cDNAs were provided by Dr. Jim 
Patrick, Baylor College of Medicine, Houston. Dr. David Julius, University of 
California, provided the mouse 5HT3A subunit cDNA (Maricq et a l , 1991) in the 
mammalian expression vector pCDM6xl. The 5HT3A gene was excised from pCDM6xl 
with the restriction enzyme Xbal and subcloned into the Xbal site of the mammalian 
expression vector pRK5.
The rat nAChR a9 and alO subunit cDNAs (Elgoyhen et a l , 1994; Elgoyhen et a l, 
2001) in the mammalian expression vector pClneo, were provided by Dr. Jim Boulter, 
Los Angeles, CA and Dr. Belen Elgoyhen, Buenos Aires, Argentina, respectively. The 
a9 cDNA was excised from pClneo with Xbal (5') and HindUl (3') and subcloned into 
the Xbal (5') / HindUl (3') sites of pRK5. The alO sequence was excised from pClneo 
with Smal (5') and Sail (3') and subcloned into the Smal (5') / Sail (3') sites of pRK5.
2.2 CONSTRUCTION OF CHIMERIC cDNA
Chimeric subunit cDNAs similar to a7(V201)/5HT3A described previously (Eisele et a l, 
1993; Cooper and Millar, 1998) were constructed containing the extracellular N-terminal 
domain of the nAChR subunits (a2, a3, a4, a5, a6, a9, alO, P2, P3 and P4), fused to 
the transmembrane and intracellular domain of the mouse 5HT3A subunit in the 
mammalian expression vector, pRK5. The a3/5HT3A, a4/5HT3A, a5/5HT3A, P2/5HT3A, 
P3/5HT3A and P4/5HT3A chimeras were constructed during an undergraduate research 
placement, prior to this PhD project, but details of their construction are included to 
allow direct comparison with the other chimeras. For specific details of the construction 
of the chimeras, see Section 3.2. For brevity, chimeras are referred to using the Greek 
letter, chi (%).
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Each nAChRs/5HT3A chimera was generated from an original a7(V201)/5HT3A chimera 
created by Dr. Sandra Cooper (this laboratory) in the pZeoSV expression vector (Cooper 
and Millar, 1997), subsequently subcloned into pRK5. In generating the pZeoSV- 
a7(v2oi)/5HT3A chimera, Dr. Cooper subcloned a7(V201)/5HT3A into pZeoSV(+) at HindUl 
(5') and BelI (3') sites, joining the a l  and 5HT3A subunit fragments at a BelI site at 
residue V201 of the a l  sequence.
The a7(V201)/5HT3A sequence was excised from the pZeoSV(+) mammalian expression 
vector with EcoRI (5') and Seal (3') and subcloned into the EcoBl (5') / Smal (3') sites of 
the pRK5 expression vector to produce pRK5-a7(V201)/5HT3A (a7%). The pRK5 plasmid 
was used to simplify the subcloning strategy as it does not contain a BelI site 
(T/GATCA). A unique BelI site was introduced to each nAChR cDNA at a position 
analogous to V201 in the a l  sequence, just prior to M l, by silent mutagenesis using 
PCR. Details of the primers used are listed in Table 3.2. PCR thermocycling was 
performed as detailed in Section 2.1.2. PCR fragments were ethanol precipitated by the 
addition of l/10th volume 3 M sodium acetate (pH 5.2) and 2 volumes 99% ethanol. 
Samples were chilled at -20°C for 1 h and centrifuged at 13000 rpm in a bench-top 
microfuge. DNA pellets were washed with 70% ethanol and resuspended in 50 \i\ MQ 
water.
Ethanol precipitated PCR products were digested with a suitable 5' restriction enzyme 
and BelI (3’). The a l  portion of pRK5-a7(V201)/5HT3A was removed by restriction 
enzyme digest to produce a pRK5-/5HT3A cloning cassette. Gel purified nAChR 
fragments were cloned into the pRK5-/5HT3A cloning cassette to create the pRK5- 
nAChR/5HT3A subunit chimeras (Section 3.2). The fidelity of the chimeric constructs 
was verified by restriction mapping and sequencing.
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2.3 CONSTRUCTION OF HA-EPITOPE TAGGED SUBUNITS
Epitope tags were introduced to the sequence of the a9, alO, a9% and a  10% subunit 
cDNAs to allow detection of these subunits expressed in mammalian cells with an 
antibody raised to the epitope tag. A nine amino acid epitope tag (YPYDVPDYA) from 
human influenza haemagglutinin (HA) protein (Kolodziej and Young, 1991) was used in 
each case. HA epitope tags were introduced at one of three different positions to each 
subunit: into the N-terminal region following the putative signal peptide cleavage site, 
into the intracellular loop region, or at the extreme C-terminus. All constructs were 
verified by sequencing (Section 2.4) and immunoprecipitation (Section 2.8).
2.3.1 Introduction of the HA tag to the N-terminal region
The HA epitope tag was introduced into the sequence of each subunit or subunit chimera 
at a position following the putative cleavage site of the leader peptide, positioning the tag 
close to the extreme N-terminal end of the mature protein to create a9N HA, alONHA, 
a 9%N HA and alO%NHA in the pRK5 expression vector. The HA tag was inserted at a 
unique NheI site (G/CTAGC), created in the subunit sequence by site-directed 
mutagenesis (SDM). The HA tag was carefully designed and the position for the tag 
insertions selected to ensure that the reading frame of the subunit sequence would be 
maintained.
The QuikChange™ Site-Directed Mutagenesis Kit (Stratagene) was used to create point 
mutations in the cDNA sequence. Two primers were designed for each a9 and alO 
subunit to create the desired mutations. The mutagenic primers anneal to the same 
sequence on opposite strands of the DNA and both have melting points (Tm) above 78°C.
Tm= 81.5 +0.41f%GQ- 675
primer length in base pairs - %mismatch
67
The mutation is in the middle of the primer, the primers have a GC content above 40%, 
were PAGE purified and terminate in a C or G residue.
SDM Primers for HA tags at the N-terminal:
OL559 NheI a9(+): 5’ - GGA ATC AGA GCC GTA GAG CTA GCA AAT GGG AAA TAT GC - 3' 
OL560 Nhel a9(-): 5' - GC ATA TTT CCC ATT TGC TAG CTC TAC GGC TCT GAT TCC - 3’
OL561 Nhe I al0(+): 5' - GCT GAG GGG AGG CTA GCT CAC AAG CTG TTT CGT GAC - 3' 
OL562 Nhe I alO(-): 5’ - GTC ACG AAA CAG CTT GTG AGC TAG CCT CCC CTC AGC - 3’
Nhe I: G/CTAGC (+) = forward primer; (-) = reverse primer
Each 50 p,l SDM PCR reaction contained IX reaction buffer, 50 ng template DNA, 125 
ng of each forward and reverse primers, 1 pi dNTP mix and 1 pi PfuTurbo DNA 
polymerase (2.5 U/pl; Stratagene). Reactions were heated to 95°C for 30 sec, then 12 
thermocycling steps were performed that included denaturation at 95°C for 30 sec, 
annealing at 55°C for 1 min and extension at 68°C for 2 min/kb cDNA length (13.5 min 
for pRK5-cc9 [6654 bp], pRK5-a9% [6536 bp] and pRK5-al0^ [6482 bp] and 15.5 min 
for pClneo-alO [7644 bp]). PCR products were cooled on ice and digested with 1 pi 
Dpnl (10 U/pl) at 37°C for 1 h. 1 pi digested DNA was added to 50 pi XLl-Blue 
supercompetent cells in a pre-chilled Falcon 2059 polypropylene tube and incubated on 
ice for 30 min. Transformation was carried out via heat shock at 42°C for 45 sec, 
followed by incubation in 0.5 ml NZY+ broth (10 g/L casein hydrolysate (NZ amine), 5 
g/L yeast extract, 5 g/L NaCl, pH 7.5 with NaOH, 12.5 ml/L 1 M MgCl2, 12.5 ml/L 
MgS04 and 10 ml/L 2M glucose) for 1 h at 37°C, with shaking at 225 rpm. 200 pi 
transformation mix was plated onto LB agar plates containing 50 pg/ml ampicillin, pre­
treated with 20 pi 10% (w/v) X-Gal and 20 pi 100 mM isopropyl-l-thio-P-D- 
galactopyranoside (IPTG) and incubated at 37°C for 18 h. Colonies were screened for 
the presence of the mutation by digestion of mini-prep DNA (Section 2.1.8) with Nhel at 
37°C for 1 h. Maxi-prep DNA was prepared from positive clones, digested with Nhel at 
37°C for 1 h and gel purified.
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Two oligonucleotides were generated that contained the sequence for the HA tag and 
complementary ends for subcloning into the Nhe I site:
OL563 HA Nhel(+): 5' - CTAGCATACCCCTACGACGTGCCCGACTACGCC - 3'
OL564 HA Nhel{-)\ 5' - CTAGGGCGTAGTCGGGACCGTCGTAGGGGTATG - 3' 
n Bases complementary to overhang created by digestion with Nhe I
n LINKERS to maintain reading frame 
O HA epitope tag
The OL563 and OL564 oligonucleotides were mixed at an equal molar ratio and 
annealed by heating to 80°C for 20 min in a hot block and cooling slowly to room 
temperature. The annealed primer duplex was subcloned into the subunit DNA digested 
with Nhel to produce pRK5-a9NHA, pRK5-a9%N HA, pClneo-alONHA and pRK5-al0%N HA 
constructs. The alONHA construct was subsequently excised from pClneo and subcloned 
into pRK5 using the Smal (5') and Sail (3*) sites of both vector and insert, to produce 
pRK5-al0NHA.
2.3.2 Introduction of the HA tag to the intracellular loop region
The HA epitope tag was introduced into the sequence of each subunit or subunit chimera 
within the putative intracellular loop region, at positions avoiding potential 
phosphorylation motifs (for example, the S/TxK/R consensus motif for phosphorylation 
by PKC predicted using the PROSITE Database of Protein Families and Domains; 
http://ca.expasy.org/gci-bin/scanprosite). The HA tag was inserted at a unique Nhel site, 
created by SDM (Section 2.3.1). The HA tag was carefully designed and the position for 
tag insertions selected to ensure that the reading frame of the subunit sequence would be 
maintained.
69
SDM Primers for HA tags in the intracellular loop:
OL593 a9 Nhe I i/c(+): 5’ - C CAC AGC CAG GAG CTA GCA CAA GTC ACG AAG G - 3'
OL594 a9 Nhel i/c(-): 5' - C CTT CGT GAC TTG TGC TAG CTC CTG GCT GTG G - 3'
OL595 5HT3a Nhel(+): 5* - G GAT GAG ATG CGG GAG CTA GCA AGG GAC TGG C - 3'
OL596 5HT3a NheI(-): 5’ - G CCA GTC CCG CAT CTC ATCC-3'
OL602 alO Nhel(-): 5’ - CTC CTG CTG GGA CAG CTA GCC AAA GGC CTG TG - 3*
OL603 alO Nhel(-): 5’ - CA CAG GCC TTT GGC TAG CTG TCC CAG CAG GAG - 3'
Nhe I: G/CTAGC
The annealed primer pair containing the HA tag sequence (OL563/OL564 Nhel HA; 
Section 2.3.1) was subcloned into the subunit DNA digested with Nhe I to produce 
pRK5-cc9IHA, pRK5-oc9%IHA, pClneo-alOIHA and pRK5-alO%IHA constructs. The alOIHA 
construct was subcloned into pRK5 using the Smal (5') and Sail (3') sites of both vector 
and insert, to produce pRK5-alOI HA.
2.3.3 Introduction of the HA tag to the extreme C-terminus
The HA epitope tag, followed by a stop codon, was introduced at the end of the coding 
sequence of each subunit cDNA by PCR to produce pRK5-a9CHA, pRK5-alOCHA, 
pRK5-a9%CHA and pRK5-al0xCHA. The forward primer (+) contained a unique Xbal 
site, an ATG start codon and the sequence of the N-terminus of the a9 or a  10 subunit. 
The reverse primer (-) contained a unique Hindlll site, a stop codon, the HA epitope tag 
sequence and the DNA sequence for the C-terminus of the a9, alO or 5HT3A subunit. 
The Xbal and Hindlll sites were introduced to allow subcloning of the purified PCR 
fragment into pRK5 (Xbal/Hindlll).
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PCR Primers for the introduction of C-terminal HA-epitope tags:
OL497 a9 Xbal(+y. 5’ - TGG TCT AGA ATG AAC CGG CCC CAT TCC TGC CTC TCC TTT - 3'
OL576 a9 HA(-): 5' - CGC a a g  c t t  TCA GGC..G.TA .GXC.GGG.MG.G.TC..GTA .G.QG
Q J A  ATC TGC TCT TGC TAT GAT - 3'
OL498 alO Xbal(+): 5' - GGT TCT AGA ATG ACA AGG AGC CAC TAC CTG GAC GTC - 3'
O L571 a lO  H A (-): 5' - CGC a a g  c t t  t c a  GGC..G.T.A..G.TC..GGG. AAG.GTC..G.TA..G.GG
G.TA CAG GGC TTG CAC - 3'
OL495 5HT3a HA(-): 5’ - CGC AAG CTT TCA GGC..GTA..G.T.C.GGG. AAC..GTC..GTA .G.GG
G.IA AGA ATG CCA AAT GGA - 3'
Xbal: T /C TA G A  
HindHI: A /A G C T T  
HA.epi.tQP<?.t.ag
Start (ATG) or Stop (TGA) codon (where the Stop codon in the reverse sequence = TCA)
Thermocycling steps followed incubation at 95°C, 1 min and involved denaturation at 
95°C for 30 sec, annealing at 70°C (5°C below the Tm of the primer pair) for 60 sec and 
extension at 72°C for 3 min, repeated for 30 cycles. A final extension step involved 
incubation at 72°C for 10 min.
2.4 SEQUENCING
Fluorescence-based cycle sequencing was carried out using the ABI Prism® BigDye® 
Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems) according to 
the manufacturer's instructions. Briefly, template DNA (0.1 -1.0 pg) and specific primer 
are mixed with 8 pi Terminator Ready Reaction Mix in 20 pi reaction volumes. 
Terminator Ready Reaction Mix contains BigDye® (dye-labelled ddNTP) terminators, 
FS. AmpliTaq® DNA polymerase, unlabelled dNTPs, MgCl2 and buffer. FS. AmpliTaq® 
DNA polymerase is a variant of Taq DNA polymerase, with a point mutation in the 
active site that reduces discrimination for dideoxynucleotides (ddNTPs). Thermocycling
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steps involve denaturation at 96°C for 30 sec, annealing at 50°C for 15 sec and extension 
at 60°C for 4 min, for 25 cycles. Reactions are ethanol/sodium acetate precipitated using 
2 pi sodium acetate, pH 5.2 and 50 pi 99% ethanol per 20 pi reaction, incubated on ice 
for 10 min and centrifuged at 13000 rpm, 15 min in a microfuge. Pellets are washed in 
250 pi 70% ethanol, air-dried and resuspended in 4 pi loading buffer (1 part 25 mM 
EDTA, pH 8.0 with blue dextran (50 mg/ml) to 5 parts deionised formamide). 
Fluorescent DNA fragments are resolved using an ABI Prism® 377 DNA Sequencer 
(Applied Biosystems) on a 4% polyacrylamide gel (19:1 acrylamide/bis-acrylamide 
solution; Amresco) containing 6 M urea and IX TBE (National Diagnostics).
The pRK5 vector contains a SP6(+) priming site that was used to sequence the chimeric 
constructs in the forward direction. The following primers were also used to sequence 
the chimeric constructs (bp = base pair):
OL557 SP6(+): 5' - AT TTA GGT GAC ACT ATA G - 3’ from start
OL606 cc9 [400bp](+): 5' - C TCC ATC AGG ATT CCC AGC G - 3' from bp 400
OL608 a9 [750bp](+): 5' - C TCC GAG CCT TAC CCA GAT GTC - 3’ from bp 750
OL597 a9 i/c loop(+): 5’ - G GTG ATG AAT ATT CAC TTC TGT GGA GC - 3’ from bp 1050
OL578 a9 M4(+): 5’ - G GGC AGC GAG TGG AAG AAG GTC G - 3’ from bp 1420
OL607 alO [400bp](+): 5’ - GG CGA CCA GAC ATC GTA CTT TAC - 3’ from bp 400
OL432 alO [660bp](+): 5’ - G GAG AAC GTT GAA TGG CGG GTG - 3’ from bp 660
OL598 alO i/c loop(+): 5’ - G CAC TAC TGT GGC CCT AAT GCA CAT CC - 3’ from bp 1030
OL577 alO M4(+): 5’ - GTA ATG GAC CGC TTT TTC CTA GGC - 3’ from bp 1330
OL428 5HT3A(-): 5’ - GG TAC CGG CCA CTG TAG GTC CTG - 3’ from bp 1080
OL276 pRK5(-): 5’ - AAG CTG CAA TAA ACA AGT TGG GC - 3’
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2.5 CELL CULTURE AND TRANSFECTIONS
2.5.1 Cell lines
The human embryonic kidney cell line, tsA201, derived from the human embryonic 
kidney HEK293 cell line, was obtained from Dr. William Green, University of Chicago, 
IL. The rat pituitary-derived cell line, GH4Cl5 was obtained from the American Type 
Culture Collection. The conditionally immortal auditory hair cell lines, UB/OC-1 and 
UB/OC-2 (University of Bristol/Organ of Corti), derived from the H-2Kb-taA58 
transgenic mouse (Jat et al., 1991; Holley et al., 1997; Rivolta et al., 1998) were 
obtained from Dr. Matthew Holley, University of Bristol, UK.
2.5.2 Cell culture
Human tsA201 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) 
containing 2 mM L-Glutamax™ plus 10% heat-inactivated foetal calf serum (Sigma, 
Poole, UK), with penicillin (100 U/ml) and streptomycin (100 fig/ml) and were 
maintained in a humidified incubator containing 5% C 02 at 37°C. G H ^  cells were 
cultured in Nutrient Media F10 (HAMS) supplemented with 10% FCS, 5% horse serum, 
penicillin and streptomycin and maintained in a humidified incubator containing 5% C 02 
at 37°C. UB/OC-1 and UB/OC-2 were cultured in Modified Essential Medium (MEM) 
containing 10% FCS and 50 U/ml y-interferon (Gibco BRL) in a humidified incubator 
containing 5% C02 at 33°C. Differentiation of UB/OC cells was induced by incubation 
of cells at 37°C for 14 days in MEM containing 10% FCS, but lacking y-interferon.
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2.5.3 Transient Transfection
Cells were trypsinised and re-plated 6 - 24 h before transfection to allow transfection at ~ 
40% confluence. Cells were transiently transfected using the non-liposomal lipid 
formulation, Effectene™ Transfection Reagent (Qiagen, Crawley, UK) according to the 
manufacturer's instructions. Briefly, for transfection of each 10 cm culture dish 
(Coming) of cells, 0.6 \ig total DNA is added to a microfuge tube and mixed with 120 pi 
Buffer EC. 4.8 pi Enhancer is added and incubated at room temperature for 5 min to 
condense the DNA (ratio of DNA to Enhancer is always 1 pg : 8 pi). 13 pi Effectene is 
added to the condensed DNA and incubated at room temperature for 10 min to produce 
condensed Effectene-DNA complexes. The Effectene-DNA complexes are mixed with 
600 pi culture medium and added directly to the cells in 3 ml medium. Cells were 
transfected overnight, adding 6 ml fresh culture medium after approximately 17 h. 
When cells were transfected in 12-well plates (Coming) on 13 mm coverslips pre-coated 
with poly-D-lysine and collagen, 0.4 pg DNA, 80 pi Buffer EC, 3.2 pi Enhancer, 10 pi 
Effectene and 400 pi culture media were used and the final transfection mixture divided 
between 4 wells of cells in 0.5 ml medium, providing a final concentration of 0.1 pg total 
DNA per well. After overnight transfection, 1 ml fresh medium was added per well of 
the 12-well plate. Cells were assayed for expression approximately 40 - 48 h after 
transfection.
2.6 RADIOLIGAND BINDING
Reaction conditions for equilibrium radioligand binding, including the transfected cell 
line, the radioligand and the compounds used to determine non-specific binding all 
depended on the particular cDNA combinations being assayed. Typically, transiently 
transfected cells were washed in phosphate-buffered saline (PBS) and harvested by 
gentle scraping into 1 ml PBS. Cells were pelleted by centrifugation at 2000 rpm for 2 
min and resuspended in 10 mM potassium phosphate buffer (per 100 ml of 1 M stock, 
pH 7.2: 71.7 ml 1 M K2HP04, 28.3 ml 1 M KH2P04) (for crude membrane preparations) 
or Hanks Buffered Saline Solution (HBSS; for intact cell suspensions) containing
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protease inhibitors leupeptin (2 pg/ml) aprotinin (2 pg/ml) and pepstatin (1 pg/ml). 
Samples were kept on ice where possible. Cell preparations were typically incubated 
with radioligand for 150 min at 4°C in a total volume of 300 pi. Total and non-specific 
binding was determined in triplicate samples. The maximum number of radioligand 
binding sites detected can vary between experiments, due to variations in cell passage 
number or confluence, transfection efficiency or experimental technique. However, the 
binding affinities and patterns exhibited by cells expressing different subunit 
combinations were reproducible between experiments.
The protein concentration of cell membrane preparations was determined by a BioRad 
DC protein assay according to the manufacturer's instructions. Briefly, 20 pi cell 
suspension or bovine serum albumin (BSA) standard sample is added to a semi­
microcuvette (Starstedt) and mixed with 100 pi Reagent A (alkaline copper tartrate 
solution). 800 pi Reagent B (a dilute Folin Reagent) is added, mixed and incubated at 
room temperature for 15 min. Colour development occurs after reduction of the Folin 
reagent by the copper-treated protein and provides a colorimetric assay. Protein 
concentration is determined by measurement of A750 and comparison against a standard 
curve constructed using BSA at concentrations of 0.1, 0.2, 0.4,0.8,1.2 and 1.5 mg/ml.
2.6.1 Tritiated radioligand binding
Samples were harvested using a Brandel Cell Harvester (Model M-36, Semaat, UK) in 
ice-cold 10 mM potassium phosphate buffer (for membrane preparations) or ice-cold 
PBS (for intact cells) onto GF/B glass fibre filters (Whatman) pre-soaked for 2 h in 0.5% 
(w/v) polyethylenimine (PEI). Filters were equilibrated for 24 h in 5 ml "Ready Safe" 
scintillation cocktail (Beckman) and counted for radioactivity in a scintillation counter.
For radioligand binding assays with tsA201 and UB/OC cells transiently transfected with 
combinations of chimeric and wild-type a9 and a  10 subunit cDNAs (Chapter 4), cell 
membranes were incubated with 30 nM [3H]-epibatidine (PerkinElmer Life Sciences, 
Boston; specific activity 56.2 Ci/mmol), 10 - 15 nM [3H]-methylcarbamylcholine ([3H]-
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MCC; PerkinElmer Life Sciences; specific activity 80 Ci/mmol), 30 nM [3H]- 
methyllycaconitine ([3H]-MLA; Tocris Cookson Ltd, Avonmouth, UK; specific activity 
26 Ci/mmol) or 50 nM [3H]-strychnine (PerkinElmer Life Sciences; specific activity 23 
Ci/mmol) for 2 h on ice. Non-specific binding was typically determined by addition of 1 
mM nicotine and 1 mM carbamylcholine chloride (carbachol). For [3H]-MLA binding 
to tsA201 cells expressing chimeric a9 and a  10 subunit cDNAs (a9% and a  10%), non­
specific binding typically yielded values of 200 cpm, representing ~ 5% of total binding.
For binding studies involving comparison of the expression of chimeric and wild-type 
a2 - a6 nAChR subunit cDNAs (Chapters 6 and 7), membrane preparations were 
incubated with saturating concentrations of [3H]-epibatidine (15 nM). Non-specific 
binding was determined by the addition of 1 mM nicotine and 1 mM carbachol, giving 
typical values of 200 cpm and representing 1 - 5% of total binding.
During radioligand binding assays with the a7 or a7% subunits (Chapters 4 and 6), cell 
membranes were incubated with 5 - 1 5  nM [3H]-MLA for 2 h on ice. Non-specific 
binding was determined by the addition of 1 mM nicotine, 1 mM carbachol and 10 pM 
MLA and typically yielded values of 4000 cpm, representing 5% of total binding.
2.6.2 Saturation binding
Saturation binding studies were performed with membrane preparations of tsA201 cells 
transiently transfected with a7% or a9% and al0% cDNAs. Increasing concentrations of 
[3H]-MLA were used (0.01 - 50 nM). To obtain a sufficient block of the receptors to 
measure non-specific binding, 1 mM carbachol, 1 mM nicotine and 10 pM MLA were 
added. Care was taken to ensure that the number of nAChR binding sites used for 
binding studies was low enough to avoid significant (>10%) ligand depletion at low 
concentrations of radioligand. Preliminary experiments were conducted to ensure that 
incubation times were long enough to enable radioligand binding to reach equilibrium. 
Curves for equilibrium binding were fitted with the Hill equation by equally-weighted 
least-squares (CVFIT program, David Colquhoun, University College London). In all 
cases the calculated Hill coefficients (nH) did not differ significantly from 1.
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2.6.3 Competition binding
For competition binding assays with [3H]-MLA, non-specific binding to cells transfected 
with the chimeric a9% and a  10% cDNA was determined by addition of 10 mM nicotine, 
10 mM carbachol and 100 pM d-tubocurarine. For cells transfected with cx7% cDNA, 
non-specific binding was determined in the presence of 3 pM MLA. Following 
estimation of Kd by saturation binding, [3H]-MLA was used at a concentration 
approximating the KA. Curves for equilibrium binding were fitted with the Hill equation 
by equally-weighted least-squares. In all cases the calculated Hill coefficients (%) did 
not differ significantly from 1. K{ values were derived from the competition curves using 
the equation: Kt = IC50 / (1 + ([radioligand] / Kd))
Competition binding for [3H]-MLA binding sites to membrane preparations of 
transiently transfected tsA201 cells was tested using the following ligands:
a9x<xl0% a 7 x
Acetylcholine (ACh) 0.01 - 5000 pM 0.1 - 50000 pM
Atropine (Sigma) 0.01 - 5000 pM 0.5 - 30000 pM
Bicuculline (Sigma) 0.005 -1 1 8  pM 0.005 - 118 pM
a-Bungarotoxin (a-BTX) 0.5 -10000 nM 0.0001-30000  nM
Carbachol 0.1 - 50000 pM 0.01 - 50000 pM
l,l-D im ethyl-4- 
phenlypiperazinium (DMPP)
0.01 -10000 pM 0.001 -10000  pM
5-Hydroxytryptamine (5HT) 0.1 -10000 pM 0.001 -10000  pM
Methylcarbamylcholine (MCC) 0.1 - 5000 pM 0.01 -10000 pM
Nicotine 0.5 - 5000 pM 0.01 - 5000 pM
Strychnine 0.01 - 5000 pM 0.01 - 5000 pM
d-Tubocurarine (d-TC) 0.5 - 50000 pM 0.0001 - 5000 pM
Table 2.2. Summary of the ligands used in competition binding studies with a7% and 
a9xal0x.
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2.6.4 Estimation of surface [3H]-MLA binding sites
Levels of radioligand binding sites on the surface of intact tsA201 cells transiently 
transfected with chimeric a9% and/or a  10% subunit cDNAs were determined using [3H]- 
MLA. Due to the concern that [3H]-MLA may be able to cross the cell membrane 
(Davies et al., 1999), a modified version of the tritiated radioligand binding method 
(Section 2.6.1) was used, in a protocol similar to that described by Whiteaker et al., 
1998. Transfected cells, grown in 10 cm plates, were gently resuspended in HBSS. 
Intact cells (typically 5 x 105 cells) were incubated in a total volume of 300 pi with 15 
nM [3H]-MLA in the presence of either (a) HBSS - to measure the total population of 
[3H]-MLA binding sites, (b) 1 mM nicotine, 1 mM carbachol and 10 pM MLA - to 
measure non-specific binding or (c) 1 mM ACh - to block [3H]-MLA binding sites on the 
cell surface. To determine the proportion of specific binding on the cell surface, binding 
assays with intact cells were performed in parallel with assays on cell membrane 
preparations (Section 2.6.1). Samples were harvested onto GF/B glass fibre filters in ice- 
cold PBS and assayed by scintillation counting.
2.6.5 Iodinated oc-bungarotoxin ([125I]-a-BTX) binding
Cell preparations were incubated with 1 - 5  nM [125I]-a-BTX (specific activity 150 
Ci/mmol; Amersham) in the presence of 2% BSA for 2 h on ice. Non-specific binding 
was determined by addition of 1 mM nicotine and 1 mM carbachol to triplicate samples. 
Samples were harvested using a Brandel Harvester (Model M-36, Semaat, UK) onto 
GF/A glass fibre filters (Whatman) pre-soaked in 0.5% PEI for 2 h with 4 washes in ice- 
cold PBS (intact cell suspensions) or 10 mM potassium phosphate buffer (membrane 
preparations). Bound [125I]-a-BTX was determined by counting the filters in a Wallac 
1261 gamma-counter.
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2.7 ANTIBODIES
Antibody Species
Immunised
Isotype Specificity Source
mAbHA-7 Mouse IgG HA peptide1 Sigma
mAb a-HA Peroxidase Mouse IgG HA peptide+ Sigma
Goat a-mouse IgG 
Peroxidase
Mouse IgG (H+L) Pierce
pAb5HT3 Rabbit IgG Intracellular loop 
region of 5HT,
Dr. R.
McKeman*
Goat a-rabbit IgG 
Peroxidase
Rabbit IgG (H+L) Pierce
Table 2.3. Summary of the antibodies used in this study.
* The nine amino acid synthetic peptide (YPYDVPDYA) corresponding to residues 98- 
106 of human influenza virus haemagglutinin (Kolodziej and Young, 1991)
* Merck Sharp and Dohme Research Laboratories, Harlow (Turton et al.y 1993).
2.8 METABOLIC LABELLING AND IMMUNOPRECIPITATION
Mammalian tsA201 cells were transiently transfected overnight (Section 2.5.3), washed 
twice and incubated for 20 min in L-methionine (Met) and L-cysteine (Cys) free media 
to starve cells of methionine. Cells were labelled with 250 pCi [35S]-“Pro-mix” 
(Amersham), containing a mixture of [35S]-Met and [35S]-Cys, in 3 ml Met/Cys-free 
medium for 3 h at 37°C. Labelling was terminated by addition of 5 ml complete DMEM 
(containing 30 mg/ml Met and 48 mg/ml Cys and supplemented with 10% FCS) and 
chased for 2 h at 37°C. Cells were washed three times and harvested into 1 ml ice-cold 
PBS. Cells were pelleted in a benchtop centrifuge at 6000 rpm, 5 min at 4°C and 
resuspended in 400 pi ice-cold low salt lysis buffer (150 mM NaCl, 50 mM Tris/Cl pH 
8.0, 5 mM EDTA, 1% Triton X-100) containing protease inhibitors (0.2 mM 
phenylmethylsulfonyl fluoride (PMSF), 2 mM TV-ethylmaleimide (NEM) and 10 pg/ml 
each of pepstatin, leupeptin and apoprotinin).
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Solubilised samples were pre-cleared by incubation with 40 jul Protein G-sepharose 
beads (Calbiochem) at 4°C overnight, rotating the tubes to ensure good mixing. Non­
solubilised material and Protein G beads were pelleted by centrifugation at 13000 rpm, 
30 min at 4°C in a benchtop centrifuge. The supernatant was transferred to a fresh tube 
and this cell lysate incubated with an appropriate antibody for 4 h, rotating at 4°C. The 
antibody-nAChR protein complex was immunoprecipitated by incubation with 20 pi 
Protein G beads for 3 h, rotating at 4°C. Beads carrying the antibody-nAChR complex 
were pelleted by centrifugation at 13000 rpm, 5 min and washed once in high salt lysis 
buffer (500 mM NaCl), once in medium salt lysis buffer (300 mM NaCl) and once in 
low salt lysis buffer (150 mM NaCl). Pellets were resuspended in 20 pi sodium dodecyl 
sulphate (SDS)-loading dye (50 mM Tris/Cl pH 6.8, 200 mM dithiothreitol (DTT), 2% 
SDS, 0.2% bromophenol blue, 10% glycerol) and separated on a SDS-polyacrylamide 
gel (Amresco) with a 5% stacking gel and a 7.5% resolving gel. The gel was fixed for 
30 min in 30% methanol, 10% glacial acetic acid, then incubated for 30 min in Amplify 
solution (Amersham). The gel was dried and exposed to Kodak X-OMAT photographic 
film at -80°C with intensifying screens.
2.9 ENZYME-LINKED ASSAY
All antibodies used in enzyme-linked assays were diluted in HBSS supplemented with 
Ca2+ and Mg2+, through addition of 25 pM CaCl2 and MgCl2 (HBSS++) and containing 
2% BSA and 5% FCS. Cells transfected with HA-tagged subunits were assayed using 
either mouse mAbHA-7 (1:1000 dilution of 3.1 mg/ml) and goat a-mouse IgG 
peroxidase conjugate (1:2000 dilution of 0.8 mg/ml) or a single mouse a-HA peroxidase 
conjugate (1:2000 dilution of 1.2 mg/ml).
Note: In assays using mouse a-HA peroxidase conjugate, incubation in secondary 
antibody (and the subsequent washing steps) was not required.
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Cells were transiently transfected on 13 mm coverslips, pre-coated with poly-L-lysine 
and collagen. Cells were fixed in 3% paraformaldehyde (PFA) made up in PBS. 
Fixation in PFA can cause cell permeabilisation, so cells assayed for staining of cell 
surface nAChRs were fixed after labelling with primary antibody. During staining of 
permeabilised cells, cells required fixation prior to permeabilisation and were fixed prior 
to incubation in primary antibody Levels of staining were normalised to staining of 
permeabilised cells expressing a9%N HA (Sections 2.3.1 and 5.3.2), which were included 
as a positive control in each set of transfections and were reproducible between 
experiments, generating A665 values approximating 2.
2.9.1 Staining of permeabilised cells
Cells were washed in HBSS++ and fixed for 15 min. Cells were permeabilised in 0.1% 
Triton X-100 for 10 min and incubated in a blocking solution of HBSS++ containing 2% 
BSA and 0.1% Triton X-100 for 10 min at room temperature. Cells were incubated with 
primary antibody for 1 h in a humidified chamber at room temperature, then washed 4 
times in HBSS4^ . Cells were incubated with horseradish peroxidase (HRP)-conjugated 
secondary antibody for 1 h in a humidified chamber and washed 4 times in HBSS++. For 
quantification of labelled nAChR, coverslips were incubated with 3,3’,5,5’-tetramethyl 
benzidine (TMB) liquid substrate for HRP (Sigma) for 30 min. The soluble blue 
reaction product formed was transferred to a cuvette and A655 measured.
2.9.2 Staining of surface receptors
Cells were washed in HBSS++ and incubated in a blocking solution of HBSS++ containing 
2% BSA for 10 min at room temperature. Cells were incubated with primary antibody 
for 1 h in a humidified chamber at room temperature, washed 4 times in HBSS++ and 
fixed for 15 min. Cells were washed 4 times in HBSS** and incubated with HRP- 
conjugated secondary antibody for 1 h in a humidified chamber. Cells were washed 4 
times in HBSS++, incubated with TMB liquid substrate for 30 min, the supernatant 
transferred to a cuvette and A655 measured.
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CHAPTER 3 
CONSTRUCTION OF CHIMERIC cDNA
3.1 Introduction
Heterologous expression of nicotinic subunits is a valuable tool for investigating aspects 
of nAChR assembly, but recombinant nAChRs have proved especially difficult to 
express efficiently in mammalian cell lines in comparison to other members of the 
ligand-gated ion channel superfamily. For example, expression of the homomeric al 
and a8 nAChRs is dependent upon the nature of the host cell environment (Cooper and 
Millar, 1997; Cooper and Millar, 1998; Sweileh et al., 2000). Folding and assembly of 
the homomeric 5HT3A receptor appears to be considerably less dependent upon the host 
cell type (e.g. Baker et al., 2004). Chimeric subunits containing the N-terminal region of 
the al and a8 subunits, fused to the C-terminal domain of the 5HT3A receptor subunit 
are readily expressed at the cell surface of cell types which inefficiently fold wild-type 
subunits (Eiseld et al., 1993; Blumenthal et al., 1997; Cooper and Millar, 1997; 
Rangwala et al., 1997; Cooper and Millar, 1998). Construction of subunit chimeras 
allows investigation into the influence of different regions of an individual subunit upon 
aspects of receptor folding and assembly and also provides a model system by which 
nicotinic-type subunits can be expressed and investigated in mammalian cell lines.
3.2 Construction of nAChR/5HT3A subunit chimeras
Chimeric subunit cDNAs similar to the a7(V201)/5HT3A chimera described previously 
(Eisele et al., 1993; Cooper and Millar, 1997) were constructed containing the 
extracellular N-terminal domain of the rat nAChR subunits (a2, a3, a4, a5, a6, a9, 
a  10, (32, (33 and 04), fused to the transmembrane and intracellular domain of the mouse 
5HT3A subunit in the mammalian expression vector, pRK5 (Figure 3.1; Table 3.1). The 
a3/5HT3A (for brevity, referred to as oc3%), a4/5HT3A (a4%), a5/5HT3A (a5%), 02/5HT3A
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(P2%), P3/5HT3A (P3%) and P4/5HT3A (P4%) chimeras were constructed during a six 
month undergraduate placement project prior to the start of this PhD project, but details 
of their construction are included to allow their direct comparison with the other 
chimeras.
An a7(V201)/5HT3A chimera was used to generate each of the other subunit chimeras. The 
original pZeoSV-a7(V201)/5HT3A chimera was constructed by Dr. Sandra Cooper (this 
laboratory) (Cooper and Millar, 1997). The a7(V201)/5HT3A construct cDNA was 
subcloned into pZeoSV(+) at Hindll! (5') and BelI (3') restriction enzyme sites, fusing 
the a l  and 5HT3A subunit cDNA fragments at a Bell site at residue V201 of the a l  
sequence, located just prior to the first predicted transmembrane region, Ml (Cooper and 
Millar, 1997).
The a7 (V201)/5HT3A chimera was excised from the pZeoSV(+) mammalian expression 
vector with ZscoRI (5') and Seal (3') and subcloned into the EcoRl (5') / Smal (3') sites of 
the pRK5 expression vector to produce pRK5-a7(V201)/5HT3A (oc7%). Digestion with both 
Seal (AGT/ACT) and Smal (CCC/GGG) produces blunt ended fragments that are 
compatible for ligation, but ligation does not regenerate either the Seal or Smal site. The 
pRK5 vector was used to simplify the subcloning strategy as it does not contain a Bell 
site (T/GATCA). A unique Bell site was introduced to the cDNA of each nAChR 
subunit at a position just prior to Ml, by silent mutagenesis using PCR (Section 2.1.2; 
Figure 3.1). The PCR primers used are listed in Table 3.2. The fidelity of the chimeric 
constructs was verified by restriction mapping and sequencing.
To construct each of the a2%, a3%, a4%, a5%, a6%, a9%, (32% and (34% subunit chimeras 
in pRK5, PCR was performed using a T7 forward primer and a novel reverse primer to 
introduce a BcR{-) site just prior to Ml (Table 3.2). The pRK5-a7(V201)/5HT3A (alx) 
construct was digested with ZscoRI (51) and Bell (3’) to excise the al portion of the 
chimera and produce a pRK5-/5HT3A (EcoRUBclT) cloning cassette. PCR-amplified
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nAChR subunit N-terminal domains, purified by ethanol precipitation (Section 2.2), 
were digested with EcoRl (5’) and Bell (3’) and cloned into the pRK5-/5HT3A 
(EcoKUBcll) cloning cassette to create the pRK5-a2(F204)/5HT3A, p R K S -a S ^ /S K T ^ , 
pRK5-a4(F204)/5HT3A, pRKS-aS^VSHT^, pR E S -ab^/S H T ^, pRK5-a9^m)/5 m 3A, 
pRK5-P2(F201)/5HT3A and pR K S ^^Y S H T ^  subunit chimeras (Table 3.1).
To construct the p3% chimera, the PCR products were digested with Sacl (5’) and BcB 
(3’) and cloned into the pRK5-/5HT3A (EcoRl/Bell) cloning cassette with the addition of 
an 8 base pair linker (AATTAGCT) to join the 3'-overhang (TTAA) and 5'-overhang 
(TCGA) created by digestion with EcoRl (G/AATTC) and Sacl (GAGCT/C), 
respectively, to generate pRK5-P3(F202)/5HT3A:
fscoRI
G AATTC
CTTAA G
Sacl
GAGCT C 
C TCGAG
G C
CTTAA TCGAG
i + AATTAGCT Linker
GAATTAGCTC
CTTAATCGAG
To construct the a  10% chimera, a unique Xbal site was introduced to the 5’ end of the 
alO cDNA and a unique Bell site was introduced just prior to Ml by PCR using novel 
forward (OL431 alO Xbal) and reverse (OL404 alO Bell) primers (Table 3.2). PCR 
products were digested with Xbal (5’) and Bell (3’). The pRKS-aT^^VSHT^ construct 
was digested with Bell (5’) and SaR(3’) to excise the 5HT3A portion of the chimera. The 
alO (Xbal/Bell) and 5HT3A (BclUSaU) fragments were subcloned into pRK5 (Xbal/Sail) 
to create pRKS-cclO^VSHT^.
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FIGURE 3.1. Construction of nAChR/5HT3A subunit chimeras. Each subunit chimera 
contains the N-terminal domain of an nAChR subunit (either oc2, a3 , a4 , a5 , a 6 , a9 , 
a  10, P2, p3 or p4) up to the first putative transmembrane region, M l, fused to the C- 
terminal region of the 5-hydroxytryptamine type 3 receptor (5HT3A) subunit. Chimeric 
cDNAs were inserted into the mammalian expression vector, pRK5.
(A) The N-terminal region of the nAChR subunit up to M l was generated by PCR 
using a forward primer specific to the RNA promoter 5’ to the multiple cloning site of 
the mammalian expression vector, and a mutant reverse primer containing a Bell site. 
The PCR fragment was digested with restriction enzyme I (RE-I) (5') and Bell (3’) and 
gel purified.
(.B) pR K 5-a7(V201)/5HT3A was digested with RE-I (5') and BelI (3’) to excise the a l
portion of the chimera and produce a pRK5-/5HT3A (RE-I/Z?c/I) cloning cassette.
(O  The nAChR (RE-I/flc/I) PCR fragment was cloned into the pRK5-/5HT3A (RE- 
UBcll) cloning cassette to create the pRK5-nAChR/5HT3A subunit chimera.
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Plasmid-cDNA
Construct
nAChR Subunit 
Restriction Sites
Subcloned From Plasmid Restriction  
Sites
Forward Primer Reverse Primer
pRK5-a2(F204)/5HT3A E c o K U B c W S c a l pcDNA lneo-a2 E c o K U S m a l OL427 OL404
p R K S - a S ^ /S in V E c o K U B c W S c a l pcDNAlneo-oc3 E c o K U S m a l OL427 OL269
pRK5 -a4(F204)/5HT3Afl E c o K U B c W S c a l pcDNA lneo-a4 E c o K U S m a l OL427 OL260
pRK5-a5(F201)/5HT3Aa E c o K U B c W S c a l pcDNAlneo-a5 E c o K U S m a l OL427 OL274
pRK5-a6(F204)/5HT3A E c o K U B c W S c a l pBSSK-a6 E c o K U S m a l OL400 OL401
pRK5-a7(V201)/5HT3Afl E c o K U B c W S c a l pZeoSV2-a7(V201)/5HT3A* E c o K U S m a l - -
pRK5-a9(L209)/5HT3A E c o K U B c W S c a l pClneo-a9 E c o K U S m a l OL427 OL469
pRK5-alO(L206)/5HT3A X b a U B c W  S a il pClneo-alO X b a U  S a il OL431 OL413
pRK5-P2(F201)/5HT3A° E c o K U B c W S c a l pcDNAlneo-{32 E c o K U S m a l OL427 OL261
p R K S -lt t^ V S M V S a c U B c W  S e a l pcDNAlneo-P3 E c o K U S m a l OL427 OL273
E c o K U B c W S c a l pcDNAlneo-|34 E c o K U S m a l OL427 OL270
TABLE 3.1. Summary o f the constructed rat/mouse nAChR/5HT3AR chimeras. Each subunit chimera contains the N-terminal domain o f the rat nAChR subunit up 
to M l, fused to the C-terminal region o f the mouse 5HT3A receptor subunit, in the mammalian expression vector, pRK5. The restriction enzyme sites, the original 
rat nAChR subunit plasmid DNA and the PCR primers used in the subcloning are listed. The chimeras were typically generated using the original pRK5- 
a7(V2oi)/5HT3A chimera0, following excision o f the a l  portion o f this chimera to generate a pRK5-/5HT3A cloning cassette (Section 3.2). 
a Constructed during a six month undergraduate placement.
b The pZeoSV2-a7(V201)/5HT3A chimera was constructed by Dr. Sandra Cooper (Cooper and Millar, 1997).
Oligonucleotide Details Oligonucleotide sequence (5f - 3')
OL260 a4 BelI(-) CG TCG GAT GAT CAC GGC ATA GGT G
OL261 P2 Belli-) CG ACG AAT GAT CAC GTC ATA GGT G
OL269 a3 Belli-) CAG GCG ACG GAT GAT CAC CGA GTA CGT GAT
OL270 p4 flc/I(-) GTT GCG CTT GAT GAT CAC GTC ATA GGT CAC
OL273 (33 Bcll(-) G CAG GCG TCT CAT GAT CAA AGA GTA GGT AAC
OL274 a5 Belli-) CAG CCG CTT AAT GAT CAA GGA GTA CGT GAT G
OL400 T7pBS(+) GTA ATA CGA CTC ACT ATA GGG CGA ATT GGG
OL401 a6 Belli-) GGG CAG CCT TCT GAT GAT CAC GGA GTA GGT
OL404 a2 Belli-) CAG CCG GCG GAT GAT CAC GTA GTA GGT
OL413 alO Belli-) GCG GCG CAT GAT CAG AGT AAA G
OL427 T7(+) TAA TAC GAC TCA CTA TAG GG
OL431 alOXhaI(+) CA TCG CTC TAG AAG ACT TGC GG
OL469 a9 Belli-) CCT CCT CTT GAT GAT CAC AGT GAA GGT
TABLE 3.2. The PCR primers used to generate the nAChR/5HT3A subunit chimeras.
(+) Forward primer
(-) Reverse primer
BcR T/GATCA 
Xbal T/CTAGA
n Mutations introduced into the native nAChR subunit sequence to create the 
primer
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3.3 Expression of chimeric subunit protein in tsA201 cells
To confirm that each subunit chimera could be expressed in mammalian cells, human 
embryonic kidney tsA201 cells transiently transfected with the chimeric subunit cDNAs 
were subjected to metabolic labelling and immunoprecipitation using an antiserum raised 
to the intracellular loop region of 5HT3A (pAb5HT3, Turton et al., 1993) (Figure 3.2).
The molecular weights of mature unglycosylated nAChR subunits and their 
corresponding subunit chimeras were calculated from the protein amino acid sequences, 
using the Protein Information Resource at Georgetown University Medical Center, 
(http://pir.georgetown.edu/pirwww/search/comp_mw.shtml). Potential N-glycosylation 
sites were identified by searching the amino acid sequence of each subunit for NxS/T 
motifs (where x is any residue) (Tables 3.3 and 3.4).
Protein bands were detected for each nAChR/5HT3A subunit chimera following 
metabolic labelling and immunoprecipitation with pAb5HT3 (Figure 3.2). The 
immunoreactive band detected for the (33% chimera was faint in comparison to those 
detected for the other subunit chimeras in the exposure shown in Figure 3.2. However, 
additional immunoblotting experiments revealed the detection of a specific 
immunoreactive band for the 03% subunit and this is highlighted in Figure 3.2.
The apparent molecular weights are indicated as molecular weight ranges in Table 3.4 to 
account for the detection of multiple protein bands for chimeras such as a9% and 02% 
and for the error in measuring the migration distance of the broad immunospecific bands. 
Each chimeric subunit possesses more than one potential site for N-glycosylation (Table
3.4) and may explain the detection of multiple specific immunoreactive bands. The 
protein bands detected are of a size comparable to that expected from the predicted 
molecular weights (Table 3.4), suggesting full-length subunit protein is produced 
following the transient transfection of tsA201 cells with cDNA of chimeric constructs.
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The molecular weight of each chimera is predicted to be 51 - 52 kDa (Table 3.4), with 
little variation in size between the chimeras. In Figure 3.2, slightly more variation in 
apparent molecular weight is observed, with the chimeric a  10% subunit migrating more 
rapidly on the SDS-polyacrylamide gel than the a4% chimera, for example. The slight 
differences in the apparent molecular weight of the chimeric subunits, estimated 
according to their migration position on the SDS-polyacrylamide gel relative to protein 
molecular weight markers, may be a consequence of differences in glycosylation of the 
mature proteins. The a4% chimera possesses 3 potential sites for N-glycosylation in its 
N-terminal domain, while the al0% chimera contains only 2 potential N-glycosylation 
sites (Table 3.4). The comparison of predicted and apparent molecular weights shown 
for the wild-type nAChR subunits in Table 3.3 also demonstrates that some variation is 
observed between the expected size of mature proteins and the apparent size determined 
experimentally.
As full length protein was successfully produced for each of the nAChR/5HT3A subunit 
constructs, these chimeras were considered suitable for use in the investigation of 
nAChR expression in mammalian cell lines (Chapters 4 - 7).
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66kDa
46kDa
66kDa-
45kDa-
FIGURE 3.2. H eterologous expression  of subunit chim eras determ ined by 
immunoprecipitation of metabolically labelled proteins from detergent-solubilised cells. 
Mammalian tsA201 cells were transfected with nAChR/5HT3A subunits constructed in 
the mammalian expression vector, pRK5. Cell lysates were immunoprecipitated with 
pAb5HT3, a polyclonal antiserum raised to the intracellular loop region of the 5HT3A 
subunit. The positions of molecular weight markers are indicated. Immunoreactive 
bands were detected corresponding to the each of the nAChR/5HT3A chimeric subunits. 
Due to the faint band produced for the 03% subunit, an additional figure is included from 
a separate im munoblotting (rather than im m unoprecipitation) experim ent, using 
pAb5HT3, to demonstrate the production of protein for this subunit upon expression in 
tsA201 cells.
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Rat
Subunit
Number of 
residues in the 
mature protein
Predicted
molecular
weight
Apparent
molecular
weight
Number of potential 
N-terminal N- 
glycosylation sites
a l 479 55 59a 2
oc3 474 55 57b 2
a4 594 67 68a 3
a5 424 49 51 - 56a,b 2
a6 463 54 57c 2
a l 480 54 59d 3
a9 457 52 55* (human) 2
alO 423 47 55* (human) 2
(32 473 54 54 - 57a,b 2
(33 433 50 55* 2
(34 471 53 52* 4
5HT3A 464 51 61f 3
TABLE 3.3. Molecular weights of the wild-type neuronal nAChR (rat) and 5HT3A 
(mouse) receptor subunits. Molecular weights were predicted from the amino acid 
sequence of the mature subunit, using the Protein Information Resource (Georgetown 
University Medical Center website; http://pir.georgetown.edu/pirwww/search/comp_ 
mw.shtml). Apparent molecular weights are data from previous studies (aBalestra et al., 
2000; bWang et al., 1996; cVailati et al., 1999; dDominguez del Toro et al., 1994; eSgard 
et al., 2002; ^ukeiji et al., 1996). Potential N-glycosylation sites within the N-terminal 
domain of each subunit were identified by searching the amino acid sequence of each 
subunit for NxS/T motifs (where x is any residue).
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Subunit Number of 
residues in the 
mature protein
Predicted
molecular
weight
Apparent
molecular
weight
Number of potential 
N-terminal N- 
glycosylation sites
cc2F204/5HT3A 451 52 45-48 2
a3™4/5WT3A 451 52 46-50 2
a4F204/5HT3A 451 52 48-50 3
a5F201/5HT3A 448 51 47-49 2
a6F204/5HT3A 451 52 48-50 2
a7V201/5HT3A 449 52 47-49 3
a9L209/5HT3A 456 52 47-49 2
alOL2075HT3A 453 51 45-46 2
P2F201/5HT3A 448 51 47-49 2
PS ^/S H T ^ 449 51 45-46 2
p4F201/5HT3A 448 51 47-50 4
5HT3A 464 51 52-53 3
TABLE 3.4. Molecular weights of the chimeric nAChR/5HT3A subunits. Predicted 
molecular weights were calculated from the amino acid sequence of the mature subunit 
protein, using the Protein Information Resource (Georgetown University Medical Centre 
website; http://pir.georgetown.edu/pirwww/search/comp_mw.shtml). Apparent 
molecular weights are data from this study, estimated following metabolic labelling and 
immunoprecipitation using the pAb5HT3 antiserum, raised to the intracellular loop 
region of the 5HT3A receptor subunit (Figure 3.2). Searching the amino acid sequence of 
each subunit for NxS/T motifs (where x is any residue) identified potential N- 
glycosylation sites.
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CHAPTER 4
PHARMACOLOGICAL CHARACTERISATION OF nAChRs 
CONTAINING cc9 AND cclO SUBUNITS
4.1 Introduction
Expression of the a9 and a  10 subunits is largely restricted to the hair cells of the inner 
ear (Elgoyhen et al., 1994; Hiel et al., 1996; Elgoyhen et al., 2001; Lustig et al., 2001) 
and consequently, nAChRs containing a9 and a  10 do not fall conveniently into the 
conventional classification of either muscle-type or neuronal nAChRs. Nicotinic 
receptors expressed in outer hair cells of the cochlea have been demonstrated to be 
responsible for modulating auditory nerve responses to acoustic stimulation and for 
protection from acoustic overstimulation (Sridhar et al., 1997). A role for a9-containing 
nAChRs in auditory processing has been suggested by in vivo studies conducted with 
transgenic (Vetter et al., 1999) and wild-type animals (Luebke and Foster, 2002).
When expressed alone in Xenopus oocytes, the a9 subunit, but not the a  10 subunit, is 
capable of generating functional homomeric nAChRs (Elgoyhen et a l, 1994; Elgoyhen 
et a l , 2001; Sgard et a l , 2002). When a 9 and a  10 are co-expressed in oocytes, 
considerably larger whole-cell currents are observed, suggesting that these subunits may 
normally co-assemble to form heteromeric complexes (Elgoyhen et a l , 2001; Sgard et 
a l , 2002). Despite successful studies in oocytes, there have been no reports of the 
heterologous expression of a9- or alO-containing nAChRs, as either homomeric or 
heteromeric complexes, in other expression systems. Whilst much can be achieved by 
characterisation of oocyte-expressed nAChRs, some approaches to the pharmacological 
characterisation of oc9al0 nAChRs, for example equilibrium binding studies, have been 
hindered by the lack of a suitable cultured cell-based expression system.
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4.2 Heterologous expression of a9 and alO subunits in tsA201 cells
To investigate the heterologous expression of a9-containing nAChRs in mammalian cell 
lines, rat a9 and alO subunit cDNAs were introduced by transient transfection into 
cultured tsA201 cells. Membranes were isolated from cells co-transfected with a9 and 
alO cDNAs and from cells transfected with a9 alone or a  10 alone. Binding studies 
were performed with [3H]-methyllycaconitine ([3H]-MLA), a nicotinic receptor 
antagonist reported to bind with high apparent affinity to recombinant a9 a l0  nAChRs 
expressed in Xenopus oocytes (Verbitsky et al., 2000). However, no evidence for 
specific high affinity [3H]-MLA binding was obtained. Further binding studies were 
performed with a range of nicotinic radioligands including [125I]-a-BTX, [3H]- 
epibatidine and [3H]-methylcarbamylcholine ([3H]-MCC), none of which revealed 
specific high affinity binding. This observation is consistent with previous studies, 
which have failed to detect functional nAChRs in mammalian (HEK293) cells 
transfected with a9 and alO cDNAs (Lustig et al., 2001).
To confirm that a9 and a  10 subunits were expressed in transfected cells, a9 and a  10 
cDNA constructs were tagged at their C-termini with the nine amino acid influenza 
haemagglutinin (HA) epitope tag (Kolodziej and Young, 1991) (see Sections 2.3.3 and
5.3). Cells transfected with the HA-tagged subunits (pRK5-a9CHA and pRK5-oclOCHA) 
were subjected to immunoblotting with mAbHA-7, which revealed immunoreactive 
protein bands of a size similar to that expected for full-length mature a9  and a  10 
subunits (see Sections 5.3.1 and 5.4 and Figure 5.4). The subunits were tagged at their 
extreme C-terminus, providing strong evidence that these correspond to full-length a9 
and alO subunits. However, some degradation of HA-tagged subunit protein may have 
occurred, suggested by "smearing” of the immunoreactive protein bands observed in 
Figure 5.4 may indicate that the HA-epitope tag disrupts protein stability (see Section
5.4). Since the a9 and a  10 subunit polypeptides do appear to be expressed in transfected
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cells, this suggests that the absence of a specific nicotinic radioligand binding is a 
consequence of inappropriate folding and/or assembly of the subunits.
4.3 Heterologous expression of a9 and alO subunits in a cochlea hair cell line
Difficulties have been reported in the heterologous expression of other nAChR subunits 
(in particular the al and a8 subunits) in cultured mammalian cell lines (Puchacz et al., 
1994; Quik et al., 1996; Cooper and Millar, 1997; Kassner and Berg, 1997; Rangwala et 
a l, 1997; Cooper and Millar, 1998; Sweileh et al., 2000). This has led to the conclusion 
that appropriate subunit folding and assembly events are influenced strongly by the 
nature of the host cell type (Millar, 1999; Sivilotti et al., 2000). While the al and a8 
nAChRs appear to misfold in human embryonic kidney HEK293 cells, these nAChRs 
are expressed at the cell surface of cell lines including the human neuroblastoma SH- 
SY5Y cell line and rat phaeochromocytoma PC 12 cells, both of which express an 
endogenous al subunit (Cooper and Millar, 1997; Cooper and Millar, 1998).
The a9 and alO subunits are expressed in the hair cells of the inner ear (Elgoyhen et al., 
1994; Hiel et a l, 1996; Elgoyhen et al., 2001; Lustig et al., 2001). Conditionally 
immortal cochlea hair cell lines have been derived from the H-2Kb-taA58 transgenic 
mouse (“Immortomouse”), which contains a conditionally expressed, temperature 
sensitive immortalising oncogene (a mutant of the tumour antigen, T-Ag, from the SV40 
virus) (Jat et a l, 1991; Holley et al., 1997; Rivolta et al., 1998). The presence of the 
immortalising gene prevents terminal differentiation and perpetuates cell proliferation in 
cells maintained at 33°C in the presence of y-interferon. The mouse cochlea-derived 
UB/OC-1 and UB/OC-2 (University of Bristol/Organ of Corti) cell lines express 
endogenous a9-containing nAChRs that demonstrate high calcium permeability and 
elicit ACh-induced inward currents that are blocked by nicotine and strychnine (Rivolta 
et al., 1998; Jagger et a l, 1999).
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The expression of a9-containing nAChRs was investigated in UB/OC cell lines to 
ascertain whether these cells permit the correct folding of a nicotinic binding site 
attributable to either endogenous nAChRs or to recombinant nAChRs following over­
expression of a9 and/or alO cDNAs. Membrane preparations of proliferating cultures of 
UB/OC-1 and UB/OC-2 cells (immortalised at slightly different stages of differentiation) 
(Rivolta et al., 1998) were subjected to radioligand binding with [3H]-MLA, [3H]- 
strychnine and [3H]-MCC to investigate the expression of endogenous nAChRs. 
However, no evidence for specific radioligand binding was observed in the untransfected 
cells. Similarly, cells transiently transfected with either a9, alO or a9+al0  did not 
reveal any significant levels of specific radioligand binding (data not shown; n=A).
The conditionally immortal cochlea-derived UB/OC cell lines can be compelled to 
terminally differentiate when cultured at 37 - 39°C in the absence of y-interferon (Jat et 
al., 1991; Holley et al., 1997). UB/OC-2 cells were incubated under permissive 
conditions for 6 - 1 4  days to allow differentiation of the cells, but cell membranes 
incubated with 15 nM [3H]-MLA did not reveal any evidence for specific radioligand 
binding (data not shown; n=5).
4.4 Expression of a9/5HT3A and alO/5HT3A subunit chimeras in tsA201 cells
The relatively inefficient folding and cell-surface expression of several nAChR subunits 
(including a l ,  a4, a7, a8 and 02) can be enhanced by replacing the C-terminal region of 
nAChR subunits with the corresponding region of the 5HT3A subunit (Eisele et al., 1993; 
Blumenthal et a l , 1997; Rangwala et al., 1997; Cooper and Millar, 1998; Cooper et al., 
1999; Harkness and Millar, 2002). Subunit chimeras were constructed in the pRK5 
mammalian expression vector that contained the extracellular N-terminal domain of the 
rat a9  and a  10 subunits respectively, fused to the transmembrane and intracellular 
domain of the mouse 5HT3A subunit (for brevity, these are referred to as a9% and a  10%) 
(Table 3.1).
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To examine whether these chimeras were able to generate functional receptors, as has 
been demonstrated for the a7/5HT3A chimera (Eisele et al., 1993; Blumenthal et al., 
1997; Rangwala et al., 1997; Cooper and Millar, 1998; Cooper et al., 1999), the a9% and 
alO% cDNAs in pRK5 were injected into Xenopus oocytes. This work was carried out 
by Dr. Ruud Zwart in a collaboration with Dr. Emanuele Sher's group at Eli Lilly. Clear 
evidence for the expression of functional receptors was obtained by two-electrode 
voltage-clamp recordings, although responses were significantly smaller than have been 
observed with the a7/5HT3A chimera (Eisele et al., 1993; Blumenthal et al., 1997; 
Rangwala et a l, 1997). Small whole-cell responses to ACh were detected in oocytes 
injected with either ql9% alone (13.6±7.7 nA; n=10) or with alO% alone (40.4±39.8 nA; 
n -24), demonstrating that both of these chimeras are able to form functional homomeric 
receptors (Figure 4.1). Responses detected in oocytes co-injected with the a9x  and 
alO% cDNAs (12.5±3.9 nA; n= 19) were not significantly larger than those recorded with 
either subunit alone. In all cases, responses to ACh were blocked completely and 
reversibly by a 2 min application of 1 pM a-BTX.
To examine whether problems encountered in the heterologous expression of a9 and 
alO nAChRs in a mammalian cell line could be alleviated by expression of 
nAChR/5HT3AR chimeras, the a9% and a  10% subunit cDNAs were introduced by 
transient transfection into tsA201 cells. Radioligand binding performed on membrane 
preparations derived from cells transfected with either the a9% chimera alone or the 
alOx chimera alone revealed specific binding with the nicotinic antagonist [3H]-MLA at 
levels significantly above background (166±50 fmol/mg and 68±22 fmol/mg, 
respectively; Figure 4.2). However, when a9 x  and a lO x  were co-expressed, 
substantially higher levels of specific [3H]-MLA binding were observed (8021160 
fmol/mg; Figure 4.2). Levels of [3H]-MLA binding detected in cells co-transfected with 
a9x and alOx were considerably higher than with a9x alone (4.3±0.3-fold, n=4) or with 
alOx alone (21.2±7.5-fold, n -6).
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FIGURE 4.1. Functional responses in Xenopus oocytes injected with a9x and a lO x  
subunit cDNAs. Application of 1 mM ACh to oocytes expressing ot9% or a lO x  nAChRs 
induced small, transient inward currents that were completely abolished after 2  min pre­
application of 1 pM  a-BTX. The inhibitory effect of a-B TX  on both chimeric nAChRs 
was almost completely reversed after 4-6 min of washout of the toxin. This work was 
carried out by Dr. Ruud Zwart, Eli Lilly, UK.
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FIGURE 4.2. Specific [3H]-MLA binding to cell membranes of tsA201 cells transiently 
transfected with wild-type (a9  and a  10) and chimeric (a9% and a  10%) subunits. Data 
are presented as means of 4 - 7 independent experiments performed in triplicate and 
show significant levels of radioligand binding in cells transfected with a 9 x  (166±50 
fmol/mg protein), alO% (68±22 fmol/mg protein) and a9% al0%  (802±160 fmol/mg 
protein). Significance determined by two-tailed Student’s t test (*p<0.05; **p<0.01).
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Proliferating cultures of UB/OC-1 and UB/OC-2 cells transiently transfected with the 
a9% and a  10% subunit chimeras either alone or in combination did not reveal any 
significant levels of [3H]-MLA binding (data not shown; n=3). The expression of the 
chimeric subunits in differentiating cultures of UB/OC cells has not been established (see 
Section 4.6).
4.5 Pharmacological characterisation of a9%al0% nAChR complexes in tsA201 
cells
Saturation radioligand binding performed on cells co-transfected with a9% and a  10% 
revealed that [3H]-MLA bound with high affinity (Kd = 7.5±1.2 nM, n=5; Figure 4.3). 
The data fit well to a single-site model during non-linear regression analysis (Figure 4.3). 
Scatchard analysis of the saturation binding data to membrane preparations of tsA201 
cells expressing a9%al0jc did not suggest the presence of more than one class of high 
affinity binding site for [3H]-MLA (Figure 4.3). The low levels of radioligand binding to 
a9% and al0%, when expressed alone, prevented an accurate determination of the 
affinity of [3H]-MLA binding to homomeric a9% and al0% receptors.
Equilibrium competition binding studies were performed with a range of ligands to 
determine their affinity for a9%al0% receptors (Figure 4.4; Table 4.1). The nicotinic 
antagonist a-BTX bound with high affinity (66±22 nM). Other nicotinic ligands bound 
with lower affinities, including d-tubocurarine (0.3±0.1 pM), l,l-dimethyl-4- 
phenylpiperazinium (DMPP) (2.0±0.4 pM), ACh (2.7±2.5 pM), carbachol (10.4±2.2 
pM), MCC (38.7±19.2 pM) and nicotine (42.9±6.2 pM). Specific competition binding 
was also observed with the glycine receptor convulsant strychnine, the GABA receptor 
antagonist, bicuculline and the muscarinic antagonist, atropine (66±7 nM, 0.6±0.3 pM 
and 9.9±1.3 pM, respectively). The rank order of K{ values is in good agreement with 
the relative potencies of these ligands identified from electrophysiological assays on both 
recombinant a9 and a9 a l0  nAChRs expressed in Xenopus oocytes and with native 
nAChRs expressed in hair cells (Housley and Ashmore, 1991; Fuchs and Murrow, 1992; 
Rothlin et ah, 1999; Verbitsky et al., 2000) (Table 4.1).
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A further series of radioligand binding studies were performed on tsA201 cells 
transfected with an a7(V201)/5HT3A subunit chimera (a7%) (Eisele et al., 1993; Cooper and 
Millar, 1998) constructed in the pRK5 vector (Section 3.2). The rationale of these 
studies was to facilitate a comparison of al% receptors with a9%al0% receptors, but also 
to enable a comparison with radioligand binding data which has been reported previously 
with native cc7 nAChRs (Anand et al., 1993b; Davies et al., 1999). Thus, whereas 
radioligand binding data determined with a9%al0% has been compared with EC30/IC50 
values for a 9 a l0  nAChRs (Table 4.1), a direct comparison is possible between 
equilibrium radioligand binding data from al% and a7-containing nAChRs (Table 4.2). 
A similar pharmacological profile of recombinant al% and native a l  nAChRs would 
argue that nAChR/5HT3A subunit chimeras reflect the ligand binding properties of 
corresponding wild-type nAChRs.
Saturation radioligand binding experiments performed with tsA201 cells transfected with 
al% revealed high affinity binding of [3H]-MLA (1.2±0.2 nM; Figure 4.3). This is in 
close agreement with estimates of the affinity of [3H]-MLA binding to rat brain a l  
nAChRs (1.9±0.3 nM) (Davies et al., 1999). The linear nature of the Scatchard plot in 
Figure 4.3, along with the good fit of data to a single-site model in the non-linear 
regression analysis of the saturation binding data suggests the presence of a single class 
of radioligand binding site in membrane preparations of tsA201 cells transiently 
transfected with al% (Figure 4.3). As illustrated in Table 4.2, competition binding 
studies performed on tsA201 cells transfected with al% reveal a pharmacological profile 
with close similarity to that of the native a l  nAChR (Anand et al., 1993a; Davies et al., 
1999).
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FIGURE 4.3. Specific binding of [3H]-MLA to a7% and oc9xal0% receptors expressed 
in tsA201 cells. (A) Equilibrium saturation radioligand binding was performed on 
membranes prepared from tsA201 cells transfected with al%  (upper panel) or a9x+al0%  
(lower panel) subunit chimeras. Data represent specific binding (circles) and non­
specific binding (squares). Data are from a single experiment performed in triplicate 
with Kd values of 11.8±4.0 nM (a9%al0%) and 1.6±0.2 nM (a7%), but are typical of 4 - 5 
independent determinations, giving mean Kd values of 7.5±1.2 nM (a9xotl0% ) and 
1.2±0.2 nM (a7%). (B) Scatchard Plots derived from the presented data that provide no 
evidence to suggest that the saturation radioligand binding to cells expressing a9xotl0% 
or a7% represents more than one class of [3H]-MLA binding site.
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FIGURE 4.4. Pharmacological characterisation of a9%al0% and oc7% receptors 
expressed in tsA201 cells. Equilibrium radioligand binding showing competition of 
[3H]-MLA binding by a-BTX, ACh, atropine, bicuculline, carbachol, DMPP, d- 
tubocurarine {d-TC), MCC, nicotine and strychnine. Binding was performed on 
membranes prepared from tsA201 cells transfected with a9%+al0% (closed circles) or 
al% (open circles) subunit chimeras. Data points are means of triplicate samples. Each 
graph is from a single experiment but is typical of 3 - 4 individual experiments. Mean 
values, derived from these and other competition radioligand binding studies, are 
presented in Tables 4.1 and 4.2.
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Ligand a9%al0x 
tsA201 cells
a9
oocyte
(E cS{/ i c S0y
a9 a l0  
oocyte 
(EC50/IC 50)8
a9al0* 
Hair cells
(EC50/IC50)1
MLA 7.5±1.2nM 1 nM ND ND
a-Bungarotoxin 66±22 nM 4 nM nM range nM range
Strychnine 66±7nM 18 nM 20 nM nM range
d-Tubocurarine 290±90 nM 300 nM 110 nM nM range
Bicuculline 0.6±0.3 pM 0.8 pM 1 pM ~ 1 pM
DMPP 2.0±0.4 pM ND ND ND
Acetylcholine 2.7±2.5 pM 11 pM 14 pM 7 pM
Atropine 9.9±1.3 pM 1 pM 1 pM pM range
Carbachol 10.4±2.2 pM 64 pM ND 87 pM
Methylcarbachol 38.7±19.2 pM 30 pM ND ND
Nicotine 42.9±6.2 pM 32 pM 4 pM pM range
5HT 451±21 pM 251 pM 5.4 pM 7.5 pM
TABLE 4.1. Pharmacological properties of a9%al0% nAChRs and comparison with 
native and recombinant receptors. Ligands are listed in order of decreasing affinity as 
determined by equilibrium radioligand binding with a9%al0% receptors expressed in 
tsA201 cells. The rank order for these ligands is in good general agreement with 
estimates of agonist/antagonist potency derived from functional assays performed with 
either recombinant a9 or a 9 a l0  nAChRs expressed in Xenopus oocytes or with native 
nAChRs expressed in hair cells. Kd values (for MLA) were determined by equilibrium 
saturation binding. values (for all other ligands) were determined by competition 
binding performed with [3H]-MLA. ND = data not determined.
* The subunit composition of native nAChRs expressed in hair cells is assumed to 
be a9al0 .
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t  Data (this study) are means of 4-5 experiments each performed in triplicate.
$ Data from Verbitsky et al., 2000.
§ Data from Elgoyhen et al., 2001.
1 Data from several studies, as reviewed by Verbitsky et al., 2000 and Elgoyhen et
al., 2001.
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Ligand 0.1% 
tsA201 cells 
(K yiy t
a l * 
Native (brain)
(Kd/Kj)
MLA 1.2±0.2 nM 1.9±0.3 nM *
a-Bungarotoxin 0.3±0.1 nM 1.8±0.5 nM *
Bicuculline 1.4±0.2 pM ND
d-Tubocurarine 1.6±0.2 pM ND
Strychnine 6.7±0.9 pM 5.4±0.5 pM §
Nicotine 28.8±8.7 pM 6.1±1.1 pM *
DMPP 28.9±5.3 pM ND
Methylcarbachol 90±34 pM 10.6±0.6 pM *
Atropine 140±11 pM 198±10 pM 8
Acetylcholine 129±39 pM 103±8.7 pM 8
Carbachol 698±248 pM 580±205 pM 8
TABLE 4.2. Pharmacological properties of al% nAChRs and comparison with native 
a l  receptors. Ligands are listed in order of decreasing affinity as determined by 
equilibrium radioligand binding with al% receptors expressed in tsA201 cells. The rank 
order for these ligands is in good general agreement with estimates of binding affinity 
determined with native a l  nAChRs expressed in rat or chick brain. Kd values (for MLA) 
were determined by equilibrium saturation binding. values (for all other ligands) were 
determined by competition binding performed with [3H]-MLA. ND = data not 
determined.
* The subunit composition of native a7-containing nAChRs is uncertain but data 
from rat brain ($) are expected to correspond predominantly to homomeric a l  
(Chen and Patrick, 1997; Drisdel and Green, 2000). Data from chick brain (§) are
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expected to represent binding to a mixed population ce7, a8 and a7a8 nAChRs 
(Keyser et a l, 1993).
f Data (this study) are means of three experiments each performed in triplicate.
$ Data from Davies et al., 1999, from rat brain a7 nAChR.
§ Data from Anand et al., 1993b, from chick brain a l  nAChR.
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4.6 Discussion
The expression of both functional homomeric a9 and heteromeric a 9 a l0  nAChRs has 
been demonstrated upon expression of the a9 and alO subunits in Xenopus oocytes 
(Elgoyhen et al,, 1994; Elgoyhen et al., 2001). However, in the present study, no 
evidence for specific binding of nicotinic radioligands was detected in mammalian cells 
transfected with a9 and a  10. The inability of the a9 and a  10 subunits to assemble into 
nAChRs that bind radioligands such as [3H]-MLA with high affinity when expressed in 
tsA201 cells, may suggest that subunit misfolding is a cell-specific event and is 
consistent with previous studies that have failed to detect the expression of a9- 
containing nAChRs in HEK293 cells (Lustig et al., 2001).
The UB/OC-1 and UB/OC-2 cell lines express endogenous a9-containing nAChRs 
(Rivolta et al., 1998; Jagger et al., 2000), so it was somewhat surprising that these 
receptors could not be detected by radioligand binding of either proliferating or 
differentiating cultures of cells. Under differentiating conditions, expression of a9 
mRNA is upregulated and a greater proportion of cells respond to ACh (Rivolta et al., 
1998; Jagger et al., 1999). However, the absence of radioligand binding may be due to 
low levels of receptor expression even in differentiated cell cultures. Alternatively, the 
native a9-containing nAChRs of the UB/OC cell lines may not generate ligand binding 
sites of high enough affinity to be detected with either 30 nM [3H]-MLA or 30 nM [3H]- 
strychnine. Native a9-nAChRs in cochlea hair cells are antagonised by nanomolar 
concentrations of strychnine, but the affinity for MLA has not been determined 
(Verbitsky et al., 2000). Specific [3H]-MLA binding was not detected following over­
expression of either wild-type a9 and alO or chimeric a9% and a  10% subunits in 
cultures of proliferating cells. The over-expression of these subunits in differentiating 
cultures of cells would require the generation of stable cell lines, as differentiation 
requires culture of cells under permissive conditions (37 - 39°C in the absence of y- 
interferon) for approximately 14 days. Evidence for the expression of functional
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endogenous nAChRs in these cell lines (Rivolta et al., 1998; Jagger et al., 1999) 
demonstrates the appropriate folding and assembly of nicotinic subunits in UB/OC cells, 
suggesting that the absence of radioligand binding, even upon over-expression of 
chimeric subunits, is a consequence of an alternative factor, such as a low transfection 
efficiency of these cells. The generation of stable cell lines would, therefore, be a major 
advantage to this study, allowing much greater expression of subunit protein.
The recent identification of a9 mRNA transcripts in SH-SY5Y cells (Valor et al., 2003) 
implies that this cell line may provide an alternative system in which to study a9- 
containing nAChRs. It is interesting to note that in a study where constructs containing 
regions of the a9 promoter were expressed in SH-SY5Y cells, attempts to express these 
constructs in UB/OC-2 cells failed (Valor et al., 2003). The expression of green- 
fluorescent protein under the control of a human cytomegalovirus (CMV) promoter in 
the UB/OC-2 cells revealed that the cells were efficiently transfected by calcium 
phosphate, but that the a9 constructs, under the control of SV40 promoters, were not 
expressed in these cells (Valor et al., 2003). The reason that the activity of some 
promoters is restricted in this cell line is unknown, but may reflect the cell culture 
conditions. Expression of the a9 and a  10 subunits in the present study was attempted 
using subunits in the pClneo and/or pRK5 mammalian expression vectors, both under 
the control of a CMV promoter, suggesting that appropriate expression vectors were 
employed.
Several previous studies have reported inefficient folding and/or cell-surface expression 
of nAChR subunits when expressed heterologously in a variety of host cell types (Quik 
et al., 1996; Cooper and Millar, 1997; Kassner and Berg, 1997; Rangwala et al., 1997; 
Cooper and Millar, 1998; Sweileh et al., 2000). A common feature of these studies is 
that inefficient folding and cell-surface expression of nAChRs can be attributed to 
sequences present within the C-terminal (transmembrane and intracellular) subunit 
domains (Eisele et al., 1993; Blumenthal et al., 1997; Cooper and Millar, 1998; Cooper
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et al., 1999; Harkness and Millar, 2002). High levels of functional cell-surface receptors 
have been detected in several cell lines after expression of al% or oc8% subunit chimeras, 
including host cell types in which few, if any, correctly folded nAChRs can be detected 
after expression of wild-type a l  or a8 (Eisele et al., 1993; Cooper and Millar, 1998).
While no evidence for specific binding of nicotinic radioligands was detected in 
mammalian cells transfected with a9 and a  10, it was possible to detect specific high 
affinity [3H]-MLA binding in a mammalian cell line transfected with chimeric a9% and 
al0% subunits. This permitted a detailed pharmacological characterisation of 
recombinant a9 a  10-type nAChRs by equilibrium radioligand binding for the first time. 
Successful heterologous expression of a9% and a  10% subunit chimeras is consistent with 
previous studies with chimeras such as a7(V201)/5HT3A (Eisele et al., 1993; Cooper and 
Millar, 1998) and provides further evidence that inefficient folding of neuronal nAChR 
subunits into a conformation recognised by nicotinic radioligands can be attributed to 
their C-terminal region.
Whilst low levels of [3H]-MLA binding were observed in cells transfected with either 
a9% or al0% alone, significantly higher levels of binding were detected in cells co­
transfected with a.9% and al0%, providing evidence of a requirement for heteromeric co­
assembly for the efficient formation of a nicotinic binding site. This is consistent with 
co-expression studies of wild-type a9 and alO in Xenopus oocytes, which report that 
responses in oocytes co-injected with a9 and alO are ~ 100-fold larger than in oocytes 
injected only with a9 (Elgoyhen et al., 2001; Sgard et al., 2002). The present study also 
suggests that a9 and a  10 N-terminal regions contain domains important for subunit co­
assembly and agrees with several previous studies (performed with mutated and chimeric 
nAChR subunits), which have concluded that critical assembly domains are located at 
the N-terminus of nAChR subunits (Gu et al., 1991; Yu and Hall, 1991; Sumikawa, 
1992).
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Non-linear regression and Scatchard analyses of the saturation binding data indicated the 
detection of a single class of high affinity radioligand binding sites (Figure 4.3), 
suggesting that a9% or alO% homomers (or a9%al0% heteromers with differing 
stoichiometries) were either not generated or could not be differentiated from the high 
affinity [3H]-MLA binding sites of the heteromeric oc9%al0% receptor via radioligand 
binding to membrane preparations of tsA201 cells transiently transfected with equal 
quantities of a9% and a  10% cDNAs.
The presence of the entire N-terminal extracellular ligand-binding domain of the a9 and 
alO subunits within the a9% and a  10% chimeras would suggest that such chimeras might 
exhibit pharmacological properties which mimic those of native a 9 a l0  nAChRs. 
Electrophysiological studies on recombinant a9-containing nAChRs expressed in 
Xenopus oocytes have revealed somewhat atypical pharmacological properties with 
modulation by a diverse collection of ligands including those known to bind with high 
affinity to muscarinic acetylcholine receptors, glycine receptors and GABA receptors 
(Rothlin et al., 1999; Verbitsky et al., 2000; Elgoyhen et al., 2001). The 
pharmacological profile for the chimeric a9%al0% receptor constructed in this study 
correlates well with data obtained from electrophysiological assays on both recombinant 
a9 and a 9 a l0  nAChRs expressed in Xenopus oocytes and native nAChRs expressed in 
hair cells (Housley and Ashmore, 1991; Fuchs and Murrow, 1992; Rothlin et al., 1999; 
Verbitsky et a l, 2000). The assumption that the a9%al0% receptor can serve as a viable 
model for investigation of the a 9 a l0  nAChR is supported by the comparison of 
equilibrium binding data obtained with the a7(V201)/5HT3A chimera to data obtained with 
native a l  nAChRs (Anand et al., 1993a; Davies et al., 1999).
Comparison of competition binding data conducted with a7% and a9%al0% (Figure 4.4) 
reveals that MLA, a-BTX and nicotine bind with higher affinity to a7% than to 
a9%(xl0%, whilst all other ligands tested bind with higher affinity to a9%al0% than they 
do to a7% (Tables 4.1 and 4.2). This is in agreement with previous studies, which have
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reported that a9 a l0  nAChRs exhibit an atypical pharmacological profile (Rothlin et al., 
1999; Verbitsky et al., 2000; Elgoyhen et al., 2001), while a7 nAChRs demonstrate a 
more conventional nAChR profile (Anand et al., 1993a; Davies et al, 1999).
The finding that a9% is able to generate a functional homomeric ion channel is consistent 
with the ability of both the a9 subunit and the 5HT3A subunit to form homomeric ligand- 
gated ion channels (Maricq et a l, 1991; Elgoyhen et a l, 1994). This also demonstrates 
that replacement of the C-terminal region of the nAChR subunit with the 5HT3A subunit 
sequence does not abolish the ability of the receptor to elicit functional responses and is 
consistent with previous studies of the al% chimera, for which a functional coupling 
between the a l  ligand binding domain and the channel domain of 5HT3A has been 
demonstrated (Eisele et a l, 1993).
Despite the inability of wild-type a  10 to generate functional homomeric nAChRs when 
expressed in oocytes (Elgoyhen et a l, 2001), the chimeric ocl0% subunit appears able to 
do so. This suggests that the wild-type alO subunit contains an extracellular domain 
capable of forming a nicotinic ligand binding site (when folded into an appropriate 
conformation), despite the inability of wild-type a  10 to form a functional homomeric ion 
channel. Interestingly, it has also been reported that a chimera containing the N-terminal 
region of the human a9 subunit fused to the C-terminal region of alO (a9:al0) produces 
functional ion channels in oocytes (Sgard et a l, 2002). Thus, despite the inability of alO 
to form functional homomeric nAChRs in heterologous expression systems, subunit 
chimeras containing either the N-terminus of a  10 (with the C-terminus of 5HT3A) or the 
C-terminus of alO (with the N-terminus of a9) are able to do so.
The observation that the functional responses detected in oocytes co-injected with the 
a9% and al0% cDNAs were not significantly larger than those obtained with either of the 
chimeric subunit alone is in contrast to co-expression studies of wild-type a9 and alO in
oocytes (Elgoyhen et a l, 2001; Sgard et a l, 2002). This discrepancy between chimeric
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and wild-type subunits is surprising given the synergistic effect upon [3H]-MLA binding, 
which is observed when the two chimeric subunits are co-expressed in mammalian cells. 
This may be a consequence of differences in the transmembrane pore-forming domains 
of the chimeric and wild-type subunits. In each of the homomeric or heteromeric 
receptors containing chimeric subunits, the residues of the 5HT3A subunit (see Section
1.2.4) provide the presumed transmembrane domain comprising the ion channel. If the 
coupling between agonist binding and channel opening domains in these chimeric 
subunits is relatively inefficient in both the homomeric and heteromeric complexes, this 
may explain why significantly larger whole-cell responses are not observed when a9% 
and alO% are co-expressed. Upon expression of the human a9:ccl0 chimera, containing 
the N-terminal domain of a9 fused to the C-terminal domain of alO in Xenopus oocytes, 
large ACh-evoked whole cell responses were observed that were typically larger than the 
responses observed in cells expressing the wild-type a9  subunit alone (Sgard et al.,
2002). This reveals the influence of the C-terminal region of the a  10 subunit on the 
ionic pore and gating properties of the recombinant nAChRs (Sgard et a l , 2002). In 
addition, functional characterisation of the a7/5HT3A chimera in Xenopus oocytes 
demonstrated that the ligand binding properties resembled a7, the ion channel properties 
resembled 5HT3A, while the kinetics of current onset and desensitisation, (rapid for a7 
and slow for 5HT3A) were intermediate in the chimera, suggesting that the inter- 
conversion between the functional states of the receptors involve the structure of the 
complete receptor molecule (Eisele et al., 1993).
In summary, the construction and heterologous expression of a9% and a  10% subunit 
chimeras has allowed, for the first time, an examination of the pharmacological 
properties of recombinant a9 a  10-type nAChRs in a mammalian cell line by radioligand 
binding. The equilibrium binding studies reported here, conducted with cells co­
transfected with a9% and a  10%, are in good general agreement with previous studies of 
wild-type a9 a l0  nAChRs conducted by electrophysiological techniques (Rothlin et al.,
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1999; Verbitsky et al., 2000). In particular, this study demonstrates specific high-affinity 
binding of the nicotinic antagonist MLA, together with evidence for an atypical 
pharmacological profile for a9 a l0  nAChRs.
These data have been accepted for publication in Molecular Pharmacology (Baker et al., 
2004).
4.7 Future directions
While the a9% and a  10% subunits generate functional ion channels in response to ACh 
when expressed in Xenopus oocytes (Figure 4.1), the functional capabilities of the 
homomeric a9% and a  10% or the heteromeric a9%al0% complexes have yet to be 
determined in mammalian cells. The small size of the whole-cell responses observed in 
Xenopus oocytes (13.6±7.7 nA; n=10 for a9% and 40.4±39.8 nA; n=24 for alOx) may 
hinder the detection of functional responses in tsA201 cells.
While the radioligand binding data suggest the co-assembly of the a9% and a  10x 
subunits, this has not been shown directly. Co-immunoprecipitation of subunits from 
transfected cells has not been attempted, as the two chimeric subunits migrate to similar 
positions when subjected to SDS-polyacrylamide gel electrophoresis (Figure 3.2) and 
would not be easily distinguished from each other using this technique. Sucrose gradient 
centrifugation could be used to assess whether the putative a9%al0x nAChR 
demonstrates a sediment coefficient corresponding to a pentameric complex.
The radioligand binding studies did not permit the detection of a9-containing nAChRs in 
the UB/OC cell lines and a number of modifications could improve this investigation. 
The cells require approximately 14 days culture under permissive conditions to allow 
terminal differentiation, excluding the use of transient transfection to investigate the
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over-expression of nicotinic subunits. The endogenous subunits may not be expressed at 
levels high enough to permit the detection of a9-containing nAChRs in the radioligand 
binding assay. Therefore, the production of stable cell lines expressing wild-type or 
chimeric subunits would enhance this study, by allowing the over-expression of nAChR 
subunits in differentiated cells. The use of techniques such as immunofluorescence with 
subunit-specific antibodies may also prove useful in investigating nAChR expression, 
particularly if the expression levels are low and preclude meaningful quantification via 
radioligand binding. The expression of other recombinant nAChRs, such as a4p2 or 
al% in the UB/OC cells may prove beneficial in the optimisation of transfection and 
radioligand binding assay conditions and in the comparison of the expression of different 
receptor subtypes in the cochlea-derived cell lines.
A recent study revealed that the a9 subunit is expressed in SH-SY5Y cells (Valor et al.,
2003), a cell line in which the homomeric a l  nAChR is expressed at the cell surface 
(Cooper and Millar, 1997). It would, therefore, be interesting to investigate the 
expression of a9-containing nAChRs in this cell line in comparison to nAChRs 
containing the a l  subunit.
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CHAPTER 5
THE SUB-CELLULAR DISTRIBUTION OF a9%a!0% COMPLEXES
5.1 Introduction
Chapter 4 described evidence that chimeric a9% and a  10% subunits can assemble into 
both homomeric and heteromeric complexes capable of binding [3H]-MLA when 
expressed in tsA201 cells. The [3H]-MLA binding assays were performed on membrane 
preparations of tsA201 cells transiently transfected with a9% and al0% subunits and 
measured the total levels of radioligand binding sites in the disrupted cells. The 
evidence for the formation of functional homomeric a9% and al0% receptors expressed 
in Xenopus oocytes, demonstrated by small whole cell responses to ACh, suggests that 
these chimeric receptors are expressed at the cell surface of oocytes (Figure 4.1). This 
chapter describes the experiments performed to investigate the sub-cellular distribution 
of complexes containing a9% and a  10% chimeras expressed in tsA201 cells. Two 
approaches were used to assess whether the chimeric receptors were expressed at the cell 
surface: the construction of epitope-tagged subunits (Section 5.3) and radioligand 
binding assays on intact cells (Section 5.2).
5.2 Sub-cellular distribution investigated by radioligand binding
Radioligand binding performed on membrane preparations of tsA201 cells does not 
provide information regarding the sub-cellular distribution of the chimeric nAChRs. 
When using membrane impermeant radioligands such as [3H]-MCC and [125I]-a-BTX to 
characterise nAChRs, equilibrium radioligand binding assays can be performed on intact 
cells, enabling quantification of nAChR levels at the cell surface. MCC contains a 
charged quartemary ammonium atom, making it membrane impermeable (Whiteaker et 
al., 1998), while the large size of the 8 kDa a-BTX peptide prevents permeation of the 
membrane. However, [3H]-MLA is a potentially membrane permeant ligand (Davies et
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al., 1999) and so cannot be used directly to look at the cell surface expression of 
a9xocl0% nAChRs in intact cells.
Non-radiolabelled, membrane impermeable ligands can be used to block cell surface 
receptors in an indirect approach to estimate the proportion of [3H]-MLA binding sites at 
the cell surface(Section 2.6.4) (Whiteaker et al., 1998; Fenster et al., 1999). Specific 
binding to cell surface a9%al0% receptors was determined by competition with 1 mM 
ACh, a membrane impermeant ligand (Whiteaker et al., 1998; Fenster et a l, 1999). 
Competition binding to membrane preparations of tsA201 cells transiently transfected 
with a9%al0%, established that a concentration of 1 mM ACh is sufficient to block 
a9xocl0% receptors (Kx ACh = 2.7±2.5 pM; Table 4.1). This concentration of ACh was 
found to block >95% of total [3H]-MLA binding to cell membrane preparations. 
Application of ACh to intact cells should result in the block of only surface receptors 
(Whiteaker et al., 1998; Fenster et al., 1999). Total [3H]-MLA binding was determined 
in the absence of unlabelled nicotinic ligands and non-specific binding was determined 
in the presence of 1 mM nicotine, 1 mM carbachol and 10 pM cold MLA to block both 
surface and internal [3H]-MLA binding sites. Using these reaction conditions, specific 
binding to the total pool of receptors is calculated using the difference between "total" 
and "non-specific" radioligand binding. Specific binding to internal pools is the 
difference between binding in the presence of the ACh block and non-specific binding. 
Specific binding to cell surface receptors is calculated from the difference between total 
[3H]-MLA binding and binding in the presence of ACh (Figure 5.1).
Assay of intact cells was performed in parallel with assay of disrupted cells, to compare 
the total levels of [3H]-MLA binding and assess the degree of membrane permeation by 
the radioligand (Figure 5.2). The proportion of [3H]-MLA binding sites on the cell 
surface are presented as a percentage of the total levels of radioligand binding detected in 
preparations of disrupted cells (Table 5.1).
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FIGURE 5.1. Binding protocol used to determine the proportion of nAChRs expressed 
at the cell surface with [3H]-MLA. Equilibrium radioligand binding was performed on 
suspensions of intact cells transiently transfected with a9% and alO% chimeric subunits 
to estimate the proportion of receptors expressed at the cell surface. Binding was 
performed under three different reaction conditions in parallel, using the membrane 
permeant radioligand, [3H]-MLA:
(A) Total Binding (T) in the presence of buffer to label surface and internal receptors
(B) Non-Specific Binding (NS) in the presence of 1 mM nicotine, 1 mM carbachol and 
10 pM  MLA to block surface and internal pools of receptors
(Q  In the presence of 1 mM ACh to block binding to the cell surface receptors (ACh)
(A) - (B)  = Total specific binding to the cell surface and the intracellular pools of 
receptor (T - NS)
(A) - (C) = Specific binding to cell surface receptors (T - ACh)
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Specific [3H]-MLA binding was detected to intact cells transiently transfected with 
a9%+al0% (25.7±6.0 fmol/K/* cells, n -3) (Figure 5.2). Levels of non-specific [3H]- 
MLA binding to intact cells, determined by competition with ACh, were very low 
(typically <3% total binding) and were not significantly different when binding was 
performed in competition with a combination of membrane-permeant and membrane- 
impermeant ligands (1 mM nicotine, 1 mM carbachol and 10 |iM MLA), which would 
be expected to block binding of [3H]-MLA to surface and internal sites. Comparison of 
binding with intact cells to binding studies performed in parallel with cell membrane 
preparations indicated that 83±16% (w=3) of total specific binding sites were located on 
the surface of tsA201 cells expressing a9%+al0% (Figure 5.2; Table 5.1).
As low levels of specific [3H]-MLA binding were detected in membrane preparations of 
cells expressing either the a9% or al0% subunits alone, experiments were also performed 
on intact tsA201 cells transfected with these subunits in parallel with cells co-expressing 
both of the chimeras. Intact cells revealed 9.5±2.2 fmol/106 cells («=3) of [3H]-MLA 
binding to cells transfected with a9x, with just 2.7±0.8 fmol/106 cells {n= 3) of binding to 
cells expressing al0%. However, higher levels of total specific [3H]-MLA binding were 
detected with suspensions of intact cells transfected with a9% alone, than in membrane 
preparations of the same cells (Figure 5.2). As both the intact cell suspensions and 
membrane preparations were derived from the same sample of transfected cells, this 
difference is not attributable to differences in transfection efficiency, but is related 
directly to the conditions used to disrupt the tsA201 cells. The loss of binding to 
membrane preparations of cells precluded the estimation of the proportion of [3H]-MLA 
binding sites at the surface of cells expressing a9% as a percentage of total binding in cell 
membrane preparations.
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FIGURE 5.2. Cell surface expression of cc9xcxl0x receptors determined by [3H]-MLA binding. 
Equilibrium radioligand binding was performed on intact or disrupted tsA201 cells transfected 
with a9x and alOx chimeras. Data are means (+ standard error) of 3 experiments performed in 
triplicate. (A) Binding was carried out under 3 reaction conditions using the membrane permeant 
radioligand, [3H]-MLA: (1) Total Binding (T) in the presence of buffer to label surface and 
internal pools of receptor; (2) Non-Specific Binding (NS) in the presence of 1 mM nicotine, 1 
mM carbachol +10 pM MLA to block surface and internal pools; (3) In the presence of 1 mM 
ACh to block binding to surface receptors (ACh). (B) Total specific binding to surface and 
internal pools of receptor = T - NS; Specific binding to cell surface receptors = T - ACh. The 
proportion of a9xocl0x at the cell surface = (Specific binding to surface receptors / Total specific 
binding to cell membranes ) = 83±16%.
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aStyalOx 
Intact Cells
a9%al0%
Membranes
<x9x 
Intact Cells
a9%
Membranes
alOx 
Intact Cells
alOx
Membranes
Total binding (T) (fmol/106 
cells)
26.5±6.2 35.4±7.9 13.1±3.2 2.8±1.2 3.4±0.6 7.9±2.5
Non-Specific binding (NS) 
(fmol/106 cells)
-0.1 ±0.4 1.8±0.7 0.2±0.3 0.8±0.4 -0.2±0.2 0.3±0.2
Binding with ACh block 
(ACh) (fmol/106 cells)
0.8±0.2 3.4±1.3 3.6±1.0 1.0±0.1 0.6±0.2 0.6±0.1
Total specific binding 
(fmol/106 cells) [T-NS]
26.6±6.0 33.7±7.2 12.9±3.1 0.1±0.2 3.5±0.9 7.8±2.2
Surface binding (fmol/106 
cells) [T-ACh]
25.7±6.0 N/A 9.5±2.2 N/A 2.7±0.8 N/A
Proportion of binding sites at 
cell surface (% of total specific 
binding in membranes)
83±16 N/A ND
(see Section 5.2)
N/A 35.2±1.5 N/A
TABLE 5.1. [3H]-MLA binding to nAChR/5HT3AR complexes at the cell surface. Equilibrium radioligand binding was carried out on suspensions of 
intact and disrupted cells transiently transfected with oc9% and alOx chimeric subunits to estimate the proportion of receptors expressed at the cell 
surface. Binding was carried out using the membrane permeant radioligand, [3H]-MLA in the presence of buffer (Total binding, T) or 1 mM nicotine, 
1 mM carbachol and 10 pM MLA (Non-Specific binding, NS) or 1 mM ACh (to block cell surface receptors, ACh). Data are presented as means (± 
standard error) of 3 independent experiments performed in triplicate. N/A = not appropriate. ND = data not determined.
5.3 Sub-cellular distribution investigated with epitope-tagged subunits
The expression of nAChRs at the cell surface can be investigated using subunit-specific 
antibodies. For example, mAb299 specifically recognises an extracellular epitope of the 
a4 nAChR subunit and has been used to determine the relative proportions of a4 at the 
cell surface (Cooper et al.y 1999). However, suitable antibodies specific to the a9 and 
alO subunits were not available. An alternative approach is to introduce recombinant 
epitope-tags into the sequence of a particular subunit that can be recognised by a 
monoclonal antibody (mAb). In this study, the nine amino acid epitope tag 
(YPYDVPDYA) from human influenza haemagglutinin (HA) protein was used and is 
recognised by mAbHA-7 (Kolodziej and Young, 1991) (Figure 5.3). The HA epitope 
tag was inserted into the sequence of each of the wild-type a9 and alO and chimeric a9% 
and a  10% subunits at one of three positions: (i) the N-terminus, following the putative 
cleavage site of the leader peptide (N HA), (ii) the extreme C-terminus (C HA), (iii) within 
the intracellular loop region (I HA).
5.3.1 Introduction of the HA tag to the extreme C-terminus
HA-epitope tags were introduced to the a9, alO, a9% and al0% subunits at their extreme 
C-termini by PCR to create a9CHA, alOCHA, a9%CHAand alO%CHA subunits in the 
expression vector, pRK5 (Section 2.3.3; Table 5.2). Mammalian tsA201 cells transiently 
transfected with C-terminally tagged subunits were subjected to immunoblotting with 
mAbHA-7 to demonstrate protein expression. This revealed immunoreactive protein of 
a size similar to that expected for full-length mature a9 and alO subunits (Figure 5.4; 
Table 5.2). Detection of subunits tagged at their extreme C-termini provides strong 
evidence that these correspond to full-length subunit protein. However, the 
immunodetection revealed a smear of protein bands from ~50 kDa to below 46 kDa, 
which may indicate some protein degradation.
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FIGURE 5.3. Rat nAChR-HA epitope tagged subunit constructs. A nine amino acid 
epitope tag (YPYDVPDYA) from human influenza haem agglutinin (HA) protein 
(Kolodziej and Young, 1991) was introduced into the cDNA sequence of the wild-type 
or chimeric a9  and a  10 subunits. (A) HA epitope tags were introduced by site directed 
mutagenesis (SDM) into the intracellular loop region between putative transmembrane 
domains, M3 and M4, at a restriction enzyme Nhel site (I HA). (B ) HA epitope tags were 
introduced by SDM into the N-terminal domain at a restriction enzyme Nhel site (N HA).
(C) HA epitope tags were introduced to the extreme C-terminus by PCR (C'HA). The HA 
epitope tag is recognised by the monoclonal antibody, mAbHA-7.
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Subunit Tagged at the N-terminal Subunit Tagged in the Intracellular Loop Subunit Tagged at the C-terminal
Construct Residue at 
which Nhel 
site created
Apparent
Mr
Construct Residue at 
which Nhel 
site created
Apparent
Mr
Construct Residue 
after which 
tag inserted
Apparent
Mr
pRK5-a9NHA a9-T3 46 pRK5-cc9IHA (X9-P345 45-48 pRK5-a9CHA (X9-D457 43-47
pRK5-al0NHA al0-L5 46 pRK5-al0IHA al0-L320 44-48 pRK5-al0CHA alO-L423 40-46
pRK5-a9xNHA a9-T3 46-49 pRK5-a9xIHA 5HT3A-V425 46-50 pRK5-a9xCHA 5HT3A-S465 46-50
pRK5-al0xNHA al0-L5 44 pRK5-al0xIHA 5HT3a-V425 47-49 pRK5-al0xCHA 5HT3A-S465 45-49
TABLE 5.2. Summary of HA epitope-tagged cc9, a  10, a9% and a  10% subunits. Each subunit contains the nine amino acid epitope tag 
(YPYDVPDYA) from human influenza haemagglutinin (HA) protein (Kolodziej and Young 1991). Epitope tags were introduced either at the N- 
terminal domain (N HA), within the intracellular domain (I HA) (at an Nhel site created by SDM) or at the extreme C-terminus (C IiA) (by PCR). Apparent 
molecular weights were estimated following metabolic labelling and immunoprecipitation using mAbHA-7 (Figure 5.4).
• l i f e
N-terminal HA Intracellular loop HA
tagged subunits tagged subunits
<
C-terminal HA tagged 
subunits
FIGURE 5.4. H eterologous expression of HA-tagged subunits determ ined by 
immunoprecipitation of metabolically labelled proteins from detergent-solubilised cells. 
Mammalian tsA201 cells were transfected with a9 , alO , a9% or alO% subunits tagged 
with an HA epitope at their N-termini (NHA), in the intracellular loop region (I HA) or at 
their C-termini (C HA) and constructed in the mammalian expression vector, pRK5. Cell 
lysates were immunoprecipitated with a monoclonal mouse a-H A  antibody, mAbHA-7. 
The positions of molecular weight markers are indicated. Immunoreactive bands were 
detected corresponding to the each of the HA epitope-tagged subunits.
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To investigate the expression and distribution of the HA-tagged subunits, intact and 
permeabilised tsA201 cells transfected with combinations of wild-type and chimeric 
subunits were subjected to an enzyme-linked assay using horseradish peroxidase (HRP), 
as described previously (e.g. Cooper et al., 1999). In the HRP-assay, subunit protein is 
detected through binding of a primary antibody to the specific subunit (in this case, 
mouse mAbHA-7, which specifically detects the HA epitope tag). The primary antibody 
is detected by a secondary antibody, conjugated to HRP (goat a-mouse IgG-conjugated 
HRP). Quantification of labelled nAChR is achieved via incubation with TMB liquid 
substrate for HRP, which forms a soluble blue reaction product, the absorbance of which 
is measured at 655 nm (Section 2.9). Expression of each of the pRK5-a9C HA, pRK5- 
alOCHA, pRK5-a9%CHA and pRK5-a 10%CHA subunit proteins was detected in 
permeabilised cells, but no clear evidence was obtained for the expression of any subunit 
at the cell surface (Figure 5.5). Subunits were co-expressed in pairwise combinations of 
tagged and non-tagged subunits, but no evidence for cell surface expression was 
obtained (data not shown; n=3).
5.3.2 Introduction of the HA tag to the N-terminal region
The HA epitope tag was introduced into the sequence of each wild-type or chimeric 
subunit at a position following the putative cleavage site of the leader peptide, so that the 
tag would be positioned close to the extreme N-terminal end of the mature protein, to 
create a9N HA, alONHA, a9%N HA and alO%NHA in the pRK5 expression vector. The HA 
tag was inserted at a unique Nhel site (G/CTAGC), created in the subunit sequence by 
site-directed mutagenesis (SDM) (Section 2.3.1; Table 5.2). Immunoblotting of tsA201 
cells transiently transfected with the subunits tagged at their N-termini using mAbHA-7, 
revealed specific protein bands for each subunit (Figure 5.4). The protein bands detected 
were of a size similar to that expected from the predicted molecular weights (Tables 3.3 
and 3.4) and also migrated at a similar position to the subunits tagged at their extreme C- 
termini, suggesting the production of full-length subunit protein (Figure 5.4; Table 5.2).
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Intact and permeabilised tsA201 cells transiently transfected with tagged subunits were 
subjected to HRP-assay. Specific protein expression was detected in permeabilised cells 
transfected with each of the a9NHA, alO NHA, a9%NHA and alO%NHA subunit cDNAs 
(Figure 5.5). Parallel assays carried out on intact cells revealed a significant level of 
mAbHA-7 binding at the surface of tsA201 cells transfected with a9%NHA alone (Figure 
5.5). The assay indicated that a high proportion of the total a9%NHA protein was 
expressed at the cell surface (106.3±10.9%; n= 12). Cell surface expression of the a9N* 
HA, alONHA or alO%NHA subunits was not observed.
Combinations of tagged (a9NHA, alONHA, a9%NHA, alO%NHA) and non-tagged (a9, alO, 
a9%, a  10%) subunits were co-expressed in tsA201 cells. Intact and permeabilised cells 
were subjected to HRP-assay to investigate subunit co-assembly. Tagged alONHA and 
alO%NHA subunits were co-expressed with non-tagged a9  and a9% subunits, but no 
evidence was obtained for cell surface expression of alO NHA or alO%NHA subunits as 
either homomeric or heteromeric receptors (Figure 5.6). Tagged a9N HA and a9%NHA 
subunits were co-expressed with non-tagged a  10 and a  10%, but the a9N HA subunit was 
not detected at the cell surface either as a homomeric or heteromeric complex. However, 
significant levels of specific antibody binding were detected at the surface of cells 
transfected with a9%N HA (106.3±10.9% total protein; n= 12) and a9%NHA+al0  (87±29%; 
n=3). A reduction in the levels of detectable cell surface receptors was observed with 
heteromeric a9%NHA+alO% receptors in comparison to homomeric a9%N HA receptors (to 
13±3%; n -3; Figure 5.6).
Membrane preparations of tsA201 cells transiently transfected with combinations of 
tagged a9%NHA and alO%NHA subunits and non-tagged a9% and al0% subunits were 
subjected to [3H]-MLA binding to investigate whether the epitope tags affect the ligand 
binding site. In comparison to the levels of binding to non-tagged a9%al0%, the levels 
of [3H]-MLA binding were reduced in cells expressing a9%N HA+alO%N HA, a9%N'
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HA+alO% and a9%+alO%NHA, to 2±1%, 34±20% and 5±2% of binding to a9%oA0%, 
respectively (n=5) (Figure 5.7).
5.3.3 Introduction of the HA tag to the intracellular loop region
HA epitope tags were introduced to the intracellular loop region of each of the a9, a  10, 
a9% and a  10% subunits at a unique Nhel site created by SDM to produce a9IHA, alOIHA, 
oc9%I HA and alO%IHA in pRK5 (see Section 2.3.2; Table 5.2).
Epitope tags in the intracellular loop region should not disrupt the formation of the N- 
terminal ligand binding site directly, but would also not be recognised by antibodies 
applied at the extracellular surface (this is confirmed in Figure 5.5). It may be possible 
to ascertain the distribution of subunits containing epitope tags in the intracellular loop 
domain through confocal microscopy. However, when membrane preparations of 
tsA201 cells transfected with combinations of tagged (a9%I HA and alO%I HA) and non- 
tagged (cl9x and a  10%) chimeric subunits were subjected to equilibrium radioligand 
binding using [3H]-MLA, the levels of [3H]-MLA binding were significantly reduced in 
cells expressing a9%IHA+al0%IHA and a9%+alO%I HA, to 18±2% and 15±1% of binding to 
a9%+ocl0%, respectively (Figure 5.8).
Following metabolic labelling and immunoprecipitation with mAbHA-7 on tsA201 cells 
transiently transfected with the subunits tagged in the intracellular loop region, specific 
protein bands for each subunit were detected (Figure 5.4). The protein bands detected 
are of a size similar to that expected from the predicted molecular weights (Tables 3.3 
and 3.4) and also correspond well to the protein bands detected for subunits tagged at 
their N- or C-termini (Figure 5.4), suggesting full-length subunit protein is produced 
following the transient transfection of tsA201 cells with cDNA of subunits tagged in the 
intracellular loop region. The effects of the subunit tags on [3H]-MLA binding do not, 
therefore, appear to reflect a problem with protein production.
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F IG U R E  5.5. Expression of HA epitope tagged subunits in transfected cells. 
Mammalian tsA201 cells, grown on glass coverslips were transfected with a9 , a  10, a9% 
and a lO x  subunits tagged with the HA epitope at the N-terminal (N'HA), C-terminal (C‘HA) 
or in the intracellular loop region between M3 and M4 (I'HA). Transfected cells were 
labelled with a monoclonal mouse a-H A  antibody, mAbHA-7. Levels of mAbHA-7 
binding were determined in an enzyme-linked assay. Data are the means (+ standard 
error) of 3 independent experiments carried out in duplicate. (A) Detection of mAbHA-7 
binding sites in permeabilised cells, normalised to mAbHA-7 binding to oc9xNHA. (B) 
The proportion of mAbHA-7 binding sites at the cell surface, determined from parallel 
experiments performed on permeabilised and intact cell monolayers. The background 
signal from untransfected cells has been subtracted. Specific cell surface mAbHA-7 
binding was observed to cells transfected with a 9 x NHA (106±11% of binding to 
permeabilised cells expressing a 9 x N HA).
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FIG U R E  5.6. Expression of subunits containing an N-terminal HA epitope tag (oc9NHA, 
a l 0 N HA, a 9 x N HA, a l 0 x NHA) in combination with non-tagged subunits (a 9 , a lO , a9%, 
a  10%). Transfected tsA201 cells were labelled with mAbHA-7 either after membrane 
permeabilisation or as intact cell monolayers. Levels of mAbHA-7 binding were 
determined in an enzyme-linked assay. Data are the means (+ standard error) of 3 
independent experiments performed in duplicate. (A) Detection of mAbHA-7 binding 
sites in permeabilised cells, normalised to mAbHA-7 binding to a9%N HA- (B) The 
proportion of mAbHA-7 binding sites at the cell surface, determined from parallel 
experiments performed on permeabilised and intact cell monolayers. The background 
signal from untransfected cells has been subtracted. High levels of specific cell surface 
mAbHA-7 binding was observed upon expression of a 9 x NHA alone or a 9 x NHA+alO. 
Binding to cells expressing a 9 x N HA+otlOx was reduced in comparison to binding to 
a 9 x N'HA alone (to 13±3% of binding to a 9 x N HA).
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FIGURE 5.7. Specific [3H]-MLA binding to cell membranes of tsA201 cells expressing 
chimeric subunits containing an N-terminal HA epitope tag (a9%N'HA and alO%N HA). 
M ammalian tsA201 cells were transiently transfected with combinations of tagged and 
non-tagged oc9x and oclO% chimeras. Data are means (+ standard error) of 4 - 5 
independent experiments performed in triplicate and are presented as a percentage of the 
[3H]-MLA binding to membrane preparations of cells expressing a9% +al0x. The levels 
of radioligand binding in cells transfected with a9%+ocl0% are reduced when one or both 
of the chimeric subunits is substituted with a HA epitope-tagged subunit: a9%N'HA+ a l0 x  
(34±20% of a 9 x + a !0 x  binding), a 9 x + a l0 x NHA (5±2%) and a9 x NHA+ a l0 x NHA (2±1%).
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FIGURE 5.8. Specific [3H]-MLA binding to cell membranes of tsA201 cells expressing 
chim eric subunits tagged in the intracellular loop region ( a 9%IHA and alO%IHA). 
Mammalian tsA20I cells were transiently transfected with combinations of tagged and 
non-tagged cx9% and a  10% chimeras. Data are means (+ standard error) of 3 independent 
experiments performed in triplicate and are presented as a percentage of radioligand 
binding observed with the non-tagged a9%+al0% complex. The levels of radioligand 
binding in cells transfected with a9% +al0x are reduced when the chimeric a  10% subunit 
is substituted with the HA epitope-tagged oclO%IHA subunit: a9%+oclO%I’HA (15±1% of 
a 9 x + a !0 x  binding) and a 9 x I HA+ a !0 x I HA (18±2% of a9x+a!0%  binding).
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5.4 Discussion
To determine the sub-cellular distribution of a9%al0% complexes using the membrane 
permeable radioligand, [3H]-MLA (Davies et al., 1999), binding was performed on 
suspensions of intact tsA201 cells in the presence of the membrane impermeable 
competing ligand, ACh (Whiteaker et al., 1998; Fenster et al., 1999). Using this method, 
83±16% (n=3) of total specific binding sites were located at the surface of cells 
expressing a9%+al0%. This is consistent with previous estimates of the proportion of 
nAChRs containing chimeric subunits at the cell surface. For example, 91.1±6.2% of 
a4%P2 receptors and 44.3±8.7% of a4p2% receptors are observed at the surface of 
tsA201 cells, as determined by radioligand binding with the membrane impermeable 
ligand, [3H]-MCC (Harkness and Millar, 2002).
A surprising observation during these experiments was that higher levels of [3H]-MLA 
binding were observed to intact cells transfected with a9% alone than to membrane 
preparations of the same cells. The intact cell suspensions and the membrane 
preparations were derived from the same sample of transfected cells, so this difference 
appears to be directly attributable to the conditions under which the cells were disrupted, 
namely the assay buffer or the disruption of cells through centrifugation and 
resuspension. Cell membrane preparations were assayed in the presence of protease 
inhibitors (2 pg/ml leupeptin and aprotinin + 1 (Xg/ml pepstatin) to diminish protein 
degradation. As a substantial loss of a9% [3H]-MLA binding sites was observed 
following disruption of cells, it is also possible that a proportion of a9%al0% [3H]-MLA 
binding sites were lost under these reaction-specific conditions. If so, the proportion of 
cell surface a9%al0% [3H]-MLA binding sites, determined as -83% of binding detected 
to membrane preparations, would be an overestimate of the cell surface receptor 
population. However, the total levels of [3H]-MLA binding to a9%al0% were 
comparable with both intact cells suspensions and membrane preparations (Figure 5.2). 
As [3H]-MLA is a membrane permeable ligand (Davies et al., 1999), the levels of
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specific [3H]-MLA binding to intact cells in the absence of competing ligands should 
represent populations of both surface and intracellular binding sites and should be 
comparable to the total levels of binding observed in cell membrane preparations. The 
levels of binding observed to intact cells expressing a9% alone were lower than the levels 
of binding to cells co-transfected with a9%+cxl0%, but it is possible that the estimate of 
binding sites for the a9%oclO% receptors included more than one receptor population 
(a9% and oc9%cxl0%). The low levels of binding detected in membrane preparations of 
cells expressing a9% precluded the estimation of a9% nAChRs at the cell surface, but the 
specific binding to a9% complexes at the cell surface of intact cells is consistent with the 
high levels of antibody staining observed with the tagged a9%NHA chimera.
It is unclear at this stage why the levels of specific [3H]-MLA binding to intact cells 
expressing a9% are reduced upon disruption of the cells, but does imply that the 
homomeric a9% complex is less stable than the heteromeric a9%al0% complex under the 
reaction conditions specific to disrupted cells. Under these conditions, a9% may be more 
rapidly degraded or may be less able to fold into a conformation recognised by [3H]- 
MLA. While the ability of a9% to form radioligand binding sites is compromised under 
the conditions used to disrupt the cells, co-expression with a  10% appears to enhance the 
folding of the chimeric complex into a conformation capable of binding [3H]-MLA. This 
provides further evidence for the interaction of these two subunits. It is apparent that 
some aspect of the stability or conformation of the a9%-containing complex is affected 
by its interaction with al0% and this is consistent with previous studies with chimeric 
subunits. For example, when a4% or 02% chimeras are expressed alone in tsA201 cells, 
high levels of each subunit are detected at the cell surface, although neither subunit 
produces high affinity [3H]-epibatidine binding sites (Cooper et al., 1999). The a4% and 
02% subunits assemble into complexes of the size predicted for pentameric nAChRs, but 
the homomeric subunit interactions are not resistant to detergent solubilisation during 
sucrose gradient centrifugation (Cooper et a l, 1999). In contrast, when the a4% or 02% 
chimeras are expressed as heteromeric complexes (either with wild-type or chimeric
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subunits), the subunit-subunit interactions are resistant to detergent solubilisation, 
suggesting a difference in the stability of the homomeric and heteromeric complexes 
(Cooper et al., 1999). These results suggest that while a9% (and a4%) are able to 
assemble into complexes that bind radioligand, association with another subunit is 
required for the efficient formation of a stable high affinity radioligand binding site in 
mammalian cells.
Determination of the sub-cellular distribution of nAChRs with the membrane-permeable 
radioligand, [3H]-MLA is an indirect method of ascertaining the proportion of cell 
surface receptors and is limited to the investigation of complexes that possess a high 
affinity ligand binding site. In the absence of subunit-specific antibodies, an HA epitope 
tag was inserted into each of the a9- and a  10-type subunits to allow their detection when 
expressed in tsA201 cells. Enzyme-linked assays were performed on monolayers of 
intact and permeabilised tsA201 cells transiently transfected with the HA-tagged 
subunits. In these assays, the a9%N HA subunit was detected at the cell surface in high 
levels, while all other tagged subunits were only detected in permeabilised cells. 
Subunits tagged in the intracellular loop region would not be expected to be detected at 
the cell surface, as the epitope tag would be inaccessible to the mAbHA-7 antibody.
The o9% chimera tagged at the extreme C-terminus (a9%C HA) was not detected at the cell 
surface, while the a9%N HA chimera was detected in high levels. This may suggest that 
oc9%c-ha dogs not reach the cell surface and that the introduction of the epitope tag 
disrupts nAChR assembly or trafficking. The immunoreactive bands detected for 
subunits tagged at the C-terminal following metabolic labelling and immunoprecipitation 
(Figure 5.4) revealed a smear of protein bands, which may indicate some protein 
degradation. It is possible that addition of the HA tag at this position targets the subunits 
for degradation, preventing trafficking of the subunits to the cell surface. Alternatively, 
it is possible that this chimeric receptor is at the cell surface, but the epitope tag is not 
visible to mAbHA-7. The putative structure of nAChRs and 5HT3 receptors includes a
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short hydrophobic extracellular carboxy terminal region (Figure 1.1) after which the 
epitope tag was inserted. However, it is possible that the C-terminus and/or the epitope 
tag remain embedded in the plasma membrane, which would obscure the tag from the 
antibody.
The significant reduction in the levels of detectable cell surface receptor observed upon 
co-expression of a9%N HA+alO% (13±3%, n=3) in comparison to a9%N HA alone suggests 
that a9%NHA can co-assemble with the a  10% subunit, as the addition of a  10% affects the 
levels of a9%N HA detected at the cell surface. The heteromeric receptor complex formed 
through co-assembly of oc9%NHA and a  10% subunits may not be efficiently exported to 
the cell surface, as high levels of cell surface mAbHA-7 binding are not detected. 
However, this is in contrast to the levels of cell surface receptor estimated through 
radioligand binding (Section 5.2), which suggests that ~ 83% of detectable [3H]-MLA 
binding sites are expressed at the surface of tsA201 cells transiently transfected with 
a9%+al0%. It is possible that during folding and assembly of the heteromeric receptor, 
the epitope tag is obscured from recognition by mAbHA-7, so that cell surface receptors 
are not detected. Alternatively, the reduced levels of cell surface expression may reflect 
the ability of the epitope tags to disrupt subunit oligomerisation and nAChR assembly.
Introduction of epitope tags to the N-terminal and intracellular loop regions of the a9% 
and al0% chimeras disrupted the formation of the ligand binding site of the a9%al0% 
complex. Immunoprecipitation of each tagged subunit with mAbHA-7 revealed that the 
reduced levels of radioligand binding could not be attributed to a lack of subunit protein 
produced in the transfected cells (Figure 5.4). With the a9%NHA and alO%NHA chimeras, 
the epitope tag may interfere directly with crucial residues involved in ligand binding if 
the tags are not placed at the extreme N-terminus. Alternatively, introduction of the 
epitope tag may cause a conformational abnormality, with steric effects causing 
disruption to the ligand binding site. A study looking at the N-terminal region of the a l  
subunit demonstrated a contribution of the first 24 amino acids (G23 - N46) to
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homomeric interactions in assembly of a l  nAChRs (Chio et al., 2002). If the 
corresponding residues in the a9 or alO subunits are involved in subunit co-assembly, 
then introduction of the epitope tags in this region might disrupt nAChR formation. The 
tagged subunits may, therefore, not assemble correctly and this may account for the lack 
of surface antibody binding observed with the alO%N*HA chimera in particular. 
Therefore, the reduction in antibody staining observed at the surface of cells transfected 
with a9%N HA+ al0x  in comparison to a9xNHA alone does not necessarily represent the 
retention of non-tagged a9%ocl0x within the cell. The tagged subunits may not be able 
to fold or assemble efficiently in the cell and, therefore, would not accurately represent 
the distribution of the non-tagged subunits.
Introduction of the HA epitope to the intracellular loop region of a  10% probably disrupts 
ligand binding indirectly, disrupting the appropriate folding or assembly of the subunits. 
The loop regions between M3 and M4 of nAChR subunits contain potential sites for 
interaction with intracellular proteins, such as protein kinases and molecular chaperones 
(see Section 1.5.4). The positions of the HA tags were selected to avoid putative 
phosphorylation motifs such as the S/TxK/R consensus motif for phosphorylation by 
PKC. However, the epitope tags might have disrupted binding sites of other proteins 
required for the appropriate assembly of the nAChRs.
It is somewhat surprising that the HA tags in the intracellular loop region affect al0%, 
but not a9x, as the two chimeric subunits are tagged at the same position within the 
intracellular loop region of their 5HT3A C-terminal (Table 5.2). The alO-type subunit 
appears to be more sensitive to modification than the a9-type subunit. This suggests that 
both the N- and C-terminal domains of the subunits are involved in nAChR assembly 
and may reflect the order of subunit oligomerisation in the formation of pentameric 
nAChRs. The conformation of nAChR subunits is influenced by the interaction with 
other subunits (Green, 1999; Mitra et al., 2001; Harkness and Millar, 2002). It is 
possible that when a9xI HA associates with other subunits, the resulting conformation of
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the complex intermediate permits the association of additional subunits to form either 
homomeric or heteromeric pentamers. In contrast, the interaction of alO%IHA with other 
subunits may produce a reaction intermediate with an inappropriate conformation that 
cannot complex efficiently with further subunits to generate a pentameric complex that 
binds radioligand. For a more detailed discussion of the assembly pathway of nAChRs, 
please refer to Section 7.3.
In summary, [3H]-MLA binding to intact tsA201 cells in the presence of a membrane 
impermeable competing ligand suggested that 83±16% (n=3) of total specific a9%+al0% 
binding sites were located at the cell surface, but the HA epitope tagged subunits have 
not proved ideal for the investigation of subunit distribution within the cell. The a9%NHA 
subunit does appear to be expressed at the cell surface, consistent with the specific [3H]- 
MLA binding to intact tsA201 cells expressing a9%. However, the N-terminal epitope 
tag disrupts the ligand binding site and may affect the conformation of the receptor, so it 
would be unwise to draw firm conclusions from the data obtained with this tagged 
subunit. Despite the obstacles encountered during these experiments, namely, the loss of 
[3H]-MLA binding sites to membrane preparations of tsA201 cells expressing a9% in 
comparison to intact cells and the disruption of radioligand binding caused by the HA 
epitope tags, it is apparent that the cx9% subunit behaves differently when expressed alone 
and when co-expressed with a  10%, providing further evidence to suggest the co­
assembly of the two chimeras.
5.5 Future directions
Due to the problems experienced using the HA epitope tags highlighted above, this 
particular project was not pursued further, but a number of modifications could be made 
if this project is to be continued at a later date. For example, a different epitope tag 
could be inserted, such as a FLAG (DYKDDDDK) or c-Myc (EQKLISEEDL) tag could 
be inserted at different locations, either within the N-terminal domain or the intracellular
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loop region. Changing the position of the tag by a few residues may eliminate the 
disruption to subunit folding. This could also provide information as to critical residues 
or motifs present in the subunit sequence required for the appropriate folding, assembly 
or cell surface expression of nAChRs. Ideally, the sub-cellular distribution of the 
chimeric receptors would be addressed using subunit-specific antibodies, eliminating the 
need for the introduction of epitope tags to the subunits.
The difference between levels of [3H]-MLA binding to a9% in membrane preparations 
and intact cells is a surprising observation that requires additional experiments to explain 
this phenomenon. Sucrose gradient centrifugation could be used to ascertain whether the 
a9%, a  10% and a9%al0% complexes are assembled as pentamers and whether the 
associated complexes are stable in the presence of detergent. Radioligand binding assays 
could be performed under different reaction conditions, using different buffers or 
additional protease inhibitors, to identify the source of the putative protein degradation.
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CHAPTER 6
THE INFLUENCE OF SUBUNIT CHIMERAS UPON 
HETEROLOGOUS EXPRESSION OF cc2-cc7 CONTAINING 
nAChRs: PAIRWISE COMBINATIONS
6.1 Introduction
Characterisation of recombinant nAChRs generated by heterologous expression of 
defined subunit combinations can provide evidence for the likely subunit composition of 
pharmacologically distinct nAChR subtypes. However, while heteromeric nAChRs such 
as a4(32 and a3(34 form functional channels when expressed in Xenopus oocytes and in 
mammalian cell lines, folding is relatively inefficient, with low levels of nAChRs 
expressed at the surface of many mammalian cell types (Whiting et al., 1991; Wong et 
al., 1995; Buisson et al., 1996; Lewis et al., 1997; Ragozzino et al., 1997). Expression 
of chimeric subunits can enhance the cell surface expression of a4(32 nAChRs, with a 
significant increase in binding of conformationally sensitive subunit specific antibodies 
or [3H]-epibatidine apparent when a4 is substituted with a chimeric oc4% subunit and co­
expressed with P2 (Cooper et al., 1999; Harkness and Millar, 2002). This increase in 
antibody or radioligand binding is not due to an increase in the total levels of chimeric 
subunit protein in comparison to wild-type subunit and can, therefore, be attributed to 
more efficient folding and assembly of receptors (Cooper et al., 1999).
Following the success of using a9% and al0%  chimeras to investigate the 
pharmacological characteristics of ot9-containing nAChRs (Section 4.5), an extensive 
investigation was performed using chimeric subunits constructed with the other known 
rat neuronal nAChR subunits. Chimeras were constructed analogous to the a7v201/5HT3A 
chimera (Eisele et al., 1993) using the N-terminal domain of the rat a2 - a6 and |32 - P4 
subunits up to Ml, fused to the C-terminal domain of the mouse 5HT3A subunit (Chapter
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3). Assembly of nAChRs containing a2 - a6 subunits was investigated via equilibrium 
radioligand binding with 3 -10  nM [3H]-epibatidine, which should represent a saturating 
concentration of radioligand. Epibatidine is a potent agonist of nAChRs isolated from 
the skin of the Amazonian poisonous frog, Epidobates tricolor that binds with high 
affinity to recombinant nAChRs containing a2, a 3, a4  or a6 subunits expressed in 
Xenopus oocytes (Wang et al., 1996; Parker et al., 1998; Kuryatov et al., 2000). 
Equilibrium binding with a7-containing nAChRs was performed with [3H]-MLA (5 - 10 
nM). Native a7-containing nAChRs of rat brain bind [3H]-MLA with a K{ = 1.9 nM 
(Davies et al., 1999) and the affinity of the recombinant a7% receptor expressed in 
tsA201 cells for [3H]-MLA is 1.2±0.2 nM (this study, Table 4.2).
6.2 nAChRs containing the a2 subunit
Wild-type a2 and chimeric a2% subunits were expressed alone or in combination with 
either wild-type 02, 03 or 04 subunits, or chimeric 02%, 03% or 04% subunits in tsA201 
cells. Membrane preparations of transiently transfected cells were assayed for [3H]- 
epibatidine binding and the results are presented in Tables 6.1 and 6.2 and Figure 6.1.
No evidence was obtained for the assembly of homomeric complexes capable of binding 
[3H]-epibatidine when any of the wild-type a2, 02, 03 or 04 subunits or the chimeric 
02%, 03% or 04% subunits were expressed alone in tsA201 cells (Table 6.1). Low levels 
of specific [3H]-epibatidine binding were, however, observed in cells expressing the a2% 
chimera alone (26.5±7.5 fmol/mg protein; n=4). No evidence was obtained for the 
formation of specific high affinity [3H]-epibatidine binding sites following co-expression 
of either a2 or a2% with 03 or 03% subunits.
Low levels of specific [3H]-epibatidine binding were observed upon expression of the 
wild-type a202 nAChR in tsA201 cells (7.7±0.6 fmol/mg; n - 3). The levels of 
radioligand binding to a202 increased upon substitution of one or both of the wild-type
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subunits with a chimeric subunit (Table 6.2, Figure 6.1). Increases of 41±5-fold, 
228± 14-fold and 174±46-fold were observed in cells transfected with a2P2%, a2%P2 and 
a2%p2% combinations, respectively, in comparison to a2(32 («=3). Low levels of [3H]- 
epibatidine binding to the a2p4 nAChR (41±5 fmol/mg; n -3) increased by 3.1±0.1-fold, 
9.7±0.6-fold and 20.7± 1.2-fold upon expression of the a2P4%, a2%P4 and a2%P4% 
subunit combinations, respectively (n=3; Table 6.2, Figure 6.1).
Comparison of the two wild-type a2-containing nAChR subtypes revealed greater levels 
of [3H]-epibatidine binding to a2P4 (41±5 fmol/mg) than a2P2 (7.7±0.6 fmol/mg). In 
addition, the influence of the chimeras on the a2P2 subtype was greater than on the 
a2p4 nAChR. For example, by replacing a2 with a2%, a 228±14-fold increase was 
observed upon co-expression with p2, while co-expression of a2% with P4 yielded only a 
9.7±0.6-fold increase in [3H]-epibatidine binding in comparison to a2P4 (Table 6.2). 
Replacing the a2 subunit with a2%, produced a greater increase in radioligand binding in 
comparison to replacement of the P subunit with its corresponding chimeric subunit.
6.3 nAChRs containing the a3 subunit
Wild-type a3 and chimeric a3% subunits were expressed alone or in combination with 
wild-type or chimeric P2 - P4 subunits in tsA201 cells. Cell membrane preparations 
were assayed for [3H]-epibatidine binding and the results are presented in Figure 6.2 and 
Tables 6.1 and 6.2. Low levels of specific radioligand binding were observed in cells 
transfected with the a3% chimera alone (67±28 fmol/mg protein; n -3; Table 6.1). No 
evidence was obtained for the assembly of homomeric a3 nAChRs or heteromeric 
nAChRs containing P3 or P3% subunits detectable by [3H]-epibatidine binding (n=3).
Low levels of specific radioligand binding were detected in cells transiently transfected 
with a3P2 (7.9±2.0 fmol/mg; n=3) and a3P4 (92.4±30.3 fmol/mg; n=3). Levels of [3H]- 
epibatidine binding were enhanced upon replacement of one or both of the wild-type
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subunits with a chimeric subunit (Figure 6.2). The levels of [3H]-epibatidine binding to 
a3p2 nAChRs increased by 7.4±2.0-fold, 353±91-fold and 16±57-fold with the a3P2%, 
a3%P2 and a3%p2% combinations, respectively. In comparison to a3P4, levels of 
radioligand binding observed in cells expressing a3P4%, a3%P4 and a3^P4% increased 
by 3.6±0.6-fold, 11.6±2.7-fold and 8.1±1.3-fold, respectively (n=3; Table 6.2, Figure 
6.2).
The levels of [3H]-epibatidine binding were higher in cells expressing a3P4 than in cells 
expressing a3p2. Replacing the a3 subunit within the a3P2 or a3P4 nAChR subtypes 
with a subunit chimera produced a greater increase in radioligand binding than 
replacement of the wild-type P subunit. The effect of the subunit chimeras upon 
radioligand binding was greater for nAChRs containing p2 than those containing P4.
6.4 nAChRs containing the a4 subunit
Wild-type a4 and chimeric a4% subunits were expressed alone or in combination with 
wild-type or chimeric P2 - P4 subunits in tsA201 cells and cell membrane preparations 
assayed for [3H]-epibatidine binding. The results are presented in Table 6.2 and Figure 
6.3. Low levels of specific [3H]-epibatidine binding were observed in cells expressing 
the a4% chimera alone (6.2±2.8 fmol/mg protein; n=3; Table 6.1). No evidence was 
obtained for the formation of homomeric a4 nAChRs or heteromeric nAChRs containing 
P3 or p3% subunits (n=3).
Low levels of specific [3H]-epibatidine binding were observed in cells transfected with 
a4+P2 (36±7 fmol/mg; n -3). In comparison to a4P2, increases of 14±3-fold, 49±7-fold 
and 60±17-fold were observed in cells expressing the a4P2%, a4%P2 and a4%P2% 
subtypes, respectively (Figure 6.3). The low levels of specific [3H]-epibatidine binding 
in cells expressing the a4P4 nAChR (106±15 fmol/mg; n -3) increased by 3.3±0.5-fold, 
6.2±0.7-fold and 16±57-fold with the a4P4%, a4%P4 and a4%P4% combinations, 
respectively («=3; Table 6.2, Figure 6.3).
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Comparison of wild-type a4|32 and a4^4 revealed higher levels of [3H]-epibatidine 
binding to nAChRs containing (34 than those containing p2. Upon replacement of one 
wild-type subunit with a chimeric subunit, the increase observed in the levels of 
radioligand binding was greater for (32-containing subtypes than those containing |34.
6.5 nAChRs containing the a5 subunit
Wild-type a5 and chimeric a5% subunits were expressed alone or in pairwise 
combination with wild-type or chimeric P2 - p4 subunits in tsA201 cells. Membrane 
preparations of cells were assayed for [3H]-epibatidine binding. No evidence for [3H]- 
epibatidine binding was obtained in preparations of cells transfected with any pairwise 
combination of subunits containing either wild-type a5 or chimeric ot5% (Tables 6.1 and 
6.2; n=3).
6.6 nAChRs containing the a6  subunit
Results from the [3H]-epibatidine binding with wild-type a6 and chimeric a6% subunits 
expressed either alone or in combination with wild-type or chimeric neuronal P2 - P4 
subunits in tsA201 cells are presented in Figure 6.4 and Tables 6.1 and 6.2. No evidence 
was obtained for the formation of a high affinity [3H]-epibatidine binding site 
corresponding to homomeric a6 or a6% nAChRs (Table 6.1). Specific [3H]-epibatidine 
binding was not observed in cells in which the wild-type a6 subunit was expressed in 
any combination with wild-type or chimeric p subunits. However, high levels of specific 
radioligand binding were observed following pairwise expression of a6%p2, a6%P2%, 
a6%P4 or a6%p4% subunit combinations (Table 6.2, Figure 6.4). The levels of specific 
[3H]-epibatidine binding observed with complexes containing a6% were greater in cells 
expressing a6%P2 than in those expressing a6%P4. The a6% chimera did not form a 
[3H]-epibatidine binding site when co-expressed with wild-type p3 or chimeric p3% 
subunits (Table 6.2).
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6.7 nAChRs containing the al subunit
Assembly of putative heteromeric a7-containing nAChRs was investigated via [3H]- 
MLA binding. Wild-type a l  and chimeric a7% subunits were expressed alone or in 
pairwise combinations with wild-type 02, 03, 04 or chimeric 02%, 03% or 04% subunits 
in tsA201 cells (Figure 6.5; Table 6.3). No evidence for specific [3H]-MLA binding was 
observed in cells transfected with wild-type a l  either alone or in combination with any 
of the wild-type or chimeric 0 subunits (n=3). High levels of [3H]-MLA binding were 
detected in cells transfected with each of the pairwise combinations of subunits that 
included the a7% chimera. However, the levels of [3H]-MLA binding detected to these 
pairwise combinations did not differ significantly from the levels of binding observed in 
cells expressing a7% alone (Figure 6.5; Table 6.3).
The a l  and a7% subunits were also co-expressed with a5 and a5% subunits. Specific 
[3H]-MLA binding was not observed in cells in which wild-type a l  was expressed with 
a5 or a 5%. High levels of specific [3H]-MLA binding detected to membrane 
preparations of cells expressing al%a5 and a7%a5% subunit combinations did not differ 
significantly from levels of binding to a7% alone (Figure 6.5; Table 6.3).
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Expressed Subunit Specific [3H]-Epibatidine 
Binding (fmol/mg Protein)
n
cc2 - 4
a3 - 5
a4 - 3
a5 - 3
a6 - 4
02 - 6
P3 - 6
P4 - 5
a2% 26.5±7.5 4
03% 67±28 5
a.4% 6.2±2.8 5
o(5% - 3
a6% - 4
P2x - 6
P3% - 6
P4* - 6
Expressed Subunit Specific [3H]-MLA Binding 
(fmol/mg Protein)
n
al - 3
alx 4377±587 7
TABLE 6.1. Summary of radioligand binding to tsA201 cells expressing single nAChR 
subunits. Membrane preparations of tsA201 cells transiently transfected with wild-type 
or chimeric a2 - a6 and (32 - 04 subunits were subjected to [3H]-epibatidine binding (5 - 
15 nM), while specific radioligand binding to cell membranes expressing a l  and a7% 
was determined using [3H]-MLA (5 - 10 nM). Data are means (± standard error) of 
experiments performed in triplicate and are listed as fmol/mg protein.
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Wild-type nAChR a-Chimera P-Chimera Both Chimeras
nAChR
subtype
fmol/mg
Protein
nAChR
subtype
fmol/mg
Protein
Fold
Increase
nAChR
subtype
fmol/mg
Protein
Fold
Increase
nAChR
subtype
fmol/mg
Protein
Fold
Increase
a2p2 7.7±0.6 cx2%P2 1732±66 228±14 a2P2x 305±29 41±5 a2xP2x 12761320 174146
a2p3 - «2xP3 - - a2P3x - - a2xp3x - -
a2P4 41±5 a2%P4 387±41 9.7±0.6 a2P4x 106±9 3.110.1 a2xP4x 8431133 20.711.2
a3p2 7.9±2.0 o3xP2 2375±569 353±91 o3P2x 48±10 7.412.0 a3xP2x 14671367 216157
a3p3 - cc3%P3 - - a3P3x - - a3xP3x - -
a3p4 92±30 cx3xP4 866±91 11.6±2.7 a3P4x 383±182 3.610.6 a3xP4x 637183 8.111.3
a4p2 36±7 cx4%P2 1363±259 49±7 a4P2x 369±57 1413 a4xP2x 1453175 60117
a4p3 - cc4%P3 - - a4P3x - - a4xP3x - -
a4P4 106±15 cx4%P4 389±61 3.9±0.7 a4P4x 360±98 3.310.5 a4xP4x 632168 6.210.7
a5P2 - o5xP2 - - o5P2x - - a5xP2x - -
a5P3 - cx5%P3 - - cx5P3x - - a5xP3x - -
a5P4 - a5xP4 - - ct5P4x - - ct5xP4x - -
a6P2 - a6%P2 3124±258 N/A a6P2x - N/A a6xp2X 3189±257 N/A
a6P3 - a6%P3 - - oc6P3x - - a6xP3x - -
a6P4 - a6xP4 862±74 N/A a6P4x - N/A a6xP4X 915±104 N/A
TABLE 6.2. Summary of [3H]-epibatidine binding to tsA201 cells expressing pairwise combinations of wild-type and chimeric subunits. Data are presented as 
means (± standard error) of 3 independent experiments performed in triplicate and are listed as fmol/mg of protein and as the fold increase in binding observed 
above the wild-type nAChR subtype upon replacement of wild-type subunits with the corresponding subunit chimeras. N/A = not appropriate.
nAChRs containing a2
a2+ P2 a2 + 32 a2
a2x + P2X
a2 + 32x
a2x + 32
a2x + 32x
a2 + P2x
a2x+P2
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FIGURE 6.1. Specific [3H]-epibatidine binding to a2-containing pairwise combinations 
of subunits. Mammalian tsA201 cells were transiently transfected with wild-type a2  and 
chimeric a2% subunits in pairwise combinations with wild-type or chimeric 02 or 04 
subunits. Data are presented as means of 3 independent experiments (+ standard error) 
performed in triplicate and reveal low levels of radioligand binding to membrane 
preparations when a2  is co-expressed with 02 or 04 subunits. Replacing wild-type a2 , 
02 or 04 subunits with the corresponding chimeric subunit enhances the levels of [3H]- 
epibatidine binding. Absolute values for [3H]-epibatidine binding (fmol/mg protein) and 
the relative fold increases above wild-type values observed upon expression of subunit 
chimeras are listed in Table 6.2.
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nAChRs containing a3
a 3  + p2
a3  + 32x
a3x  + 62
a3x+P2y
a 3  + 34
a3 + 34x
a3x  + 64
«3x + P4x
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a3x + 32
a3x+32x
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PHJ-Epibatidine Binding (fmol/mg)
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a3x + 34x
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Mnrm fioldJ?cre®®e in^J-Epibatidine Binding 
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»■ J  — | i—r 11 I 1 1  I U
wild-type(a3+32ora3+34) nAChR 
F IG U R E  6 .2 . Specific [3H]-epibatidine binding to a3-containing pairwise subunit 
combinations. Mammalian tsA201 cells were transiently transfected with wild-type a3  
and chimeric a3% subunits in pairwise combinations with wild-type (32 or (34 and 
chim eric (32% or (34% subunits. Data are presented as means of 3 independent 
experim ents (+ standard error) perform ed in triplicate and reveal low levels of 
radioligand binding to membrane preparations when a3  is co-expressed with p2 or p4 
subunits. Replacing wild-type a3 , P2 or P4 subunits with the corresponding chimeric 
subunit enhances the levels of [3H]-epibatidine binding. Absolute values for [3H]- 
epibatidine binding (fmol/mg protein) and the relative fold increases above wild-type 
values observed upon expression of subunit chimeras are listed in Table 6.2.
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nAChRs containing a4
a 4  + (32 a 4  + B2
a 4  + (32% a 4  + P2v
a 4 y  + 62 a4x  + p2
a 4 y  + p2y a 4 y  + B2y
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FIGURE 6.3. Specific [3H]-epibatidine binding to a4-containing pairwise subunit 
combinations. Mammalian tsA201 cells were transiently transfected with wild-type a 4  
and chimeric a4% subunits in combination with wild-type or chimeric p2 or (34 subunits. 
Data are presented as means of 3 independent experiments (+ standard error) performed 
in triplicate and reveal low levels of radioligand binding to membrane preparations when 
a 4  is co-expressed with (32 or p4 subunits. Levels of [3H]-epibatidine binding are 
enhanced by replacing wild-type a4 , (32 or P4 subunits with the corresponding chimeric 
subunit. Absolute values for [3H]-epibatidine binding (fmol/mg protein) and the relative 
fold increases above wild-type values observed upon expression of subunit chimeras are 
listed in Table 6.2.
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a6x + P2X
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FIGURE 6.4. Specific [3H]-epibatidine binding to a6-containing pairwise subunit 
combinations. Mammalian tsA201 cells were transiently transfected with wild-type oc6 
and chimeric a6% subunits in combination with wild-type 02 or 04 and chimeric 02% or 
04% subunits. Data are presented as means of 3 independent experiments (+ standard 
error) performed in triplicate. Significant levels of radioligand binding are only 
observed in cell membrane preparations when the wild-type a 6  subunit is replaced with 
the a6% chimera and co-expressed with wild-type or chimeric 02 or 04 subunits. 
Absolute [3H]-epibatidine binding values (fmol/mg protein) are listed in Table 6.2.
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Wild-type nAChR a7% chimera P-type chimera Both chimeras
nAChR
Subtype
fmol/mg
Protein
nAChR
Subtype
fmol/mg
Protein
nAChR
Subtype
fmol/mg
Protein
nAChR
Subtype
fmol/mg
Protein
oc7 - al% 4377±587
(X7P2 - «7xp2 4068±717 «7P2x - «7xP2x 4186±820
oc7P3 - cc7Zp3 3712±750 ct7P3x - a7xP3% 4017±724
cc7P4 - a7%P4 3840±728 a7P4% - a7xP4x 4052±718
a7a5 - al%a5 5429±1216 a7a5x - a7xa5x 3872±539
TABLE 6.3. Summary of [3H]-MLA binding to a7-containing nAChRs in tsA201 cells expressing combinations of wild-type and chimeric subunits. 
Data are presented as means (± standard error) of 3 independent experiments performed in triplicate. Expression of a5, p2, p3, p4, a5%, $2%, $3% or 
P4% subunits alone did not generate any significant levels of [3H]-epibatidine binding (Tables 6.1 and 6.2). Specific radioligand binding is observed 
only when the chimeric a7% subunit is included in the nAChR complex. Levels of binding detected with pair-wise combinations of cc7%-containing 
nAChRs do not differ significantly from the levels of binding observed with the al% alone.
nAChRs containing a l
Mock 
a 7  
a 7 +  (32 
a 7  + (32% 
a 7  + 3 3  
a 7  + P3x 
a 7  + (34 
a 7  + |34x 
a7x 
a 7 x  + f32 
a7* + P2x 
a 7 x  + (33 
a7x + P3x 
a7x + 34 
a 7 x  + (34*
F IG U R E  6.5 . Specific [3H]-MLA binding to a7-containing pairwise combinations of 
subunits. The a l  subunit was expressed with wild-type or chimeric p2, (53 or P4 
subunits or expressed with wild-type or chimeric a5  in tsA201 cells. Specific [3H]-MLA 
binding to cell membrane preparations is presented as means (+ standard error) of 3 
independent experiments performed in triplicate. Significant levels of radioligand 
binding were only observed when the wild-type a l  subunit was replaced with the al%  
chimera. Levels of [3H]-MLA binding detected with a7% were not influenced by co­
expression with any of the wild-type or chimeric a5 , P2, P3 or p4 subunits. The host­
cell dependent misfolding of the wild-type subunit was not alleviated upon co-expression 
with any of the wild-type or chimeric oc5, p2, p3 or p4 subunits in tsA201 cells. 
Absolute values for [3H]-MLA binding (fmol/mg protein) are listed in Table 6.3.
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6.8 Discussion
6.8.1 The effects of chimeras on the a-BTX-insensitive nAChR subtypes
A large degree of variation is observed in the levels of [3H]-epibatidine binding in cells 
expressing the different heteromeric nAChR subtype pairs (Table 6.2). There is an -11- 
fold difference between the low levels of binding observed to cells expressing a2(32 
nAChRs and the highest levels of binding to a4p4  nAChRs. The rank order of 
radioligand binding levels is a4P4 > a3P4 > a2P4 > a4P2 > a3P2 > a2p2. No binding 
was observed upon expression of a6P2 or a6P4 subtypes. A clear difference between 
the nAChRs containing the P4 subunit and those containing P2 is apparent, with greater 
levels of radioligand binding observed with P4-containing nAChRs. This suggests that 
either the folding of the p4 subunit is more efficient than the P2 subunit, or that p4 
assembles with the a  subunits more efficiently than P2 does.
The nature of the a-type subunit also appears to influence nAChR expression, reflected 
by the differences in radioligand binding levels between subtypes in which the p subunit 
is constant and the a-type subunit varied. For example, levels of [3H]-epibatidine 
binding to the a3P4 subtype (92±30 fmol/mg) were considerably higher than those 
observed with a2P4 (7.7±0.6 fmol/mg). This may reflect differences in the folding 
efficiency of the a-type subunit or in the efficiency of the co-assembly of the a  and P 
subunits.
The effects of the different nAChR subunits on the efficiency of radioligand binding site 
formation are highlighted by the studies with chimeras. For each of the a2-, a3- and a4- 
containing nAChR subtypes, replacement of either one or both of the wild-type subunits 
with subunit chimeras increased the detectable levels of [3H]-epibatidine binding. The 
extent of the observed increase is dependent on nAChR subtype and is influenced by the 
nature of both the a  and the P subunit. For example, the low levels of [3H]-epibatidine
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binding observed to a2P2 increased by 228±14-fold upon replacement of a2 with the 
a2% chimera. In comparison, replacing the wild-type a4 subunit with a4% resulted in a 
49±7-fold increase in radioligand binding. This difference may reflect the levels of 
radioligand binding observed with the wild-type nAChRs, which appear higher for the 
a4|32 nAChR subtype (41±5 fmol/mg) than the a2|32 subtype (7.7±0.6 fmol/mg). 
Therefore, assembly of wild-type a2P2 nAChRs appears to be less efficient than 
assembly of a4p2 nAChRs.
In the majority of cases, replacement of the wild-type a  subunit with a subunit chimera 
caused a greater increase in the levels of radioligand binding than replacement of the P 
subunit with the corresponding chimeric subunit. Therefore, in comparison to the 
influence of the P subunit, the a  subunit appears to exert the more dominant effect on the 
efficient formation of ligand binding sites. Previous studies have revealed a dominant- 
negative effect of the a4 subunit on nAChR assembly (Cooper et al., 1999; Harkness 
and Millar, 2001; Harkness and Millar, 2002), with the high cell surface levels of p2x 
reduced by 40% upon co-expression with a4 (Harkness and Millar, 2002). The critical 
influence of the a-type subunit is demonstrated particularly well by the a6-type nAChRs 
(Figure 6.4), where there is no evidence for high affinity [3H]-epibatidine binding upon 
co-expression of wild-type a6 with any P-type subunits. However, when a6 is replaced 
with a6%, radioligand binding is observed upon co-expression with each of the P2, P2%, 
P4 or p4% subunits. These results strongly implicate the use of chimeras as a valuable 
tool for investigation of a6-containing nAChRs in tsA201 cells. In a previous study, in 
which the C-terminal region of human a6 was replaced with the corresponding region of 
the a4 subunit, high levels of [3H]-epibatidine binding were detected in HEK293 cells 
upon co-expression of the a6/a4 chimera with P2 or p4 subunits, while wild-type human 
a6P2 and a6p4 nAChRs were not detected by radioligand binding (Evans et a l, 2003). 
Therefore, the rat a6/5HT3A chimera (this study) and the human a6/a4 chimera 
(Kuryatov et al, 2000; Evans et a l, 2003) both implicate the C-terminal region of 
nAChR subunits in receptor assembly.
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With the a404 nAChR, the increases in the levels of radioligand binding observed in 
preparations of cells expressing the a4%04 and a404% combinations were not 
significantly different (3.9±0.7-fold and 3.3±0.5-fold respectively; Figure 6.3) and may 
reflect the relative efficiency of a404 nAChR assembly in comparison to other nAChRs.
An interesting observation was the occurrence of specific [3H]-epibatidine binding (albeit 
low levels) when the chimeric cl2%, a3% and aA% subunits were expressed alone in 
tsA201 cells. Homomeric a4% complexes that bind [3H]-epibatidine with low affinity 
have been noted previously (Cooper et a l , 1999). When expressed alone in tsA201 
cells, the chimeric a4% and 02% subunits assemble into pentameric complexes that are 
expressed at the cell surface in high levels (Cooper et al., 1999; Harkness and Millar,
2002). There have been no reports of the successful heterologous expression of 
homomeric a2 or a3 subunits, but small functional responses to high concentrations of 
ACh have been detected in Xenopus oocytes injected with rat a4 mRNA (Sargent, 1993). 
The formation of chimeric homomers suggests that the N-terminal domains of the a2, a3 
and a4 subunits contain residues capable of forming a nicotinic ligand binding site when 
folded into an appropriate conformation. It is possible that the wild-type subunits rarely 
achieve this conformation without the presence of other nicotinic subunits. Also, as the 
levels of binding observed with the homomeric receptors are low, these complexes may 
fold inefficiently or demonstrate lower affinities for nicotinic ligands than heteromeric 
nAChR complexes, such as a3%04. It is clear that upon co-expression of 02 or 04 with 
the chimeric a  subunits, the levels of [3H]-epibatidine binding greatly increase, 
suggesting that while a2%, a3% and a4% can fold to form a nicotinic ligand binding site, 
the presence of both the a  and non-a subunit are required for the efficient formation of 
high affinity [3H]-epibatidine binding site. This is consistent with evidence suggesting 
that the a  subunits contain the primary determinants responsible for ligand binding, but 
that residues in the N-terminal domain of the non-a subunits contribute to the ligand 
binding sites (Section 1.2.3) (Kao and Karlin, 1986; Parker et al., 1998; Brejc et al., 
2001).
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6.8.2 The effects of chimeras on the a7-containing nAChRs
The a l  subunit is able to form functional homomeric ion channels when expressed alone 
in Xenopus oocytes (Couturier et al., 1990a; Eisele et a l, 1993; Seguela et a l, 1993; 
Gerzanich et al., 1994). but it has also been suggested that a l  may co-assemble with 
other subunits, such as p2 and a5, in vivo (Anand et a l, 1993b; Yu and Role, 1998b; 
Palma et al., 1999b; Khiroug et al., 2002; Virginio et al., 2002). The al% chimera also 
forms functional homomeric ion channels when expressed in Xenopus oocytes and is 
able to overcome the host-cell specific misfolding observed with the a l  subunit (Eisele 
et al., 1993; Cooper and Millar, 1997; Sweileh et al., 2000).
No evidence for the formation of heteromeric a7-containing nAChRs was obtained via 
[3H]-MLA binding performed on cells transfected with a l  or al% in combination with 
wild-type or chimeric a5 or neuronal P subunits. Misfolding of the wild-type a l  subunit 
in tsA201 cells was not alleviated by co-expression with any of the wild-type a5, P2, P3 
or P4 subunits or the chimeric a5%, P2%, P3% or P4x subunits. Therefore, while the host 
cell-dependent misfolding of a l  can be alleviated through replacement of the C-terminal 
domain of a l  with that of the 5HT3A subunit (Cooper and Millar, 1997; Cooper and 
Millar, 1998), the misfolding of a7-containing nAChRs in tsA201 cells is not due to the 
inefficient folding of a partnering a5 or neuronal p subunit.
In addition, co-expression of wild-type or chimeric a5 or P subunits with the al% 
chimera did not affect the levels of [3H]-MLA binding observed to homomeric al% 
complexes (Figure 6.5; Table 6.3). While this does not provide any evidence for subunit 
co-assembly, it does not preclude the possibility, as co-assembly may not affect the 
ligand binding properties of the receptor complex. However, homomeric a l  nAChRs 
possess five ligand binding interfaces (Palma et a l, 1996), so the addition of a subunit 
that does not form a ligand binding interface might be expected to influence the ligand 
binding properties. Assembly of the al% homomer may be the preferred stoichiometry
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in tsA201 cells, such that the effect of the putative heteromeric nAChR population on the 
observed levels of [3H]-MLA is not detectable. Studies with wild-type a l  could be 
attempted in cell lines in which a l  folds more efficiently, such as the rat pituitary GK^Cj 
cells (Sweileh et al., 2000), to assess the possible co-assembly of a l  with chimeric 
subunits.
6.8.3 Summary and conclusions
The rationale for using chimeric subunits was to enhance the inefficient folding and 
assembly of nAChRs in mammalian cells and this has been successfully achieved within 
this study. Expression of chimeric subunits in combination with wild-type or other 
chimeric subunits enhanced the expression of nAChRs containing each of the a2, a3, a4 
and a6 subunits and implicates the C-terminal domain of nicotinic subunits in aspects of 
nAChR assembly. Expression of the homomeric a l  nAChR is also enhanced through 
construction of a chimeric subunit and has been shown in previous studies (Eisele et al., 
1993; Cooper and Millar, 1997).
The extent to which chimeras increase radioligand binding is influenced by both the a  
and P subunit. For wild-type nAChRs containing a2, a3 or a4 subunits, expression 
levels are greater in cells in which the expressed nAChRs contain |34 rather than (32 
subunits. Upon replacement of the P subunit with the corresponding chimera, the 
observed increase in radioligand binding is greater for P2-containing nAChRs than 
nAChRs containing P4, suggesting that P2 folds or assembles with the a  subunits less 
efficiently than the P4 subunit is able to. The role of the a  subunit is illustrated by 
differences in binding observed when the p subunit is constant and the co-expressed a  
subunit is varied, where the enhancing effect of chimeras is greater for a2-containing 
nAChRs than those containing a4.
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The patterns of subunit co-assembly following pairwise co-expression of wild-type and 
chimeric subunits in tsA201 cells are highly consistent with previous data (for example, 
see Papke et al., 1989; Wang et al., 1996; Stauderman et al., 1998; Kuryatov et a l , 2000; 
Millar, 2003). Specifically, the a2, a3, a4 and a6 subunits are able to co-assemble with 
p2 and P4 subunits. No evidence for specific radioligand binding was observed upon co­
expression of any a-type subunit in combination with P3 or upon co-expression of any 
P-type subunit with a5. This is consistent with the suggestion that a5 and P3 subunits 
do not contribute directly to the ligand binding site, but demonstrate a more structural 
role within the pentameric complex (Sargent, 1993; Ramirez-Latoire et a l , 1996; Wang 
et a l , 1996; Kuryatov et a l , 2000). Replacement of wild-type subunits with 
nAChR/5HT3A subunit chimeras did not influence the ability of the a5 or P3 nAChR 
subunits to assemble with other subunits to form a ligand binding interface, though 
whether the subunits are able to associate to form complexes that do not possess a ligand 
binding site is not apparent from this particular study. Previous studies have suggested 
that a5  can associate with p2 when expressed in Xenopus oocytes, forming non­
functional aggregates that do not bind [3H]-epibatidine (Wang et a l , 1996).
In addition to providing further direct evidence for the co-assembly of subunits such as 
a2 and P4, the use of chimeras has been used effectively to enhance nAChR expression 
in a heterologous expression system. This is particularly apparent for nAChRs 
containing a6, where wild-type a6 subunits do not generate detectable [3H]-epibatidine 
binding sites when expressed with neuronal p subunits in tsA201 cells (Section 6.6). 
The use of chimeras also provides information regarding the regions of individual 
subunits that are responsible for aspects of receptor folding and assembly, implicating 
the C-terminal region of the subunits in efficient nAChR assembly (see also Cooper and 
Millar, 1997; Cooper and Millar, 1998; Cooper et a l , 1999; Baker et a l , 2004). 
Comparison of different nAChR subtypes implies that the nature of the N-terminal 
domain contributes to nAChR assembly and that formation of the ligand binding site is 
influenced by both the a- and p-type subunits. As the patterns of subunit co-assembly
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suggested by this study appear to confirm previous suggestions of subunit co-assembly, 
they are equally validated by these accounts, providing strong evidence to suggest that 
nAChR/5HT3A subunit chimeras can serve as viable models for the characterisation of 
nAChRs in mammalian cell lines.
6.9 Future directions
It would be particularly interesting to investigate the functional capabilities of nAChRs 
containing chimeric subunits in comparison to wild-type nAChRs. This would also help 
to ascertain whether the different nAChR subtypes form pentameric complexes. 
Expression in Xenopus oocytes suggests that the a9% and a  10% chimeras are able to 
form functional homomeric ion channels (Section 4.4), though the functional capabilities 
of these chimeras in mammalian cell lines are as yet unknown. The cfl% chimera is able 
to form functional homomeric ion channels when expressed in both Xenopus oocytes 
(Eisele et al., 1993) and mammalian cells (Rakhilin et al., 1999).
The subunit chimeras suggest that the C-terminal region of nAChR subunits contribute to 
nAChR folding and assembly. Additional chimeras could be constructed containing 
different proportions of nAChR/5HT3A receptor subunits in order to ascertain whether 
specific sequences within the nAChR subunit govern receptor expression.
The radioligand binding assays performed on membrane preparations of cells do not 
establish the sub-cellular distribution of the assembled nAChRs. Previous studies 
suggest that nAChRs containing chimeric subunits are expressed at the cell surface of 
tsA201 cells at high levels (Cooper and Millar, 1997; Cooper and Millar, 1998; Cooper 
et al., 1999; Harkness and Millar, 2002) (this study, Section 5.2). Cell surface 
expression of the nAChRs could be estimated via radioligand binding to intact cells or 
with quantitative HRP-assays using subunit-specific antibodies (e.g. Cooper et al., 1999; 
Harkness and Millar, 2002).
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CHAPTER 7
THE INFLUENCE OF SUBUNIT CHIMERAS UPON nAChR 
SUBTYPES CONTAINING THREE DIFFERENT SUBUNITS: 
TRIPLET COMBINATIONS CONTAINING a5
7.1 Introduction
In Chapter 6, the influence of subunit chimeras upon the heterologous expression of 
pairwise combinations of nAChR subunits in tsA201 cells was described. There is, 
however, also evidence for the assembly of nAChRs containing more than two different 
nAChR subunit types in both native and heterologous expression systems (see Millar,
2003). The aim of the work described in this chapter was to examine whether evidence 
for co-assembly of the a5 or a5% subunits could be obtained from their co-expression 
with a range of nAChR subunit combinations. Since a5 and a5% are unable to form 
binding sites when expressed in pairwise combinations with any other subunit (Section 
6.5, Sargent, 1993), changes in the levels of binding upon expression of a5 as a third 
subunit in a triplet combination would provide evidence for subunit co-assembly.
7.2 Triplet combinations of nAChR subunits including a5
Wild-type a5 and chimeric a  5% subunits were co-expressed with a variety of 
heteromeric nAChR subtypes containing wild-type or chimeric a2, a3 , a4 or a6 
subunits in combination with wild-type or chimeric P2 or P4 subunits in tsA201 cells. 
Cell membrane preparations were assayed for [3H]-epibatidine binding and the results 
are presented in comparison to data obtained with pairwise combinations of subunits 
discussed in Sections 6.2 - 6.6.
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Pairwise combinations of wild-type or chimeric a  subunits expressed with a5 or a5% 
were performed as control reactions. No evidence for specific [3H]-epibatidine binding 
was observed upon co-expression of a5 or a5% with any other wild-type or chimeric a  
subunit.
7.2.1 The a2- and oc2%-containing nAChRs
The a5  and a5% subunits were co-expressed with nAChRs containing pairwise 
combinations of wild-type or chimeric a2 and 02 or 04 subunits in tsA201 cells. The 
results are presented in Table 7.1 and Figures 7.1 and 7.2.
The levels of [3H]-epibatidine binding detected in membrane preparations of cells 
expressing nAChR subtypes containing wild-type a2 (Figure 7.1) or chimeric a2% 
(Figure 7.2) were not affected by the addition of the wild-type a5 subunit.
The levels of [3H]-epibatidine binding to the a202 nAChR subtype increased 
significantly upon addition of the chimeric a5% subunit (540±100% of binding in the 
absence of a5%; p<0.05; Table 7.1, Figure 7.1). In contrast, upon co-expression of a5% 
with the a202%, a2%02 and a2%02% subtypes, the levels of [3H]-epibatidine binding 
were significantly reduced to 13±3%, 85±3% and 70±20% of binding in the absence of 
a5%, respectively (Table 7.1). Addition of a5% to a204 and a204% caused a complete 
elimination of [3H]-epibatidine binding (Figure 7.1), while co-expression of a5% with 
a2%04 and a2%04% substantially reduced binding to 44±2% and 33±4% of binding in 
the absence of a5%, respectively (p<0.001; Figure 7.2).
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7.2.2 The a3- and oc3%-containing nAChRs
The results obtained following expression of a5 or a5% with nAChRs containing the a3 
and a3% subunits in combination with wild-type or chimeric (32 or (34 subunits are 
presented in Table 7.2 and Figures 7.3 and 7.4.
Addition of the wild-type a5 subunit did not significantly affect the levels of [3H]- 
epibatidine binding to tsA201 cells expressing any of the a3- or a3%-containing nAChR 
subtypes. The levels of specific [3H]-epibatidine binding observed to tsA201 cells 
transiently transfected with nAChRs containing wild-type a3 (a3P2, a3p2x, a3P4 or 
oc3p4%), were not affected by co-expression with a5% (Figure 7.3). However, addition 
of a5% to nAChR complexes containing the chimeric a3% subunit (oc3%P2, a3%P2%, 
a3%P4 and a3%p4%) resulted in significant reductions in the levels of radioligand 
binding (to 60±10%, 40±10%, 60±4% and 50±3% of binding in the absence of a5%, 
respectively; Figure 7.4; Table 7.2).
7.2.3 The a4- and cc4%-containing nAChRs
The results obtained following co-expression of a5 or a5% with nAChRs containing a4 
or a4% subunits in combination with wild-type or chimeric P2 or P4 subunits are 
presented in Table 7.3 and Figures 7.5 and 7.6. Co-expression of wild-type a5 with the 
a4P2 nAChR subtype resulted in a small, but significant increase in [3H]-epibatidine 
binding (160±20% of binding in the absence of a5). The levels of [3H]-epibatidine 
binding to the a4P2%, a4^P 2 or a4%P2% nAChR subtypes were not significantly 
affected by co-expression with the a5 subunit (n=3; Table 7.3). Addition of a5 did not 
affect the levels of binding to the a4p4 and a4$A% nAChR subtypes (Figure 7.3), while 
small, but significant increases in radioligand binding to the a4%P4 and a4%P4% 
nAChRs were observed upon co-expression with the a5 subunit (140±3% and 130±2% 
of binding in the absence of a5, respectively; p<0.05; Table 7.3, Figure 7.4).
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Upon co-expression with the chimeric a5% subunit, a small, but significant increase in 
[3H]-epibatidine binding to the a4P2 nAChR was observed (260±40% of binding in the 
absence of a5%', p<0.05; Figure 7.3, Table 7.3). The levels of binding to the a4P2% 
nAChR subtype were significantly reduced upon addition of a5% (to 20±1% of binding 
in the absence of a5%; p<0.001), but addition of a5% did not influence the levels of 
binding to the a4%p2 or a4%P2% nAChR subtypes (Table 7.3). Upon co-expression with 
cx5%, [3H]-epibatidine binding to the a4P4 and a4$A% subtypes was completely 
abolished (Figure 7.3), binding to a4%p4 was unaffected by a5% (Figure 7.4) and 
binding to the a4%P4% nAChR was reduced (to 60±2% of binding in the absence of a5%; 
p<0.001; Table 7.3).
7.2.4 The a6- and a6%-containing nAChRs
The results obtained following expression of a5 or a5% with nAChRs containing a6 or 
a6% subunits in combination with wild-type or chimeric P2 or P4 subunits in tsA201 
cells are presented in Table 7.4 and Figure 7.7. No evidence for specific [3H]-epibatidine 
binding was observed to membrane preparations of tsA201 cells expressing any nAChR 
subtype that contained the wild-type a6 subunit.
Specific [3H]-epibatidine binding was detected in cells in which a6% was included in the 
subunit combination (Figure 7.7). Upon co-expression with the wild-type a5 subunit, 
the levels of radioligand binding observed to cells expressing the a6%P2, a6?cp2% and 
a6%p4% subtypes were significantly reduced to 77±3, 69±6 and 81±3% of binding in the 
absence of a5, respectively (Table 7.4). Co-expression of a5 with the a6%P4 subtype 
did not significantly affect the levels of [3H]-epibatidine binding. Addition of a5% to the 
a6%P2% and a6%p4% complexes reduced ligand binding to 59±6% and 52±4% of 
binding in the absence of a5%, respectively, while the reductions observed with the 
a6%P2 and a6%p4 subtypes were not statistically significant (n=3).
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nAChR
Subtype
[3H]-Epibatidine Binding: 
fmol/mg Protein
+a5 +o5x
fmol/mg Protein % of Total fmol/mg Protein % of Total
a l - - - - -
p2 - - - - -
P4 - - - - -
«2p2 7.7±0.6 1715 240180 4117 5401100*
a2(52x 305±29 345126 120120 3914.4 1310.3***
a2f4 40±5 56111 140110 1.912.1 4_l_tj***
a2(34x 106±9 203143 110130 2.714.4
a2x 26±8 3.8±3.7 - 0±0.5 -
P2Z - - - - -
M x - - - - -
«2xP2 1732±66 1819194 11012 1471128 8513*
a2xP2x 1276±320 20541404 190140 742121 70120*
a2xP4 387±41 438160 110110 171120 44+2***
a2xP4x 8431133 9861103 120110 260116 32+4***
TABLE 7.1. Summary of [3H]-epibatidine binding to the a2- and a2%-containing triplet subunit combinations. Mammalian tsA201 cells were 
transiently transfected with triplet combinations of wild-type and chimeric subunits. Data are means (± standard error) of 3 independent experiments 
performed in triplicate and are listed as fmol/mg of protein and as the effect of co-expression of a5 or a5% upon binding to each nAChR subtype (% of 
Total). Significance determined by a two-tailed Student's f-test (*p<0.05; ***p<0.001).
a2-containing nAChRs
a 2 +  p2 
a2  + p2 + a5  
a2 + P2 + a5x
a 2  + p2x 
a 2  + 32x + a5  
a2+p2x+a5x
a 2  + 34 
a2  + P4 + a5  
a2 + P4 + a5x
a2  + (34X 
a2  + P4x + a5  
a2  + P4x + a5x
0 100 200 300 400 0 100 200 300 400 500 600 700
pHJ-Epibatidine Binding (fmol/mg) % 0f Total Binding
(Normalised to binding in 
the absence ofa5 ora5x)
FIGURE 7.1. Specific [3H]-epibatidine binding to a2-containing triplet subunit 
combinations. Cell membranes were prepared from tsA201 cells transiently transfected 
with the wild-type a 2  subunit in combination with wild-type a5  and 02 or 04 subunits or 
their corresponding chimeric subunits (a5% and 0 2 x  or 04%). Data are means (+ 
standard error) of 3 independent experiments performed in triplicate and are presented in 
comparison to selected data obtained with pairwise combinations of subunits shown in 
Figure 6.1. Absolute values for [3H]-epibatidine binding (fmol/mg protein) and the 
effect of co-expression of a5  or a5% upon binding to each nAChR subtype (% of Total 
Binding) are listed in Table 7.1. Pairwise combinations of wild-type a 2  with wild-type 
a 5  or chim eric a5%  did not yield significant levels of [3H]-epibatidine binding. 
Significance determined by a two-tailed Student's t test (*/?<0.05; ***p<0.001).
*
a2 + P2 + a5 
a2 + p2 + a5x
a2 + P2x + a5 
a2+p2x+a5x
a2 + P4 + a5 
a2 + P4 + a5x
a2 + P4x + a5 
a2 + P4x + a5x
i  i r
168
a2%-containing nAChRs
a 2 X + p 2  
a2% + P2 + a5  
a  2x + p2 + a5x
«2x + P2X 
a 2x  + P2x + a5  
a2x  + p2x + a5x
a2x  + p4 
a 2x  + P4 + a5  
a2x + P4 + a5x
a2x + P4x 
a 2x  + P4x + a5  
a2x  + P4x + a5x
a2x  + P2 + a5  
a2x + p2 + a5x
a2x  + p2x + a5  
a2x  + p2x + a5x
a2x + P4 + a5  
a 2 x  + P4 + a 5 x
a2x + p4x + a5  
a2x  + p4x + a5x
500 1000 1500 2000 2500
pHJ-Epibatidine Binding (fmol/mg)
100 150 200 250
% of Total Binding 
(Normalised to binding in the 
absence of a5  or a5x)
FIGURE 7.2. Specific [3H]-epibatidine binding to a2%-containing triplet subunit 
combinations. Cell membranes were prepared from tsA201 cells transiently transfected 
with the chimeric a2% subunit in combination with wild-type a5  and 02 or 04 subunits 
or their corresponding chimeric subunits (a5% or 02% or 04%). Data are means of 3 
independent experiments (+ standard error) performed in triplicate and are presented in 
comparison to selected data obtained with pairwise combinations of subunits shown in 
Figure 6.1. Absolute values for [3H]-epibatidine binding (fmol/mg protein) and the 
effect of co-expression of a5  or a5% upon binding to each nAChR subtype (% of Total 
Binding) are listed in Table 7.1. Pairwise combinations of chimeric a2% with wild-type 
a 5  or chimeric a5% did not yield significant levels of high affinity [3H]-epibatidine 
binding. Significance determined by a two-tailed Student's t test (*p<0.05; ***p<0.001).
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nAChR
Subtype
[1H]-Epibatidine Binding: 
fmol/mg Protein
+ot5 +oc5%
fmol/mg Protein % of Total fmol/mg Protein % of Total
a3 - - - - -
P2 - - - - -
P4 - - - - -
03(52 7.9±2.0 11.5±1.2 190±50 13.4±1.3 220170
a3P2x 48±10 57±18 120±30 40±8 90110
a3(M 92±30 154±50 170±30 88±16 110120
a3|34x 383±182 603±69 260±80 270±49 110130
a3x 67±28 61±28 - 5.2±2.0 -
P2x - - - - -
P4x - - - - -
a3xP2 2375±569 2086±234 90±20 1144±43 60110*
«3xP2x 1467±367 1691±470 110±10 564±116 40110**
a3xP4 866±91 860±186 100±10 473±38 6014***
a3xP4x 637±83 641±67 100±10 304±24 5013***
TABLE 7.2. Summary of [3H]-epibatidine binding to the a3- and a3x-containing triplet subunit combinations. Mammalian tsA201 cells were 
transiently transfected with triplet combinations of wild-type and chimeric subunits. Data are means (± standard error) of 3 independent experiments 
performed in triplicate and are listed as fmol/mg of protein and as the effect of co-expression of a5 or cx5% upon binding to each nAChR subtype (% of 
Total). Significance determined by a two-tailed Student's f-test (*p<0.05; **p<0.01; ***p<0.001).
a3-containing nAChRs
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a3+(32+a5
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F IG U R E  7.3. Specific [3H]-epibatidine binding to a3-containing triplet subunit 
combinations. Cell membranes were prepared from tsA201 cells transiently transfected 
with the wild-type a3  subunit in combination with wild-type a5  and (32 or (34 subunits or 
their corresponding chimeric subunits (oc5% and (32% or (34%). Data are means (+ 
standard error) of 3 independent experiments performed in triplicate and are presented in 
comparison to selected data obtained with pairwise combinations of subunits shown in 
Figure 6.2. Absolute values for [3H]-epibatidine binding (fmol/mg protein) and the 
effect of co-expression of a5  or oc5% upon binding to each nAChR subtype (% of Total 
Binding) are listed in Table 7.2. Pairwise combinations of wild-type a3  with wild-type 
a 5  or chim eric a5%  did not yield significant levels of [3H]-epibatidine binding. 
Significance determined by a two-tailed Student's t test.
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a3%-containing nAChRs
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FIGURE 7.4. Specific [3H]-epibatidine binding to cc3x-containing triplet subunit 
combinations. Cell membranes were prepared from tsA201 cells transiently transfected 
with the chimeric a3% subunit in combination with wild-type a5  and P2 or |34 subunits 
or their corresponding chimeric subunits (a 5 x  and P2% or P4%). Data are means (+ 
standard error) of 3 independent experiments performed in triplicate and are presented in 
comparison to selected data obtained with pairwise combinations of subunits shown in 
Figure 6.2. Absolute values for [3H]-epibatidine binding (fmol/mg protein) and the 
effect of co-expression of a5  or a5% upon binding to each nAChR subtype (% of Total 
Binding) are listed in Table 7.2. Pairwise combinations of chimeric oc3% with wild-type 
a5  or chimeric a5% did not yield significant levels of high affinity [3H]-epibatidine 
binding. Significance determined by a two-tailed Student's t test (*p<0.05; ***p<0.001).
172
nAChR
Subtype
[’H]-Epibatidine Binding: 
fmol/mg Protein
+oc5 +a5%
fmol/mg Protein % of Total fmol/mg Protein % of Total
a4 - - - - -
(32 - - - - -
p4 - - - - -
a4(52 36±7 57112 160120* 101132 260140*
a4[?2x 369±57 494198 130110 6919 2011***
a4(i4 106±15 111114 11012 1.310.02 211***
a4fS4x 360±98 340119 9012 3.010.5 0.910.2***
aA% 6.2±2.8 15111 - 2.613.2 -
P2x - - - - -
P4x - - - - -
a4xP2 13631259 18901179 150130 15111157 120110
a4xP2x 1453175 1840199 130110 12331161 80110
a4xP4 389161 533171 14013*** 34113.8 90110
«4xP4x 632168 815198 13012*** 3011127 6012***
TABLE 7.3. Summary of [3H]-epibatidine binding to the a4- and a4x-containing triplet subunit combinations. Mammalian tsA201 cells were 
transiently transfected with triplet combinations of wild-type and chimeric subunits. Data are means (± standard error) of 3 independent experiments 
performed in triplicate and are listed as fmol/mg of protein and as the effect of co-expression of a5 or a5% upon binding to each nAChR subtype (% of 
Total). Significance determined by a two-tailed Student's /-test (*p<0.05; ***/?<0.001).
a4-containing nAChRs
a4+p2
a4+p2+a5
a4+p2+a5x
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FIGURE 7.5. Specific [3H]-epibatidine binding to a4-containing triplet subunit 
combinations. Cell membranes were prepared from tsA201 cells transiently transfected 
with the wild-type a 4  subunit in combination with wild-type a5  and (32 or 04 subunits or 
their corresponding chimeric subunits (a5% and 02% or 04%). Data are means (+ 
standard error) of 3 independent experiments performed in triplicate and are presented in 
comparison to selected data obtained with pairwise combinations of subunits shown in 
Figure 6.3. Absolute values for [3H]-epibatidine binding (fmol/mg protein) and the 
effect of co-expression of a5  or a5% upon binding to each nAChR subtype (% of Total 
Binding) are listed in Table 7.3. Pairwise combinations of wild-type a4  with wild-type 
a5  or chimeric a  5% did not yield significant levels of [3H]-epibatidine binding. 
Significance determined by a two-tailed Student's / test (*p<0.05; ***p<0.001).
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FIGURE 7.6. Specific [3H]-epibatidine binding to a4%-containing triplet subunit 
combinations. Cell membranes were prepared from tsA201 cells transiently transfected 
with the chimeric a4% subunit in combination with wild-type a5  and p2 or p4 subunits 
or their corresponding chimeric subunits (a5% and (32x or P4%). Data are means (+ 
standard error) of 3 independent experiments performed in triplicate and are presented in 
comparison to selected data obtained with pairwise combinations of subunits shown in 
Figure 6.3. Absolute values for [3H]-epibatidine binding (fmol/mg protein) and the 
effect of co-expression of a5  or a5% upon binding to each nAChR subtype (% of Total 
Binding) are listed in Table 7.3. Pairwise combinations of chimeric a4% with wild-type 
a5  or chimeric a5% did not yield significant levels of high affinity [3H]-epibatidine 
binding. Significance determined by a two-tailed Student's t test (***p<0.001).
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nAChR
Subtype
[3H]-Epibatidine Binding: 
fmol/mg Protein
+a5 +05%
fmol/mg Protein % of Total fmol/mg Protein % of Total
a6 - - - - -
P2 - - - - -
|34 - - - - -
<x6p2 - - - - -
a6(32x - - - - -
a6p4 - - - - -
a6(34x - - - - -
a6x - - - - -
P2% - - - - -
P4x - - - - -
a6xP2 3124±258 2392±183 77±3** 2009±387 65±13
a6xP2x 3189±257 2211±322 69±6* 1906±287 59±6**
a6xp4 862±74 645±52 80±10 538±46 65±9
a6xP4x 915±104 773±81 81±3* 464±47 52±4***
TABLE 7.4. Summary of [3H]-epibatidine binding to the oc6- and a6%-containing triplet subunit combinations. Mammalian tsA201 cells were 
transiently transfected with triplet combinations of wild-type and chimeric subunits. Data are means (± standard error) of 3 independent experiments 
performed in triplicate and are listed as fmol/mg of protein and as the effect of co-expression of a5 or a5% upon binding to each nAChR subtype (% of 
Total). Significance determined by a two-tailed Student's /-test (*p<0.05; **p<0.01; ***p<0.001).
a6%-containing nAChRs
a6x+p2
a6x+P 2+a5
a6x+P2+a5x
a6x+P2X
a6x+P 2x+a5
a6x+P2x+a5x
a6x+p4
a6x+P 4+a5
a6x+P4+a5x
a6x+p4x
a6x+P 4x+a5
a6x+p4x+a5x
0
a6x+P 2+a5
a6x+P2+a5x
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F IG U R E  7.7. Specific [3H]-epibatidine binding to a6x-containing triplet subunit 
combinations. Cell membranes were prepared from tsA201 cells transiently transfected 
with the chimeric a6% subunit in combination with wild-type a5  and 02 or 04 subunits 
or their corresponding chimeric subunits (a5% and $2% or 04x). Data are means (+ 
standard error) of 3 independent experiments performed in triplicate and are presented in 
comparison to selected data obtained with pairwise combinations of subunits shown in 
Figure 6.4. Pairwise combinations of chimeric a6% with wild-type a5  or chimeric a5 x  
did not yield significant levels of high affinity [3H]-epibatidine binding. Absolute values 
for [3H]-epibatidine binding (fmol/mg protein) and the effect of co-expression of a5  or 
a5% upon binding to each nAChR subtype (% of Total Binding) are listed in Table 7.4. 
S ignificance determ ined by a tw o-tailed Student's t test (*p<0.05; **p<0.01;
***p<0.001).
177
7.3 Discussion
7.3.1 The influence of the a5 and a5% subunits
Figure 7.8 illustrates the effects of a5 (or a5%) on the levels of [3H]-epibatidine binding 
to a2(32, cx2p4, a3(32, a3(34, a4(32 and a4P4 wild-type nAChR subtypes. Expression of 
the a6P2 and a6(34 subtypes in tsA201 cells did not lead to the formation of detectable 
radioligand binding sites (Sections 6.6 and 7.2.4) and this lack of binding was not 
alleviated through co-expression with the a5 subunit. The absence of radioligand 
binding observed upon expression of rat a6 with p2 or P4 in mammalian cell lines 
(Section 6.6) does not, therefore, reflect a requirement for the a5 subunit. An alternative 
or additional nAChR subunit or a different cell-specific factor, such as a molecular 
chaperone may be required. Additional studies have suggested that the P3 subunit does 
not alleviate the inefficient folding of a6P4 nAChRs in tsA201 cells, as co-expression of 
a6P4p3 or a6P4P3% subunit combinations did not generate high affinity [3H]- 
epibatidine binding sites (data not shown; n=3).
Upon addition of the wild-type a5 subunit, the levels of binding to the a4P2 nAChR 
increased slightly (160±20% of binding in the absence of a5; Table 7.3), suggesting that 
a5 is able to co-assemble with the a4P2 nAChR in tsA201 cells. In a previous study, in 
which wild-type chick a4, P2 and a5 subunits were co-expressed in HEK293 cells, the 
levels of [3H]-epibatidine binding to a4P2 nAChRs were not significantly altered upon 
addition of the a5 subunit, though co-assembly of a5 with a4P2 nAChRs was 
demonstrated by immunoprecipitation (Conroy and Berg, 1998). In the present study, 
the increase in [3H]-epibatidine binding observed upon co-expression of a5 with rat 
a4P2 nAChRs in tsA201 cells was very small (Figure 7.5) and suggests that cellular 
factors other than the a5 subunit influence the inefficient folding of the recombinant 
a4p2 nAChR in tsA201 cells. The difference between the results of this and previous 
studies may also reflect host-cell or species differences.
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FIGURE 7.8. Specific [3H]-epibatidine binding to wild-type nAChR subtypes and the 
effect of a5  and a5%. Data are means (+ standard error) of 3 independent experiments 
performed in triplicate and are taken from Figures 7.1, 7.3 and 7.5 to compare the effects 
of adding a5  or a5% to each of the wild-type nAChR combinations. Absolute values for 
[3H]-epibatidine binding (fmol/mg protein) and the effect of co-expression of a5  or a5% 
upon binding to each nAChR subtype (% of Total Binding) are listed in Tables 7.1 - 7.3. 
Significance determined by paired Student's t test (*p<0.05; ***/?<0.001).
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The levels of radioligand binding to each of the other wild-type nAChR subtypes 
expressed in tsA201 cells were not significantly affected by co-expression with the wild- 
type a5 subunit (Figure 7.8). Previous studies have demonstrated the co-assembly of a5 
with each of the a2|52, a3p2, a3P4, a4p2 and a6p2 nAChR subtypes (see Millar, 2003). 
The a5 subunit may occupy a position within the nAChR pentamer analogous to that of 
the pi subunit within the muscle-type nAChR complex (Figure 1.2). In this position, the 
a5 subunit may not contribute directly to the ligand binding interfaces, but would 
contribute to the lining of the ion channel (Wang et al., 1996; Conroy and Berg, 1998; 
Gerzanich et a/., 1998). For example, co-expression of a5 with a3P2 or a3P4 nAChRs 
in Xenopus oocytes does not affect [3H]-epibatidine binding affinity, but does increase 
the rate of nAChR desensitisation (Wang et al., 1996). It is possible that incorporation 
of the a5 subunit into the pentameric complex of nAChR subtypes, such as a3P4, in 
tsA201 cells does not affect the ligand binding properties of the nAChR and is, therefore, 
not detected by [3H]-epibatidine binding.
Chimeric subunits were used to investigate whether incorporation of a5 into nAChR 
complexes could alter the efficiency of nAChR expression, as demonstrated previously 
with other combinations of chimeric subunits (Chapters 4 and 6, Cooper et al., 1999; 
Harkness and Millar, 2002; Baker et al., 2004). Increases in the levels of radioligand 
binding to a2P2 and a4P2 nAChRs were observed upon co-expression with a5% 
(540±100% and 260±40% of binding in the absence of a5%, respectively; p<0.05). 
These data suggest that aS% is able to co-assemble with these nAChR subtypes and 
enhance the formation of [3H]-epibatidine binding sites when expressed in tsA201 cells. 
This is consistent with previous studies that have suggested the formation of a2P2a5 and 
a4P2a5 nAChRs in chick brain (Conroy and Berg, 1998; Balestra et al., 2000). The 
levels of radioligand binding detected to the a3P2 and a3P4 nAChR subtypes were not 
significantly altered by co-expression with a5%. While this does not provide any 
evidence for the co-assembly of an cx5-type subunit with the a3|32 or a3|34 nAChRs, it 
does not eliminate the possibility that the chimeric a5% subunit is incorporated into the
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nAChR complex at a position that does not affect the formation of the ligand binding 
site. The results do suggest that the inefficient folding of these particular wild-type 
nAChR subtypes in tsA201 cells is not due to the absence of the a5 subunit.
An interesting observation was that the levels of binding observed to a2|34 and a4(34 
were completely abolished upon expression with a5% (Figure 7.8). There have been no 
reports to suggest the formation of oc2p4a5 or a4(34a5 complexes (Millar, 2003), but the 
a2[54 and a4|34 subtypes were significantly influenced by the addition of a5%. 
Abolition of radioligand binding upon co-expression of a5% with a2|34 or a4(34 nAChRs 
suggests that a5% associates with at least one of the a-type or (34 subunits. However, the 
subunit-subunit interactions that occur are not beneficial with respect to the formation of 
ligand binding sites. Specific [3H]-epibatidine binding was not observed upon pairwise 
co-expression of a5  or a5% with a2, a  4 or |34, though whether these subunit 
combinations can form protein aggregates that do not bind radioligand has not been 
determined. Immunoprecipitation and sucrose gradient studies have demonstrated the 
assembly of a5P2 aggregates in Xenopus oocytes that do not possess ligand binding 
capabilities (Wang et al., 1996). In contrast, a5 does not form complexes with a3 in 
Xenopus oocytes that are stable in Triton X-100 (Wang et al., 1996).
The abolition of radioligand binding to the a2|34 and a4|34 nAChR subtypes upon co­
expression with a5% is in contrast to the influence of this chimera on the levels of 
binding to the a2p2 and a4|32 subtypes, which increased upon addition of a5%. 
Therefore, the interaction of the a5% subunit with the different nAChR subtypes is 
influenced by the nature of the p subunit. However, a5% did not affect the levels of 
radioligand binding to the a3P2 or a3P4 nAChRs, suggesting that the nature of the a- 
type subunit also influences nAChR assembly.
Significant reductions in the levels of [3H]-epibatidine binding to a number of the 
nAChR subtypes containing other chimeric subunits were observed upon co-expression
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with a5%. For example, the levels of binding to a2%(34, a4P2% and a6%$2% and to each 
of the nAChR subtypes containing a3%, decreased upon co-expression with a5%. 
Therefore, a5% displaces a proportion of the ligand-binding interfaces of each of these 
chimeric receptor subtypes. It is possible that a5% interacts with other chimeric subunits 
in a promiscuous manner, allowing interactions to occur that would not be observed 
between wild-type subunits. For example, it has been suggested that the a5 subunit does 
not associate with the wild-type a3 subunit until a3 has associated with p2 (Wang et a l , 
1996). If this association is prevented by the nature of the C-terminal domain, the 
restrictive interactions may be eliminated in the subunit chimeras, as the 5HT3A subunit 
is able to assemble into functional homomeric complexes (Maricq et al., 1991; Eisele et 
al., 1993). However, it does not appear that subunit chimeras assemble without regard 
for the N-terminal domain, as co-expression with a5% did not reduce the levels of 
radioligand binding observed to every nAChR subtype that contained another chimeric 
subunit. For example, the levels of [3H]-epibatidine binding observed in cells expressing 
a3|54% and a4%p4 combinations were unaffected by co-expression with a5%. In 
addition, the levels of [3H]-MLA binding to membrane preparations of cells expressing 
homomeric al% complexes were unaffected by the addition of oc5% (Section 6.7). Also, 
the negative effect of a.5% on the formation of the ligand binding site was not restricted 
to nAChRs containing another chimeric subunit, as radioligand binding to the wild-type 
a2P4 and a4P4 nAChRs was abolished upon co-expression with a5% (Figure 7.8) and 
binding to a6%P2, oc6%p2% and oc6%p4% was reduced upon co-expression with wild-type 
a5 (Figure 7.7).
The chimeric a.5% subunit exerted different effects on different nAChR subtypes. For 
example, co-expression of a5% with a2%p4 and a2%p4% substantially reduced binding 
(to 44±2% and 33±4% of binding in the absence of a5%, respectively; p<0.001), while 
the addition of a5% to a2P4 and a2p4% abolished [3H]-epibatidine binding completely 
(p<0.001; Table 7.1). The associations that occur between chimeric a2% and the P4-type 
subunits thus appear to differ to the interactions between wild-type a2 and the P4-type
182
subunits. The association between a2 and (34 also differs to the association between a2 
and (32. Therefore, the nature of both the N- and C-terminal domains of each of the a  
and P subunits appear to influence subunit association and nAChR assembly. This is 
consistent with previous studies, where the effects of mutated and chimeric nAChR 
subunits have been used to identify critical assembly domains located at the N-terminus 
of nAChR subunits (Gu et al., 1991; Yu and Hall, 1991; Sumikawa, 1992) and have also 
implicated the C-terminal region in cell-specific folding and subunit oligomerisation 
(Cooper and Millar, 1997; Cooper and Millar, 1998; Eertmoed and Green, 1999).
Co-expression of human a6 and P2 subunits in Xenopus oocytes generates high levels of 
specific [3H]-epibatidine binding that are reduced upon addition of human a5 (Kuryatov 
et al., 2000). This is consistent with the reduction in binding to the a6%P2 and a6%P2% 
complexes observed upon co-transfection with a5 observed in this study (Table 7.4). 
When expressed in Xenopus oocytes, the human a6 and p2 subunits do not assemble into 
functional pentameric arrays, but form large ligand-binding aggregates (Kuryatov et al., 
2000). The a5 subunit is able to disrupt the formation of a6P2 aggregates, leading to the 
production of a proportion of functional a6P2a5 nAChRs (Kuryatov et al., 2000). In 
addition, the aggregation of a5 and P2 subunits has been demonstrated in Xenopus 
oocytes (Wang et al., 1996). Therefore, the addition of a5 to the a6%P2 and a6%$2% 
complexes may reduce the formation of potential ligand binding aggregates and/or 
increase the formation of a5P2 aggregates, creating a reduction in the detectable levels 
of ligand binding. It would be interesting to examine the functional capabilities of the 
a6%P2 and a6%P2% complexes, to establish whether disruption of the a6%p2 binding 
interfaces by a5 results in a detrimental or beneficial effect with respect to the formation 
of viable pentameric receptor complexes. While it is not clear which interactions are 
taking place, it is apparent that the a5 subunit is able to disrupt the ligand binding 
interfaces formed between a6% and the P-type subunits.
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7.3.2 Models of nAChR assembly and the influence of a 5% on pathways of subunit 
oligomerisation
Two models have been proposed for subunit oligomerisation and assembly pathways of 
muscle-type nAChRs and are illustrated in Figure 7.9 (see Green and Millar, 1995; 
Green, 1999). In these models, the ordered pathways of nAChR assembly indicate the 
importance of each individual subunit-subunit interaction and suggest that subunit 
conformation is affected by interaction with other subunits, where only certain 
conformations are permissive for nAChR assembly.
The pathways of nAChR assembly were proposed following experiments in which the a- 
BTX binding capabilities of nAChR complex intermediates were monitored (Green and 
Millar, 1995). Upon heterologous expression and immunoprecipitation of incomplete 
recombinant nAChRs, the simplest combinations of [125I]-a-BTX-labelled subunits that 
could be co-precipitated were a-y and a-8 heterodimers (Figure 7.9A). Co-expression of 
a  and P subunits did not allow precipitation of [125I]-a-BTX with anti-p antibodies. The 
first model of nAChR assembly (the Heterodimer Model; Figure 7.9A), suggests that the 
mature a  subunit (Opx), which possesses a-BTX-binding ability, associates with y or 8 to 
form a-y and a-8 heterodimers. The two heterodimers oligomerise with each other and 
with the P subunit to form the pentameric a 2Py8 nAChRs (Blount and Merlie, 1989; 
Green and Millar, 1995; Green, 1999).
In the second model (Sequential Model; Figure 7.9B), suggested following the stable 
expression of all four nAChR subunits in mammalian cells cultured at low temperature 
(Green and Claudio, 1993), a-P-y trimers form rapidly. These trimers may be preceded 
by a-p, a-y and P-y heterodimers, but these species were not isolated in these 
experiments (Green, 1999). Pulse-chased labelling with [35S]-methionine demonstrated 
the subsequent assembly of a-p-y-8 tetramers, before the addition of the second a  
subunit to form the final a 2PyS pentamers (Green and Claudio, 1993; Green, 1999).
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Therefore, while a-8 heterodimers (Heterodimer Model) may be able to assemble when 
expressed in the absence of other subunits in heterologous systems, this may not 
represent the natural pathway of assembly in vivo (Green and Wanamaker, 1998; Green, 
1999).
The nAChR subunits are synthesised and undergo folding transitions and post- 
translational modifications within the endoplasmic reticulum (Green and Millar, 1995; 
Green, 1999; Keller and Taylor, 1999). Initial subunit associations may occur prior to 
the completion of subunit folding, due to the rapidity of some subunit associations 
(Green and Millar, 1995). The subunit N-terminal domains probably mediate these 
initial subunit-subunit interactions, where the N-terminal domains of partially-translated 
subunits interact with other completed subunits (Green and Millar, 1995; Keller and 
Taylor, 1999). The initial interactions appear to lack specificity and may occur to protect 
critical subunit domains from the cellular environment or to prevent misfolding of these 
domains (Eertmoed and Green, 1999). This would suggest that the initial interactions 
that occur between a5% and the other nAChR or nAChR/5HT3AR subunits are governed 
by the N-terminal domains and may not be affected by the presence of the C-terminal 
5HT3a sequences within the chimeras.
In the Sequential Model of nAChR assembly, folding and receptor maturation is a 
continuous process, with folding events occurring after each step of subunit 
oligomerisation to allow the association of the next subunit (Green, 1999). Subunit 
conformation is modified upon association with a partnering subunit for both muscle- 
type and neuronal nAChRs, where the proportion of nAChR subunits recognised by 
subunit-specific antibodies is altered upon co-expression with other subunits (Mitra et 
al., 2001; Harkness and Millar, 2002). Evidence to implicate subunit C-terminal 
domains in subunit oligomerisation has also been provided by chimeras containing 
regions of Torpedo electric organ y and 8 subunits (Eertmoed and Green, 1999). 
Chimeras containing the N-terminal domain of the 8 subunit up to M l, fused to the C-
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terminal domain of the y subunit (822 ly) are able to substitute for the 8 subunit, but not 
for the y subunit when expressed with the other Torpedo electric organ nAChR subunits 
in tsA201 cells. However, the corresponding y2158 chimera does not substitute for 
either the y or 8 subunits and blocks the formation of all intracellular a-BTX binding 
sites. The y215S chimera associates with either a  or P subunits, but not with both, 
blocking nAChR assembly prior to the appearance of a-P-y trimers (see Sequential 
Model, Figure 7.9B) (Eertmoed and Green, 1999).
If the N-terminal domains of each neuronal nAChR subunit interact non-specifically, this 
suggests that both the a5 and a5% subunits are able to associate with each of the other 
wild-type or chimeric nAChR subunits upon co-expression in mammalian cells. In this 
case, it is the interactions between the C-terminal domains of each subunit that govern 
whether the association is productive. A conformational change may occur to strengthen 
the association between productive pairs that permits the association of a third subunit in 
the formation of trimers (Eertmoed and Green, 1999). Three possible situations can be 
considered, whereby the initial subunit-subunit association is:
1) Stable (or stabilised through additional conformational change) and leads to the 
formation of a pentameric nAChR complex.
2) Stable, but inappropriate for pentamer formation and either progresses no further 
along the assembly pathway or leads to the formation of protein aggregates.
3) Not stable and either dissociates or is degraded (Eertmoed and Green, 1999; Green,
1999).
The y215S chimera (Eertmoed and Green, 1999) exerts a dominant-negative effect upon 
nAChR assembly, where the associations within intermediate complexes are 
strengthened, but formation of the complete nAChR pentamer is prevented. A similar 
mechanism may explain the abolition of binding observed upon co-expression of a5% 
with the a2P4 and a4P4 nAChR subtypes. In this scheme, a5% would be able to interact 
with either the a-type subunit or the P4 subunit, but the resulting associations would not
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permit the formation of trimers. Alternatively, a5% may associate with a -(3 heterodimers 
or other intermediate complexes along the assembly pathway, but the principle would be 
the same, whereby assembly intermediates that contain a2(34a5% or a4(34a5% subunit 
combinations are not viable to progress along the assembly pathway. In contrast, where 
the levels of radioligand binding to nAChRs subtypes are unaffected by the addition of 
a5% (such as a3P4), the conformation of complex intermediates would presumably 
either exclude the assembly of a5%, or be permissive for the oligomerisation of 
additional subunits. The small increases in radioligand binding observed upon co­
expression of a5% with a2P2 and a4p2 suggests that the complex intermediates are 
permissive for the formation of pentameric nAChRs that contain a5%.
It is not clear from the binding experiments alone at which point along the assembly 
pathway a5% is able to associate with other subunits and, in certain cases, block the 
assembly pathway. However, it is tempting to attribute this association to an early stage, 
such as the formation of heterodimers, analogous to that of the y2158 chimera (Eertmoed 
and Green, 1999), or at the formation of subunit trimers, due to the complete block of 
binding observed upon co-expression of a5% with the a2P4 and a4P4 nAChR subtypes. 
This suggests that the interactions between a5% and the other subunits occur at a stage 
early enough in the pathway to reduce the pool of viable a-P interactions and prevent the 
formation of any ligand-binding pentamers. If the a5% subunit was the last subunit be 
integrated into the pentameric complex, then a mixed population of pentameric nAChRs 
might be expected (±a5%), with a proportion of a2P4 or a4P4 nAChRs that are able to 
bind radioligand. In addition, the a5 subunit has been suggested to assume a position in 
the pentameric complex analogous to that of the p i subunit of the muscle-type nAChR. 
If the pathways of the muscle-type and neuronal nAChRs are comparable, this would 
suggest that a5 associates with an a  and a P subunit at the trimer (or possibly 
heterodimer stage) of the assembly pathway (Figure 7.9B).
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The differences in the effects of a5% may also highlight differences in the efficiency of 
particular subunit-subunit interactions. For example, in order for a5% to completely 
block the formation of ligand binding interfaces when expressed with a2  and (54, the 
formation of oc5%-containing intermediate complexes must occur more efficiently than 
intermediates containing only a2 and P4 subunits, otherwise a mixed population of 
nAChRs would be expected to appear that includes a2p4 pentamers, which would 
generate ligand binding sites (these are not observed).
The studies with nAChR subunits expressed in pairwise combinations (Chapter 6) 
suggest that p4 associates more efficiently with a3% than with a3. However, the levels 
of radioligand binding to a3%(34 are reduced (though not abolished) upon co-expression 
with a5% (while a3P4 is unaffected by a5% and a3%p4 is unaffected by a5). It is 
possible that, for example, a5%-P4 associations occur efficiently, but are not permissive 
for the formation of viable ligand binding sites when the other a-type subunit is a3%. 
Therefore, upon co-expression of a3%, p4 and ol5%, the two different chimeras may 
compete for association with P4, where a3%-P4 associations are permissive for the 
formation of a3%P4 pentamers, while a5%-p4 associations do not permit the formation 
of nAChRs with equivalent ligand binding properties. This would result in a mixed 
population of subunit complexes with different ligand binding capabilities, reducing the 
observed levels of [3H]-epibatidine binding.
In the Sequential Model of nAChR assembly, the y subunit mediates subunit 
oligomerisation (Green and Wanamaker, 1998). During assembly, the 8 subunit and the 
second a  subunit associate between different subunit pairs, but both subunits interact 
with the same y interface (Figure 7.10). The P subunit also associates with this interface 
in the formation of trimers. The interface of the y subunit appears to change specificity 
to permit the incorporation of different subunits into the assembly complex (Green and 
Wanamaker, 1998). If the assembly pathways of the muscle-type and neuronal nAChRs 
are analogous, then subunit oligomerisation would be mediated by the neuronal P
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subunit. The |3 subunit would interact with the a  subunit and with a5 (or another P 
subunit) in the formation of a trimer. A conformational change would then occur that 
permits association of another (3 subunit, followed by a second a  subunit. Mediation of 
trimer formation via the |3 subunit is consistent with a study of a3|32a5 nAChRs in 
Xenopus oocytes, in which P2 associated with a5, but formed non-ligand binding 
aggregates in the absence of a3, while a3 and a5 did not form a stable association in the 
absence of P2 (Wang et al., 1996). In the present study, the role of the P subunit is 
highlighted upon co-expression of wild-type nAChRs with a5%, where a5% prevented 
the formation of ligand binding pentamers when expressed with a2P4 or a4|34, while 
ligand binding to the a2p2 or a4P2 nAChR subtypes increased upon addition of a5%. 
The a  subunit also appears to influence nAChR assembly, as the levels of ligand binding 
with a3P4 nAChRs were unaffected by the addition of a5%. This is compatible with the 
presented model, in which subunit oligomerisation is determined by the conformation of 
each assembly intermediate, where subunit conformation is modified following the 
addition of each subunit (Green and Millar, 1995; Green and Wanamaker, 1998; 
Eertmoed and Green, 1999; Green, 1999; Mitra et al., 2001; Harkness and Millar, 2002) 
and may provide a mechanism for the selective assembly of specific nAChR subtypes.
7.3.3 Summary and conclusions
Wild-type nAChR subunits and nAChR/5HT3A subunit chimeras were expressed in 
triplet combinations to investigate the potential co-assembly of a5 with different nAChR 
subtypes. In previous studies, the a5 subunit has been observed to participate in the 
formation of nAChRs containing more than one a-type subunit, including a3P2a5 and 
a4p2a5 nAChRs (Wang et al., 1996; Conroy and Berg, 1998). However, the a3P2a5 
and a4P2a5 nAChR subtypes could not be distinguished from a3P2 or a4P2 nAChRs 
through the use of radioligand binding and co-assembly was demonstrated through other 
techniques, such as immunoprecipitation (Wang et al., 1996; Conroy and Berg, 1998).
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Therefore, the aim of this study was to investigate whether the ability of the chimeric 
subunits to alter the levels of nAChRs able to generate ligand binding sites (Chapter 6) 
would be extended to a5%. If the levels of radioligand binding detected in cells 
transfected with pairwise combinations of wild-type subunits (e.g. a3|32) increased 
following addition of a5x, this would indicate the co-assembly of these nAChRs with an 
a5-type subunit and provide further evidence for the ability of subunit chimeras to 
enhance the efficiency of nAChR expression.
Upon co-expression of a5% with a2|32 and a4p2 nAChR subtypes, significant increases 
in radioligand binding were observed (540±100% and 260±40% of binding in the 
absence of a5%, respectively), suggesting that these nAChR subtypes are able to co- 
assemble with an a5-type subunit to form complexes capable of binding [3H]-epibatidine 
when expressed in tsA201 cells. However, a5% was also observed to disrupt the ligand 
binding interfaces formed between certain subunits, such as a4p4 and a3%P2, where the 
levels of radioligand binding to these nAChR subtypes decreased upon co-expression 
with a5%. Therefore, a5% appears able to associate with other nAChR or nAChR/5HT3A 
subunits, but for the majority of nAChR subtypes tested, this interaction is not beneficial 
with respect to the formation of a high affinity nicotinic binding site. Replacing the C- 
terminal region of a5 with the corresponding region of 5HT3A appears to alter the ability 
of the a5-type subunit to interact efficiently with other nicotinic or chimeric subunits and 
this is consistent with the studies with the other chimeras (Chapters 4 and 6, Cooper et 
al., 1999; Harkness and Millar, 2002; Baker et al., 2004). These studies have provided 
an insight into nAChR assembly, where the differences in the ligand binding profiles of 
each nAChR subtype support previous evidence to suggest that both the N- and C- 
terminal regions of each of the a  and P nAChR subunits are involved in aspects of 
subunit oligomerisation (Green and Millar, 1995; Eertmoed and Green, 1999; Keller and 
Taylor, 1999).
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FIGURE 7.9. Models of the assembly of the muscle-type nAChR. Two models 
suggested for the pathway of nAChR subunit oligomerisation in the assembly of 
pentameric nAChRs. (A) The mature a  subunit (a ^ )  associates with y or 8 subunits to 
form ay and aS heterodimers. The heterodimers oligomerise with the P subunit and with 
each other to form a 2PyS pentamers. (B ) Rapidly formed aPy trimers (possibly 
preceded by aP, ay and Py dimers) associate with 8 to form aPyS tetramers. Addition of 
the second a  subunit completes the formation of the a 2Py8 pentamers. "oCjx" represents 
the mature a  subunit as determined by the ability of the subunit to bind a-BTX. 
Adapted from Green and Millar, 1995.
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FIGURE 7.10. Subunit oligomerisation of the muscle-type nAChR. Folding events 
following subunit oligomerisation result in a change in subunit specificity at the site at 
which the a s and y subunits associate in the final pentamer, such that the interface of the 
y subunit mediates subunit oligomerisation and nAChR assembly. Adapted from Green 
and Wanamaker, 1998.
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7.4 Future directions
Sucrose gradient centrifugation and immunoprecipitation techniques may reveal which 
subunit combinations associate as pentameric complexes or protein aggregates. The 
nAChR/5HT3A subunit chimeras may prove useful in these studies, as the interactions 
between chimeras and other subunits appear more stable than the associations between 
wild-type subunits. This would be particularly relevant to the studies with the a5% 
chimera, where assessing the possible associations between different subunits may help 
to elucidate the nature of the intermediate complexes proposed to form along the nAChR 
assembly pathway.
It would be interesting to perform a similar set of binding assays to those described with 
the a5 and a5% subunits, using the p3 and (33% subunits to assess whether the dominant 
negative effect exerted by a5% on subunit combinations such as a4P4, with respect to 
the formation of viable ligand binding interfaces, is unique to this particular subunit.
Further pharmacological characterisation of selected subunit combinations could be 
performed in order to compare the pharmacological profiles of these receptors to native 
nAChRs. For example, the profiles for a2|32a5 and 0t2|32a5% could be compared to that 
of the cx2P2a5 nAChR immunodepleted from chick optic lobe (Balestra et al., 2000).
As mentioned in Section 6.9, the functional capabilities of nAChRs containing chimeric 
subunits and the sub-cellular distribution of the assembled nAChRs remain to be 
determined.
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CHAPTER 8 
DISCUSSION
8.1 Molecular and cell biological characterisation of nAChRs
Nicotinic receptors are involved in a variety of functional processes including synaptic 
transmission and modulation of neurotransmitter release. In addition, nAChRs have 
been implicated in several neurological disorders and in the mediation of nicotine 
addiction (Section 1.6). The muscle-type nAChR has been widely studied and 
characterisation of this receptor has provided a model for the study of other members of 
the ligand-gated ion channel superfamily (Devillers-Thiery et al., 1993). Thus, a 
detailed knowledge of neuronal nAChRs is not only important in understanding the 
functional roles of nAChRs and their potential as therapeutic targets, but to gaining 
insight into the function of other ion channel receptors in the nervous system.
In this study, aspects of nAChR structure, assembly and expression were analysed 
through heterologous expression of cloned nAChR subunits in mammalian cell lines. 
Heterologous expression systems allow the assembly of recombinant nAChRs from 
defined subunit combinations to be investigated and compared with native nAChRs. 
Expression of nAChRs outside the native cellular environment has demonstrated the 
influence of the host-cell environment on nAChR assembly (Millar, 1999; Sivilotti et al.,
2000) and provides a platform to identify specific cellular factors involved in nAChR 
folding, assembly and cell surface expression. However, achieving efficient expression 
of neuronal nAChRs in mammalian cell lines has proved difficult and this study was 
intended to investigate molecular and cell biological techniques to overcome some of the 
challenges of heterologous expression of recombinant nAChRs. Specifically, 
manipulation of nAChR subunit DNA was used to analyse aspects of nAChR assembly, 
pharmacology and sub-cellular distribution.
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8.2 Construction of chimeric subunits enhances the expression of a variety of 
nAChR subtypes
Previous studies have revealed that the relatively inefficient folding and cell-surface 
expression of several nAChRs can be enhanced by replacing the C-terminal region of 
some nAChR subunits with the corresponding region of the 5HT3A receptor subunit 
(Eisele et al., 1993; Blumenthal et al., 1997; Rangwala et al., 1997; Cooper and Millar, 
1998; Cooper et al., 1999; Harkness and Millar, 2002). In this study, subunit chimeras 
analogous to the previously described a7V201/5HT3A chimera (Eisele et al., 1993; Cooper 
and Millar, 1997), were constructed and comprised a series of chimeras containing the 
N-terminal domain of each of the known rat neuronal nAChR subunits (Table 3.1).
Each subunit chimera was expressed in mammalian cells, either alone or in combination 
with wild-type or other chimeric subunits in order to obtain a profile of nAChR 
expression in mammalian cells. This extensive study was by no means exhaustive, but 
has provided an insight into the assembly and expression of several nAChR subtypes and 
generated evidence to support current models of the structure-function relationship of 
nAChR subunit domains. The use of subunit chimeras has also provided a model system 
for the characterisation of nAChR subtypes that are not otherwise expressed efficiently 
in mammalian cells.
The construction of subunit chimeras has been used previously to enhance the expression 
of a7, a8 and a4P2 nAChRs (Eisele et al., 1993; Blumenthal et a l , 1997; Rangwala et 
al., 1997; Cooper and Millar, 1998; Cooper et al., 1999; Harkness and Millar, 2002). In 
this study, replacement of each of the rat a2, a3, a4, a6, a7, a9, a  10, P2 and P4 
nAChR subunits with the corresponding chimera, increased the detectable levels of 
nAChRs expressed in tsA201 cells, demonstrated by radioligand binding (Chapters 4 and 
6). In addition, the levels of [3H]-epibatidine binding to the a2p2 and a4P2 nAChR 
subtypes were increased slightly upon co-expression with a chimeric a5% subunit,
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suggesting that appropriate folding of an a5-type subunit can influence the efficient 
expression of heteromeric nAChRs in tsA201 cells (Chapter 7). Whether subunit 
chimeras also enhance the folding of the 03 subunit was not apparent from the 
radioligand binding studies, as the p3 subunit does not form ligand binding interfaces 
when expressed in pairwise combinations with other nAChR subunits in heterologous 
expression systems (Chapter 6, Sargent, 1993), but it seems likely, given that the C- 
terminal region of each of the other known nAChR subunits can be implicated in the 
inefficient folding of nAChRs in mammalian cell lines.
Each of the a2|32, a2p4, a3|32, 0(3(34, a4p2 and cx4p4 nAChR subtypes demonstrate low 
levels of [3H]-epibatidine binding when expressed transiently in tsA201 cells (Chapter 
6). Increases as great as 350-times basal levels of binding were achieved upon 
replacement of a wild-type subunit with its corresponding chimera (a3%P2). 
Replacement of either the a  or the P type subunit with the corresponding chimeric 
subunit influenced the levels of radioligand binding, suggesting that inefficient folding of 
each nAChR subunit restricts nAChR assembly. Perhaps the most striking effects 
exerted by the chimeras are observed with nAChRs containing the a6 or a9 and alO 
subunits. As observed with the homomeric a l  nAChR (Cooper and Millar, 1997), wild- 
type rat a6-containing nAChRs and a9 a l0  nAChRs fail to assemble into complexes 
able to bind radioligand when expressed heterologously in tsA201 cells (Sections 6.6 and 
4.2). Therefore, construction of nAChR/5HT3AR subunit chimeras has permitted 
expression of rat a9 a  10-type and a6-containing nAChRs in a mammalian cell line. 
With the a9%al0% complex, this allowed a detailed characterisation of the ligand 
binding properties of an a9-type nAChR in tsA201 cells that not only provided evidence 
to support the unique pharmacological profile of native a9-containing nAChRs (Housley 
and Ashmore, 1991; Fuchs and Murrow, 1992; Verbitsky et al., 2000), but also 
demonstrated the use of chimeras as a viable model for the characterisation of wild-type 
nAChRs (Baker et al., 2004).
197
The comparable pharmacological profiles of wild-type and chimeric a9-containing 
nAChRs suggests that the ligand binding domain is largely unaffected by the 
construction of subunit chimeras, consistent with the structural model that attributes 
ligand binding to the large extracellular N-terminal of the nAChR (see Figure 1.1). The 
chimeric nAChRs also appear to be expressed at the cell surface in high levels (Section 
5.2, Cooper and Millar, 1998; Cooper et al., 1999; Harkness and Millar, 2002; Baker et 
al., 2004) and are able to form functional channels (Section 4.4, Eisele et al., 1993; 
Rakhilin et al., 1999), suggesting that the modification to the C-terminal region of the 
nAChR subunits does not disrupt the ability of the subunits to form viable pentameric 
complexes. However, while the chimeras may retain functional capabilities and the 
ligand binding properties may not be altered, the ion channel properties and the coupling 
of agonist binding at the N-terminal region to the opening of the ion channel in the C- 
terminal domain (Unwin et al., 2002; Miyazawa et al., 2003) may be expected to differ 
between wild-type and chimeric nAChRs.
8.3 The a  subunit exerts a dominant-negative effect on nAChR expression in 
tsA201 cells
Replacement of either a  or P nAChR subunits with their corresponding subunit chimeras 
within heteromeric nAChR complexes enhances the levels of radioligand binding. In the 
case of the a2-, a3-, a4- and a6-containing nAChRs, the a  subunit appears to exert the 
dominant effect on restricting the efficient expression of nAChRs in tsA201 cells 
(Chapter 6). With nAChR subtypes such as a2P2 and a3P4, replacement of the a  
subunit with an a  chimera results in a greater increase in radioligand binding levels than 
replacement of the p subunit with a P chimera. This effect is most prominent with the 
a6 subunit, which fails to form detectable ligand binding complexes when co-expressed 
with wild-type or chimeric p subunits in tsA201 cells. In contrast, high levels of binding 
are observed upon co-expression of the a6% chimera with P2 or P4 subunits.
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The efficient folding of both the a9  and a  10 subunits appears necessary for the 
formation of heteromeric complexes (Chapter 4), suggesting that each a  subunit exhibits 
a strong influence with respect to nAChR expression in mammalian cells. While a9% 
homomers and a9%al0% heteromers appear to assemble in transfected tsA201 cells, the 
levels of nicotinic radioligand binding observed in cells co-transfected with chimeric 
a9% and wild-type a  10 (or a9+al0%) do not differ from the levels of binding observed 
with the a9% (or a  10%) homomer. This is in contrast to other heteromeric nAChRs, such 
as the a4p2 nAChR, where each of the a4%(32, a4P2% and a4%$2% subtypes form 
complexes that demonstrate higher levels of radioligand binding than the wild-type oc4p2 
nAChR when expressed in tsA201 cells, with the a4 subunit exerting the dominant 
effect on receptor assembly (this study, Cooper et al., 1999; Harkness and Millar, 2002). 
The C-terminal region of both the wild-type a9 and a  10 subunits appears to critically 
restrict the efficient formation of a high affinity radioligand binding site in transfected 
tsA201 cells, suggesting that the appropriate folding of each of the a-type subunits is 
essential for assembly of heteromeric a9 a l0  nAChRs.
Previous studies have demonstrated the dominant nature of the a4 subunit, with respect 
to the efficient expression of nAChRs capable of binding radioligand at the surface of 
tsA201 cells (Cooper et a l, 1999; Harkness and Millar, 2001; Harkness and Millar, 
2002). The present study suggests that the dominant-negative feature of the a4 subunit 
in nAChR assembly can be extended to each of the other neuronal nAChR a  subunits 
that participate in formation of the ligand binding site. The a5 subunit is not included, 
as this unique a-classified subunit does not appear to form ligand binding interfaces with 
other subunits in pairwise combinations (Chapters 6 and 7, Boulter et al., 1990; 
Couturier et al., 1990b; Sargent, 1993; Ramirez-Latoire et al., 1996; Wang et al., 1996; 
Conroy and Berg, 1998; Gerzanich et al., 1998).
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Each of the oc2%, cc3%, a4%, a9% and alO% chimeras appear able to form homomeric 
complexes, demonstrated by the low levels of radioligand binding observed in tsA201 
cells transiently transfected with each subunit chimera alone (Section 4.4 and Chapter 6). 
The oc5%, P2%, p3% and P4% chimeras do not form homomeric complexes able to bind 
radioligand, but the p2% chimera has been shown previously to assemble into pentameric 
homomers that are expressed at the surface of tsA201 cells in high levels (Cooper et al., 
1999; Harkness and Millar, 2002). The low levels of binding observed with the a2%, 
cx3%, a4%, a9% and a  10% homomers are greatly enhanced when these subunits 
participate in the formation of heteromeric nAChRs, supporting the suggestion that while 
the binding interface of the a  subunit provides components that are sufficient for 
radioligand binding, the complementary components of the adjacent p subunit (or ex 10% 
subunit in the case of cc9%al0%) are also required for the formation of a high affinity 
nicotinic ligand binding site (Kao and Karlin, 1986; Galzi et al., 1990; Czajkowski et al., 
1993; Fu and Sine, 1994; Corringer et al., 1995; Martin et al., 1996; Prince and Sine, 
1996; Brejc et al., 2001).
The nature of the particular a  subunit is also able to influence the efficiency of nAChR 
expression, where nAChRs containing the a4 subunit demonstrate higher basal levels of 
[3H]-epibatidine binding in tsA201 cells than a2-containing nAChRs do, irrespective of 
the nature of the p subunit. In addition, the enhancing effect of introducing subunit 
chimeras is greater for the a2-containing nAChRs than those containing a4. Therefore, 
the a4 subunit appears to fold or assemble with the P subunit more efficiently than the 
a2 subunit is able to.
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8.4 nAChRs containing the (34 subunit assemble more efficiently than |32- 
containing nAChRs
The studies with chimeric subunits suggest that the a  subunits fold less efficiently than 
the P2 or |34 subunits (Section 8.3). In addition, the radioligand binding experiments 
performed in this study with combinations of wild-type and chimeric subunits, suggest 
that the |32 subunit folds and assembles with a  subunits less efficiently than the p4 
subunit does. The levels of [3H]-epibatidine binding are consistently higher in cells 
expressing pairwise combinations of nAChRs containing the P4 subunit than those 
containing P2 (Chapter 6), despite the fact that p2-containing nAChRs demonstrate 
higher affinities for [3H]-epibatidine than nAChRs containing P4 (Parker et al., 1998). 
Also, greater increases in the levels of radioligand binding are detected upon 
replacement of the P2 subunit with 02%, than upon replacement of P4 with 04%, when 
co-expressed with any of the a2, a3 or a4 subunits.
The physiological significance of this observation is not clear, especially as P2 is the 
most widely expressed subunit in the nervous system, with fairly homogeneous 
distribution in human brain (Paterson and Nordberg, 2000). The differences in subunit 
folding efficiency may reflect the nature of the host cell environment, where the 
assembly of p2-containing nAChRs may employ subtype-specific chaperone proteins. 
There is evidence demonstrating the subtype-specific action of intracellular proteins that 
influence nAChR expression. For example, the Ric-3 protein is suggested to be involved 
in nAChR folding and assembly in the endoplasmic reticulum and while Ric-3 enhances 
the ACh-evoked whole cell currents in Xenopus oocytes expressing recombinant a l  
nAChRs, co-expression of human Ric-3 with recombinant a402 or a304 appears to 
inhibit nAChR activity (Halevi et al., 2002; Halevi et al., 2003).
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The studies in which a5% was co-expressed with different nAChR subtypes (Chapter 7), 
revealed differences in the interaction of a5% with the 02 and 04 subunits. While the 
levels of radioligand binding observed with a202 and a402 nAChRs increased upon 
addition of a5% (to 540±100% and 260±40% of binding in the absence of a  5%, 
respectively), binding to the a204 and a404 nAChR subtypes was completely abolished 
upon co-expression with a5%. While the precise nature of the subunit interactions that 
occur upon expression of these subunit combinations has not been established, this may 
suggest that the a5 subunit assembles more efficiently with 02 than with 04 to form 
viable nAChRs that contain a5 within the pentameric structure. Subtypes of nAChR that 
contain both the 02 and 04 subunits have been demonstrated in the nervous system, such 
as a3a50204 nAChRs in embryonic chick ciliary neurones (Conroy and Berg, 1995) and 
a a4020304 subtype in rat cerebellum (Forsayeth and Kobrin, 1997). These subtypes, 
containing four different nAChR subunits, are reminiscent of the muscle-type nAChR. 
The more efficient folding of 04 may indicate that the 04 subunit mediates the assembly 
of pentameric nAChRs in these subtypes, assuming the role of the muscle-type y subunit, 
while 02 assumes the role of the 5 subunit and complexes with a4-03-04 trimers during 
nAChR assembly, for example (see Figure 7.10).
8.5 The subunit N-terminal domains influence nAChR assembly
Comparing the ligand binding profiles of different nAChR subtypes demonstrates the 
importance of the N-terminal domain of nicotinic subunits in subunit oligomerisation. 
This is apparent when comparing the profiles of nAChRs in which each of the subunits 
contains the C-terminal region of 5HT3A. In complexes such as a3%02%, a3%04% and 
oc3%04%a5%, the C-terminal domain of every subunit within the complex (which may be 
a mixed population with a3%04%a5%) is identical. Therefore, any differences in the 
ligand binding profiles of these subunits implicate the N-terminal domains in nAChR 
expression. The 02%-containing subtypes demonstrate consistently higher levels of 
binding than nAChRs containing 04%, irrespective of the nature of the a-type chimera
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(Chapter 6). In addition, as mentioned in Section 8.3, subunits such as a2% are able to 
form homomeric ligand-binding complexes, but high affinity ligand binding sites are 
only detected upon co-expression of the homomers with a P-type subunit, providing 
evidence of a requirement for heteromeric co-assembly of subunit N-terminal domains 
for the efficient formation of a nicotinic binding site.
It has been suggested that the N-terminal domains of nAChR subunits mediate the initial 
interactions that occur between subunits during translational events, where the N- 
terminal domains of partially-translated subunits are able to interact with the N-terminal 
domains of other completed subunits (Green and Millar, 1995; Keller and Taylor, 1999). 
In addition, previous studies have identified specific residues in the N-terminal domain 
that direct the order of subunit assembly and the arrangement of the subunits in the 
pentameric nAChR structure (Gu et a l , 1991; Sumikawa, 1992; Sugiyama et a l , 1996; 
Keller and Taylor, 1999).
8.6 The subunit C-terminal domains influence nAChR assembly
A common feature of the studies with chimeric subunits is that inefficient folding and 
cell-surface expression of nAChRs can be attributed to sequences present within the C- 
terminal (transmembrane and intracellular) subunit domains (this study, Eisele et al., 
1993; Blumenthal et a l , 1997; Rangwala et a l, 1997; Cooper and Millar, 1998; Cooper 
et a l, 1999; Harkness and Millar, 2002; Baker et al, 2004). The high expression levels 
of nAChR/5HT3AR subunit chimeras and the homomeric 5HT3A receptor in mammalian 
cell lines suggest that the assembly of 5HT3A receptors is more efficient than that of the 
nAChRs. The nAChR and 5HT3A receptor subunits may interact with different 
intracellular proteins, where the over-expression of nAChR subunits in mammalian cells 
may require co-expression with specific cellular factors to chaperone subunit folding and 
oligomerisation.
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While the N-terminal domains of nAChR subunits appear to mediate the initial 
interactions between subunits, the nature of the C-terminal domain (or the subunit 
structure as a whole) may govern which subunit associations are productive and proceed 
along the assembly pathway (Eertmoed and Green, 1999). This has been demonstrated 
in previous studies employing chimeras (Eertmoed and Green, 1999) and in this study 
using a5%, where a5% prevents the formation of ligand binding sites upon expression 
with the a2p4 and a4|34 nAChRs. As the a5% chimera can disrupt ligand binding 
interfaces of a2p4 nAChRs, while radioligand binding is unaffected by addition of the 
wild-type a5 subunit, this suggests that the introduction of the C-terminal region of the 
5HT3a subunit to a5 permits stable subunit interactions that would not otherwise occur 
with wild-type subunits. This demonstrates the importance of the C-terminal domain of 
nicotinic subunits in subunit oligomerisation events.
8.7 Summary and Conclusions
The aim of this project was to overcome some of the challenges of heterologous 
expression of recombinant nAChRs in order to gain a better understanding of the 
structural and functional properties of neurotransmitter-gated ion channels. Through 
manipulation of nAChR subunit DNA in the construction of subunit chimeras, the 
expression of nAChRs containing each of the rat a2, a3, a4, a6, a9, a  10, P2 and p4 
subunits was enhanced, as demonstrated by radioligand binding studies performed on 
transfected tsA201 cells. These results attribute the inefficient folding of nicotinic 
subunits into conformations that are recognised by nicotinic radioligands, to the subunit 
C-terminal domain. These observations are particularly significant for the a9, a  10 and 
a6 subunits, as the construction of nAChR/5HT3A subunit chimeras has allowed the 
successful expression of rat a9/al0- and a6-containing nAChRs in a mammalian cell 
line that is not observed with wild-type subunits. The detailed pharmacological 
characterisation of cc9%al0% receptors suggest that the chimeric receptors retain the 
ligand binding properties of the wild-type nAChRs, are expressed at the cell surface in
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high levels and can form functional ion channels and can, therefore, provide viable 
models for the study of wild-type nAChRs.
Comparison of the ligand binding profiles of nAChRs with different subunit 
compositions revealed the influence of both the a  and P subunit on the efficient 
formation of nAChRs with ligand binding capabilities, demonstrating the requirement of 
appropriate interactions between subunit N-terminal domains in the formation of high 
affinity ligand binding interfaces. These conclusions correlate well with previous 
models of nAChR assembly and suggest that the entire structure of the nicotinic subunit 
is involved in the ability of these proteins to fold, assemble and access the cell surface in 
the specific internal environment of the mammalian host cells.
Elucidation of the mechanisms by which nAChRs assemble appropriately is critical to 
understanding the functional roles of these complex oligomeric proteins in vivo. The 
large number of different nicotinic subunits means that the potential for nAChR 
subtypes, each with different subunit composition and stoichiometry is immense. 
Defining pathways of subunit oligomerisation and characterisation of the various nAChR 
subtypes in heterologous systems can aid the definition of native nAChRs, of which their 
apparent roles in neurological disorders and nicotine addiction has made nAChRs 
attractive as potential therapeutic targets.
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